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Type II diabetes mellitus (T2DM) is a complex metabolic disorder resulting in chronic 
hyperglycaemia due to insulin resistance and/or impaired insulin production. A disorder 
called diabetic retinopathy (DR) occurs when hyperglycaemic damage to the retinal 
endothelial (REC) and retinal pericyte cells (RP) of the capillary beds leads to leaky vessels, 
oedema, areas of non-perfusion and ultimately vision loss. Current treatments involve laser 
therapy and anti-VEGF injections to target the proliferative stage of the disease (PDR), 
however, an early cellular intervention targeted at repairing the damaged EC layer of the 
capillary bed could prevent progression of DR to the sight threatening stage.  
Modelling DR in vitro would provide a tool to further understand changes to the retinal EC 
and pericytes in diabetic conditions and assess potential cellular therapies. Endothelial 
colony forming cells (ECFCs) can be isolated from human umbilical cord (UCB) or adult 
peripheral blood (APB) and are a potential source of cells for this application. Currently, 
ECFCs are expanded on rat tail type I collagen (col I.), but in order to enable ECFC cell therapy 
in humans, culture conditions must be xeno-free or good manufacturing practice (GMP) 
compliant. Poly-ε-lysine (pεK) hydrogels are a promising option as an expansion surface, as 
they provide a highly controlled peptide surface with amine functionality to allow cell 
binding, and the mechanical properties of the hydrogel can be tailored to best suit the cell-
type of interest. 
hREC and hRP were cultured on either side of PET transwell inserts in healthy or diabetic 
conditions for up to 21 days and hREC were analysed for cell-cell junction formation, 
angiogenic and oxidative stress response. ECFCs were isolated from the mononuclear 
fraction of adult peripheral (APB) and umbilical cord blood (UCB) and expanded in vitro on 
either col I. coated tissue culture (TC) plastic or pεK hydrogels. ECFCs were added into the 
hREC layer of the co-culture model to assess their ability to integrate with mature hREC in 
healthy and diabetic conditions. pεK microparticles were assessed as a method for controlled 
delivery of ECFCs to the hREC layer of the co-culture model. 
hREC and hRP successfully grew as co-cultures for up to 21 days in healthy and diabetic 
conditions. The optimised diabetic conditions resulted in significant differences in the 
secretome of 4 major angiogenic response proteins. The secretion profiles of mono- 
compared to co-culture hREC and hRP were different. Both APB and UCB-ECFCs incorporated 
into the co-culture models, in healthy and diabetic conditions. ECFCs grown on pεK hydrogels 
retained their endothelial progenitor morphology when cultured long term in both healthy 
and diabetic conditions, whereas some ECFCs grown on rat tail col I. coated TC plastic 
differentiated or became senescent. Additionally, ECFCs grown on pεK hydrogels remained a 
homogenous population whereas ECFCs grown on rat tail col I. coated TC plastic were 
heterogeneous in their expression of EC-phenotypic markers such as CD31. Delivery of ECFCs 
to vessels using pεk microparticles is not a viable option as ECFCs did not detach from the 
microparticles. 
An in vitro model of the retinal capillary structure using human primary, retina-specific hREC 
and hRP provides tissue and species-specific data on cellular changes in diabetic conditions, 
highlighting the advantage of co-cultures over monoculture techniques. Both APB and UCB-
ECFCs integrated into the hREC layer of the co-culture model, although in vitro expansion of 
APB-ECFCs was found to be limited. pεK hydrogels are a promising new xeno-free surface on 
which to expand ECFCs in vitro whilst retaining their progenitor phenotype.  
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1. CHAPTER 1 
1.1 INTRODUCTION 
1.1.1 OVERVIEW 
The work contained in this thesis focuses specifically on the microvessels at the back of the 
eye that supply blood to the retina. This retinal capillary bed is severely compromised in 
people with diabetes, leading to a condition called diabetic retinopathy (DR). Vision loss 
associated with DR is a huge burden to the increasing number of people suffering with 
diabetes worldwide. Earlier diagnosis could provide the opportunity for either lifestyle 
change, pharmaceutical intervention, or in the future, cellular based therapies, to either 
prevent or slow progression of the numerous complications caused by diabetes. Endothelial 
colony forming cells (ECFCs) are one type of endothelial progenitor cell that can be easily 
isolated from adult peripheral blood (ABP) or umbilical cord blood (UBC), and have the 
potential to provide autologous or allogeneic cell therapy for blood vessel repair during 
chronic diseases such as diabetes. Modelling DR in a co-culture model system will help 
improve understanding of the cellular changes that occur during the complicated progression 
of disease, and enable testing of the ability of ECFCs to repair a damaged endothelial layer. 
1.2 THE RETINA 
1.2.1 STRUCTURE OF THE RETINA 
The interior compartment of the eye is divided into the anterior and posterior segments. The 
retina is the neural portion of the eye, forming part of the central nervous system, lining the 
surface of the posterior segment (Figure 1.1). In vertebrates, the retina develops as an 
outgrowth of the brain, turned in on itself to form a cup, which accounts for the inverted 
structure of the photoreceptors positioned furthest from the light, in the deepest layer of 
neurons1. Along with the retina, the posterior segment of the eye is composed of the optic 
never head, the choroid and the vitreous humour. Light enters the eye through the 
transparent cornea and lens, both of which are involved in refracting the light, which then 
passes through the vitreous humour and is focused on to the retina.  
The retina is responsible for converting light into neural signals, which are sent along the 
optic nerve to the brain for processing. The retina is crudely divided into two parts: the neural 
retina and the retinal pigmented epithelium (RPE). The retina can be structurally divided into 
ten layers, composed of multiple different types of neural cells and an outer-most epithelial 
   




layer, illustrated in Figure 1.2. Light passes through the first eight layers to reach the 
photoreceptor layer, where light rays are processed. The RPE plays a critical role in the 
physiology of the underlying photoreceptors by: transport of nutrients from the choroid 
circulation, formation of the outer blood–retinal barrier, absorption of scattered light, 
phagocytosis of shed membranous photoreceptor discs and release of trophic factors 



















Figure 1.1. Basic anatomy of the different regions of the human eye 
Cartoon depicting the basic anatomy of the human eye. The retina (circled blue), is the yellow pseudo-











   

























Figure 1.2. The ten layers of the human retina 
Proceeding from the vitreous (inner) to the choroid (outer): internal limiting membrane (ILM), nerve 
fiber layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer 
plexiform layer (OPL), outer nuclear layer (ONL), external limiting membrane (ELM), rod and cone inner 
and outer segments (IS/OS), and retinal pigment epithelium (RPE). To supply the inner retinal layers 




Although the structure of the eye varies distinctly from species to species, all have in common 
the molecule rhodopsin, which is responsible for initiating the process of converting light into 
electrical signals1. In humans, ~5 million cones (for sensing fine resolution, spatial resolution, 
colour and bright light intensity) and ~100 million rods (for sensing, contrast, brightness, 
motion and low light levels) comprise the photoreceptor layer, which responds to light 
stimulation1 . Rods and cones are not evenly distributed across the retina, where the highest 
density of cones are found in the fovea centralis (150,000/mm2) and rods are concentrated 
at the periphery (30,000/mm2)5 (Figure 1.3). In humans, the rod and cone cells have 
1. Inner limiting membrane 
2. Nerve fiber layer 
3. Ganglion cell layer 
4. Inner plexiform layer 
5. Inner nuclear layer 
6. Outer plexiform layer 
7. Outer nuclear layer 
8. External/outer limiting membrane 
9. Inner & outer segment 
photoreceptor layer (rods & cones) 
10. Retinal pigmented epithelium  
   




photopigment-bearing regions called outer segments, and these are composed of a large 
number of disks, with ~150,000 rhodopsin molecules/disc6. These membranous outer 
segment discs undergo daily renewal at the proximal region, and shedding at the distal outer 
segment region, at a rate of roughly 2µm/day. This enables the outer segment to maintain a 
constant length while replacing components that have accumulated toxic photo-oxidative 
compounds7. Light photons are absorbed on the highly folded photoreceptor cell 
membranes, by the photopigment rhodopsin, and photon absorption contributes to the 
photoreceptor output signal to the optic nerve. Dysfunction or loss of synchronisation of this 
highly regulated diurnal photoreceptor shedding and renewal process can lead to 
photoreceptor and RPE degradation and ultimately vision loss. The photoreceptors are the 
most highly metabolically active cells in the human body8, and to fulfil this high oxygen 
demand, strict control of blood flow to the outer retina is imperative. Therefore, the retina 
is particularly vulnerable to disrupted blood flow and ischemia, which are microvascular 
complications that can arise in chronic diseases such as diabetes. 
 
Figure 1.3. Typical distribution of cones and rods in the human retina 
0° refers to centre point (fovea) of the central area (macula) of the posterior wall of eye. Cones are 
concentrated in the fovea centralis and only a small number are found in the periphery (purple). The 
fovea centralis is rod cell-free and rods are distributed across the periphery of the retina, with the 
highest amount around the edge of the fovea, radiating out (blue). There are no photoreceptors at the 



















   




1.2.3 BLOOD SUPPLY OF THE RETINA 
The arterial blood supply to the eye is provided by branches of the ophthalmic artery, 
including the central retinal artery, the short and long posterior ciliary arteries and the 
anterior ciliary arteries10. Venous outflow is mainly via the central retinal vein and vortex 
veins, which merge with the superior and inferior ophthalmic veins. In humans, the retina 
receives a dual blood supply, with the inner 2/3 supplied by branches from the central retinal 
vessels and the outer 1/3 receiving blood from the choroidal circulation. An outline of the 
blood vessels supplying the retina is shown in Figure 1.4 11. The central retinal circulation 
(supplying the inner layers) has a low flow rate of 25mm/s and high oxygen exchange whilst 
the choroidal circulation (supplying the outer layers) has a high flow rate of 150mm/s and 
low oxygen exchange5. The larger vessels supplying the retina lay close to the inner limiting 
membrane, with vessel walls running in a close spatial relationship with glial cells, mainly 
astrocytes, and form a plexus of capillaries ~5µm in diameter12. This close vascular:glial 
interaction is illustrated in Figure 1.5. 
Two of the main peculiarities of the retinal vasculature include: 1) no autonomic innervation, 
and 2) a sparse architecture of the inner retinal blood supply. Lack of autonomic nerve supply 
means the vascular tone is controlled locally. The retinal vasculature must meet the 
challenging demand of supplying the highly metabolically active tissue, whilst remaining 
anatomically sparse so as not to interfere with the path of light reaching the 
photoreceptors13. These structural and functional adaptations of the retinal 
microvasculature advocates the importance of investigating organ or tissue specific vascular 
endothelial cells (ECs) in vitro. In fact, it has been well documented that the ECs possess 
unique ultrastructural characteristics, and this is microvascular or macrovascular dependant 
as well as organ-specific, and these characteristics are intrinsic to the cells themselves and 
not determined by differential culture conditions14. Therefore, when studying the 
microvasculature of the human retina, as far as possible cells sourced specifically from the 
human retina should be studied in vitro, because these cells are structurally and functionally 
unique from cells sourced from other organs, and other species.  
 
 
   





Figure 1.4. Schematic representation of the inner retinal blood supply 
Blood supply at: (A) the optic nerve head and (B) the optic nerve. Red represents arteries, blue 
represents veins. Abbreviations: A= arachnoid; Ant. Sup. Hyp. Art.= anterior superior hypophyseal 
artery; C= choroid; CAR and CRA= central retinal artery; Col. Br.= collateral branches; CRV= central 
retinal vein; CZ= circle of Zinn and Haller; D= dura; ICA= internal carotid artery; LC= lamina cribrosa; 
LPCA= lateral posterior ciliary artery; Med. Mus.= medial muscular artery; MPCA= medial posterior 
ciliary artery; NFL= surface nerve fibre layer of the disc; OA= ophthalmic artery; OD= optic disc; ON= 
optic nerve; P= pia; PCA= posterior ciliary artery; PR and PLR= prelaminar region; R=retina; RA= retinal 
arteriole; Rec. Br. CZ= recurrent pial branches from peripapillary choroid/CZ; S= sclera; SAS= 










   











Figure 1.5. Cellular components of the retina: glia and neurons 
The different cell-types comprising a standard large mammalian retina. Interactions between the glia 
and blood vessels (BV) are circled black. Amacrine cells (A), astrocytes in green (AS), bipolar cells (B), 
cones (C), ganglion cells (G), horizontal cells (H), Müller cells (blue) (M), microglia (red) (Mi), rods (R), 
cones (C). The different layers of the retina are labelled: optic nerve (ON), nerve fibre layer (NFL), 
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer 










   




1.3 MICROVASCULAR ENDOTHELIAL CELLS 
1.3.1 STRUCTURE OF BLOOD VESSELS  
In the healthy vasculature, cells comprising the blood vessels are able to respond to changes 
in: blood pressure, blood sugar levels, flow rate, and temperature fluctuations, in order to 
maintain homeostasis16,17. In the event of vascular wounding, vessels are capable of repair 
via adult angiogenesis. Blood vessel architecture varies from macro- to microvascular, where 
larger vessels are surrounded by tunica layers, whilst capillaries lack these extra layers (Figure 
1.6). The structure of a blood vessel is directly related to differential function. The larger 
arteries are under high pressure from the pumping mechanism of the heart and, therefore, 
their elastic and media layers are thickened to counteract the pulsatile action. However, the 
blood pressure in veins is much lower, hence valves are located throughout, to prevent 
backflow of blood. The primary function of the capillary bed of any tissue is nutrient 
exchange: oxygen and nutrient delivery along with carbon dioxide and toxic metabolite 
removal, and the single layer EC structure enables this exchange to take place through either 
a fenestrated, sinusoid or continuous endothelial barrier (Figure 1.7). In the retina, the 
capillaries maintain a continuous barrier and the diameter of the capillary vessels varies from 
3.5-6µm18. 
1.3.2 RETINAL NEUROVASCULAR UNIT 
The capillaries supplying the retinal tissue are comprised of two cell-types in close contact 
with one another; ECs which form the inner lining of the vessel tube surrounded by 
perivascular pericytes. ECs and pericytes have intimate associations with glial endfeet, 
astrocytes, Müller cells and neural processes and this has led to the concept of the retinal 
neurovascular unit19 (Figure 1.5 and Figure1.8). ECs, pericytes and glial cells send auto- and 
paracrine factors to maintain vascular and tissue homeostasis, or for adaptation and survival 
responses during cellular insult or injury. ECs form tight junctions (TJs) with one another 
forming a continuous capillary bed to enable strictly controlled passages of substances from 
the blood to the surrounding cells in the retinal tissue. EC and pericytes share a basement 
membrane (BM) and the pericytes are entirely engulfed within the BM, therefore, 
dysfunction of either cell-type during injury or disease can result in the breakdown of the 
highly regulated nutrient exchange mechanism at the vascular bed, causing damage to the 
underlying tissue.  
 
 
   





















Figure 1.6. Composition of large to small diameter arteries and veins 
Their composition directly relates to their function. Thickened tunica layers and an elastic membrane 
in arteries enable elastic recoil during high pressure pulsatile forces from the heart. Veins have 
enlarged lumen and valves throughout, to direct low pressure blood back to the heart. Capillaries are 











Figure 1.7. The three main types of capillary bed: continuous, fenestrated & sinusoidal 
The main locations where each capillary-type is found are listed. The inner retina is supplied by a 
continuous capillary bed, which forms the inner blood retinal barrier21.  
CONTINUOUS       FENESTRATED     SINUSOIDAL/ 
   DISCONTINUOUS 
FAT    INTESTINAL VILLI  LIVER 
MUSCLE   ENDOCRINE GLANDS  BONE MARROW 
NERVOUS SYSTEM  KIDNEY GLOMERULI  SPLEEN 
   



















Figure 1.8. Diagram of the simplified structure of the retinal capillary 
(A) ECs and pericytes with a shared BM, and (B) the retinal neurovascular unit, demonstrating the 
close interaction between vascular cells, glial cells and neural cells of the retina. Each cell type interacts 
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1.3.3 FUNCTION OF THE MICROVASCULAR EC 
ECs were first successfully isolated from human umbilical veins (HUVECs) and cultured in the 
lab in 1973 by Jaffe et al., enabling the study of EC function in vitro22. The ECs of the blood 
vessel walls form a semi-permeable barrier which allows controlled passage of oxygen and 
nutrients from the blood to the surrounding tissues23. At the capillary level, the endothelium 
is just one cell thick. The endothelium is not simply an inert cell layer, as it plays a critical role 
in controlling homeostatic processes such as: vascular tone, blood fluidity, exchange of 
nutrients and metabolic waste products, regulating capillary permeability, immune 
responses and angiogenesis. The endothelium has emerged as the major regulator of 
vascular homeostasis, as a signal transducer enabling circulating factors to influence the 
behaviour of the vascular cell wall. ECs produce and release vasoactive mediators such as 
bradykinin, thrombin and nitric oxide, thereby mediating vessel diameter, in order to balance 
supply of oxygen according to tissue metabolic demand24. Active and passive transport 
mechanisms involved in EC homeostasis are outlined in (Figure 1.9) 25. 
 
 
Figure 1.9. Transcellular transport through ECs 
Some small molecules can cross by diffusion due to their lipophilic properties. Energy-dependent or 
receptor-mediated mechanisms include: pinocytosis, carrier-mediated transporters, ion transporters 
and efflux pumps. Retinal ECs express a low number of these transporter mechanisms25. 
   




1.3.4 PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1 (CD31) 
Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is crucial for enabling 
leukocyte transmigration through intercellular junctions on vascular ECs, to reach sites of 
injury during inflammation or infection26. CD31 is expressed constitutively on vascular EC cell-
cell junctions and is also present on platelets and leukocytes. As well as its key role in 
immunomodulation, CD31 also contributes to the barrier properties of the EC layer via 
homodimeric PECAM-1-PECAM-1 interactions at neighbouring EC contacts27. CD31 functions 
by promoting homo- and heterotypic adhesion by binding to glycosaminoglycans or αvβ3 
integrins28,29. Subjecting HUVECs to interferon-γ, a pro-inflammatory cytokine, for 24H 
(hours) resulted in EC transition to a fibroblast-like phenotype, where CD31 was no longer 
present at cell-cell junctions, and cell growth became disorganised30. Therefore, CD31 is a 
useful cell adhesion molecule to confirm endothelial phenotype in vitro and in cell-
biomaterial interactions as it remains strongly expressed by ECs grown on various surfaces31. 
1.3.5 THE ANGIOPOIETIN-TIE-2 PATHWAY 
The Angiopoietin-Tie-2 pathway is essential for vascular development and plays a role in both 
healthy and pathological angiogenesis in adulthood. The Tie-2 receptor is a tyrosine kinase 
receptor expressed selectively by ECs, and both Angiopoietin-1 (Ang-1) and Angiopoietin-2 
(Ang-2) proteins bind to the Tie-2 receptor, although Ang-1 binds with stronger affinity. Ang-
1 is stored at high levels in platelet granules whilst Ang-2 is stored in intracellular granules 
(Weibel-Palade bodies)32,33. Ang-1 is expressed by perivascular cells (such as pericytes) and 
Tie-2/Ang-1 binding is affiliated with vessel maturation, stabilisation and homeostasis, 
whereas Tie-2/Ang-2 binding is upregulated in inflammatory and angiogenic responses34. 
Adding the inflammatory cytokine TNFα or pro-angiogenic vascular endothelial growth factor 
(VEGF) to cultured ECs or subjecting cultures to hypoxia resulted in upregulation of Ang-235,36. 
In addition to this, human and mouse pericytes have recently been shown to express 
functional Tie-2 receptors, challenging current concepts that Tie-2 is EC-specific, which  
suggests a bidirectional, reciprocal EC-pericyte Tie-2 signalling pathway (Figure 1.10)37. This 
study highlights the role of both ECs and pericytes in adult angiogenesis, therefore, when 
studying angiogenesis in vitro, co-cultures of the two cell types in a contact model would 
provide more relevant data than each cell-type grown in isolation. 
 
 
   


















Figure 1.10. Advances in understanding Ang/Tie-2 signalling between ECs and 
pericytes in the retina 
Traditional model of vascular Ang/Tie-2 signalling, outlining the established endothelial-centric model 
of Ang/Tie-2 signalling (left). The revised bi-directional, reciprocal EC-pericyte model of vascular Tie-2 
signalling (right). Red routes represent newly identified pathways. Traditionally, Tie-2 was thought to 
be expressed only by ECs. Ang-1 is secreted by pericytes and other cells. Ang-2 is almost exclusively 
secreted by ECs and acts as a dynamic autocrine modulator of Ang-1/Tie-2 signalling. New data 
demonstrates that Tie-2 receptors are also expressed on pericytes. Therefore, Ang-1 produced by 
pericytes and other cells can bind to pericyte Tie-2 and drive vessel maturation. Ang-2 produced by 
ECs acts in a paracrine manner on pericytes, contributing to vascular destabilisation during wound 







   




1.3.6 INJURY AND WOUND HEALING 
In the event of vascular wounding in the adult, vessels are capable of repair via angiogenesis. 
The initiation of angiogenesis starts with disruption or loosening of the continuity of the EC 
cell-cell contacts, enabling ECs to proliferate and migrate to ‘fill the gap’. This involves cell-
cell and cell-matrix modifications. ECs and their perivascular cells can remodel their 
surrounding extracellular matrix (ECM) via secretion of proteins such as matrix 
metalloproteinases (MMPs), which are involved in the enzymatic degradation of most ECM 
proteins. For successful angiogenesis in the adult, it is crucial that ECs downregulate secretion 
of MMP-2 and MMP-9 during the maturation phase38. During migration and integration at 
the wound site, vascular endothelial cadherin (VE-Cad), a vascular endothelium-specific 
adhesion molecule, is upregulated at the cell-cell borders, causing a highly controlled 
decrease in EC secretion of MMPs allowing the EC barrier to be re-established39. VE-Cad is 
directly involved in control of vascular permeability and leukocyte extravasation and 
regulates numerous cell functions such as proliferation and apoptosis, and controls vascular 
endothelial growth factor receptor (VEGF-R) activity40. 
1.3.7 STUDYING ECs IN VITRO 
Vascular ECs can be isolated from retinal blood vessels, via type II collagenase-dispase 
digestion and tissue homogenisation and filtration. This is followed by endothelial-specific 
tissue culture conditions to favour growth of ECs over any contaminating perivascular cells23. 
However, during the characterisation of ECs isolated from different human cadaveric donors, 
Bhardwaj et al. reported donor variation in global gene expression and adhesion molecule 
expression, and discussed the importance of investigating multiple EC donors wherever 
possible to limit the confounding effect of donor-donor variability in studies. EC phenotype 
can be tested in vitro in healthy and pathological conditions, to analyse changes in: 
proliferative potential, barrier properties and wound healing capabilities, in order to improve 
understanding of EC function in vascular diseases such as atherosclerosis, cardiovascular 
disease (CVD) and diabetes.  
ECs show remarkable phenotype heterogeneity in different organs and regions of the body, 
and further phenotype changes can be induced by genetic and environmental factors in both 
health and disease13. By harvesting ‘generic’ ECs from embryonic stem cells and transplanting 
grafts of those ECs into regenerating tissues, Nolan et al. reported ECs acquiring organotypic 
features, providing evidence that ECs within different tissues possess distinct structural, 
phenotypic and functional characteristics41. Microvascular ECs isolated from the retinal 
   




vessels showed upregulation of insulin-like growth factor-1 compared to microvascular ECs 
isolated from choroidal vessels, demonstrating differences between the ECs comprising the 
inner vs. outer blood-retinal-barrier42. In the same study, unsurprisingly HUVECs showed 
enrichment for genes involved in embryological development, and therefore are not a 
suitable substitute for studying ocular disease. In the adult, ECs display enormous phenotypic 
plasticity, due to their exposure to different environments including varied oxygen levels, 
mechanical stresses, growth factors and cytokines, and the active process of maintaining 
tissue-specific EC phenotype is highly regulated43. These data highlight the importance of 
using organ/tissue specific ECs for experimental purposes, but also that ECs showed plasticity 
and, therefore, their phenotype can be influenced by controlling culture conditions to best 
mimic the in vivo-like environment. 
1.4 RETINAL PERICYTES 
1.4.1 FUNCTION AND TISSUE-SPECIFICITY 
Pericytes were first described over 100 years ago by Charles Rouget, as perivascular cells that 
wrap around blood capillaries. Pericytes function by wrapping long finger-like projections 
around the EC layer, with direct contact via gap junctions (GJs) that enable exchange of ions 
and small molecules. They also display peg-and-socket contacts that penetrate the shared 
BM and are secured with adhesion plaques, which connect EC:pericyte cytoplasm, enabling 
transmission of contractile forces44 (Figure 1.11). Unlike smooth muscle cells, pericytes are 
embedded and completely surrounded by the EC BM. Pericytes aid in both structural and cell 
signalling support to the underlying EC, and are involved in regulating vascular permeability 
as well as preventing neovascularisation, helping to maintain normal capillary function45.  
Pericyte coverage is heterogeneous throughout the vasculature, ranging from 1:100 in 
skeletal muscle to 1:1 in the brain and retina46. Similar to ECs, pericytes from the retina differ 
from pericytes in other locations in the body47. The wrapping pattern of pericytes is also 
heterogeneous, and this likely represents functional differentiation according to site-specific 
necessities as opposed to a heterologous subset of pericytes in vivo48. Pericytes from 
different species also demonstrated different responses to in vitro stress conditions such as 
hyperglycaemia and low oxygen, compared to human pericytes49. An example of this is 
bovine retinal pericyte sensitivity to apoptosis in sustained hyperglycaemic conditions 
compared to human pericytes47. These studies promote the importance of using human, 
tissue-specific pericytes to collect more clinically relevant data.  
   














Figure 1.11. EC–pericyte interactions in the retinal capillary 
Pericytes wrap around ECs and share the BM. A direct pericyte–EC contact is established via junctional 
complexes located to peg– socket contacts at sites were the BM is absent. Adhesion plaques connect 
EC:pericyte cytoplasm, enabling transmission of contractile forces, and GJs enable passage of ions and 
small molecules46.  
 
1.4.2 STUDYING PERICYTES IN VITRO 
Pericytes are relatively straightforward to isolate for use in laboratory experiments and have 
been isolated from several species: human, monkey, bovine, rat, and been successfully 
harvested from various tissues: brain, retina, lung, skin and kidney50. Freshly isolated 
pericytes grow from capillary fragments of a mixed population of pericytes and ECs, where 
in preferential culture conditions pericytes eventually become the dominant cell-type. 
Pericytes grow as large, irregular, polymorphic-shaped cells, which elongate and narrow as 
cultures become more confluent. However, Identifying pericytes in vitro is not 
straightforward due to their pluripotent nature and considering there are no definitive 
pericyte-specific markers. However a general panel of markers commonly used includes: 
desmin, platelet derived growth factor receptor-β (PDGFR-β), Neuron-glial antigen-2 (NG2), 
α-smooth muscle actin (αSMA) and Thymocyte differentiation antigen-1 (Thy-1/CD90). 
Nevertheless, pericytes from venules and arterioles express both αSMA and desmin, whereas 
pericytes from capillaries typically do not express αSMA, therefore vessel and tissue-specific 
adjustments to the marker panel need to be considered51. Loss of expression of markers such 
   




as desmin during multiple passaging or prolonged experiments may represent 
dedifferentiation in vitro, due to the pluripotent nature of the cells52.  
There is a lot of research interest surrounding pericyte biology, due to the numerous reports 
of pericyte cell drop-out in microvascular diseases such as DR, tumour-induced angiogenesis 
and age-related macular degeneration (AMD)53–55. To uncover the complicated cell-cell 
interactions between ECs and pericytes in health and pathology and to investigate the cause-
effect relationship, co-culture experiments of ECs and pericytes would provide more valuable 
data than either cell-type grown alone due to the close structural and signalling association 
between pericytes and ECs. 
1.5 THE BLOOD-RETINAL-BARRIER  
1.5.1 STRICTLY REGULATED SEMI-PERMEABLE BARRIER 
Blood vessels provide passage of blood throughout the body to deliver oxygen and nutrients 
via a semi-permeable barrier at the capillary level. The barrier allows passage of nutrients via 
direct diffusion, intercellular clefts, pinocytotic vesicles or cellular fenestrations (Figure 1.9). 
There are 3 major types of capillary bed: continuous, fenestrated and discontinuous, at 
different sites according to local tissue demand (Figure 1.7). The capillaries supplying the 
retina are continuous in structure, therefore only small molecules such as water and ions 
pass through intercellular clefts and lipid soluble molecules can passively diffuse along a 
concentration gradient. ECs in the capillary bed at the retina and in the brain have few 
vesicles and passage of substances from the blood to the tissue is highly controlled56. 
Similarly, the ECs lining the retinal capillaries must ensure the supply of oxygen and nutrients 
to the highly metabolically active neural retina, allow access to circulating cells which survey 
the retina for pathogens or maintain homeostasis, whilst also providing a barrier which 
protects against circulating toxins, pro-inflammatory leukocytes and microorganisms23. This 
highly regulated barrier is called the blood-retinal-barrier (BRB).  
1.5.2 INNER AND OUTER BRB 
The BRB has two components: an outer barrier formed by TJs between the RPE, and an inner 
barrier formed by TJs between ECs lining the inner surface of the retinal capillaries. The 
outer-BRB regulates transport between the choriocapillaris and the retina, whilst the inner-
BRB regulates transport across the retinal capillaries25. The BRB is composed of TJs, GJs and 
adherens junctions (Figure 1.12). Klaassen et al. provide a summary table of molecules 
identified in retinal endothelial junctions (Table 1.1)57. The barrier properties of the inner and 
   




outer BRB means RPE cells and the ECs lining the retinal vessels are impermeable to 
molecules >20,000-30,000Da in size5. Any alteration to the BRB, resulting in increased 
permeability of blood vessels, can lead to the progressive build-up of fluid within the retina, 
resulting in diabetic macular edema (DME), and chronic hyperglycaemia-induced damage to 






Figure 1.12. Junctions which form the inner blood-retinal-barrier 
The inner BRB, formed by GJs, TJs and adherens junctions formed between neighbouring ECs. Major 
molecules of the TJ proteins include zonula occludens (ZO), occludin, claudins and junctional adhesion 
molecules (JAMs), while adherens junction proteins include catenins and vinculins. These junctions 
form interconnections between the actin filaments of the cytoskeleton of neighbouring cells, 







   





Table 1.1. MOLECULES IDENTIFIED IN RETINAL ENDOTHELIAL CELL 
JUNCTIONS  
 
1.5.3 TIGHT JUNCTIONS (TJs) 
Zonula occuldens-1 (ZO-1) is a TJ protein involved in monolayer permeability (Figure 1.12). 
Adherens junction assembly and organisation precedes formation of TJs and in ECs, adherens 
and TJs are intertwined, whereas in epithelial cells TJs are localised apical to the adherens 
junctions59. ZO-1 TJ protein regulates tension by acting on the VE-Cad junction and as well as 
its cell-cell adhesive properties, is also involved in cell migration and angiogenesis of primary 
ECs60. Immunofluorescence (IF) imaging of antibodies against ZO-1 provides qualitative data 
on the presence of TJs, and combined with assessing permeability using dextran and trans-
endothelial electrical resistance (TEER), these simple tests can measure EC barrier function 
in vitro. 
1.5.4 ADHERENS JUNCTIONS 
Vascular endothelial cadherin (VE-Cad) is a vascular endothelial-specific, type II cadherin 
protein of the adherens junction complex, and cadherins represent one of the major cell 
adhesion molecules. Cadherins mediate homophilic cell-cell adhesion via calcium-dependent 
interactions61. As well as its cell-cell adhesive properties, VE-Cad is also involved in 
homeostasis and remodelling via contact inhibition through interfering with VEGFR-2-
stimulated cell proliferation, as well as supporting VEGFR-2-stimulated apoptosis40. One 
study showed that external stimuli from growth factors such as VEGF resulted in VE-Cad 
Category Name Gene name 
Tight Junctions Occludin OCLN 
 Claudin 1 CLDN1 
 Claudin 2 CLDN2 
 Claudin 5 CLDN5 
 Claudin 12 CLDN12 
 F11 receptor (JAM1) F11R 
 Junction adhesion molecule 2 JAM2 
 Junction adhesion molecule 3 JAM3 
 Endothelial cell-specific adhesion molecule ESAM 
 Poliovirus receptor-related 1 (Nectin) PVRL1 
 Tight junction protein 1 (zonula occludens 1) TJP1 
 Tight junction protein 2 (zonula occludens 2) TJP2 
Adherens Junctions VE-Cadherin CDH5 
 β-Catenin CTNNBIP1 
 N-Cadherin CDH2 
Gap Junctions Gap junction protein, alpha 1, 43 kDa GJA1 
   




translocation from the cell surface to the cell cytoplasm therefore disrupting EC barrier 
properties in vitro62. Stimulating ECs with flow in vitro has been extensively explored in order 
to investigate how reduced, increased, or disrupted flow influences EC behaviour, 
considering ECs would be continually stimulated by flow in vivo63. Several studies reported 
flow shear stress-mediated distribution of TJ proteins and a transient decrease or 
redistribution of VE-Cad and occludin protein expression, caused by flow-stimulated changes 
in cell shape and alignment61,64. Therefore, EC expression of VE-Cad is dynamic and can be 
altered due to environmental stimuli such as flow and presence of growth factors.  
1.6 DIABETES 
1.6.1 TYPES OF DIABETES 
Diabetes mellitus is a complex metabolic disorder in which the body no longer produces 
enough insulin, or insulin is no longer effective on target cells. There are two main types: type 
I, which is caused by autoimmune destruction of the insulin secreting β-cells of the pancreas, 
and type II, which is a heterogeneous disorder caused predominantly by lifestyle choice, as 
well as influence from genetic susceptibility, resulting in insulin deficiency and insulin 
resistance over time65. Type II diabetes mellitus (T2DM) accounts for 90% of all diabetes66. 
Another type is gestational diabetes mellitus (GD), which is a hyperglycaemic state first 
recognised during pregnancy, occurring in 1-14% of pregnancies worldwide67. Two of the 
main pathological components driving T2DM; pancreatic β-cell dysfunction and insulin 
resistance, are outlined in Figure 1.13. 
1.6.2 GESTATIONAL DIABETES (GD) 
GD is classified as ‘any degree of glucose intolerance with onset or first recognition during 
pregnancy’, however this does not clarify the difference between undiagnosed diabetes pre-
pregnancy i.e. diabetes in pregnancy (DIP) compared to GD, and the definition remains an 
evolving issue68. Figure 1.14 provides a guide to current acceptable criteria, however risk 
factors, age, ethnicity and socioeconomic status also need to be taken into consideration. 
Offspring from women who had pre-existing diabetes or experienced GD are at increased risk 
of obesity, glucose intolerance, and T2DM in late adolescence and young adulthood69. 
However, in DIP, the mother has already experienced diabetes for some time, resulting in 
progressive changes to maternal cells at a molecular level, before falling pregnant. Therefore 
miscarriage, pre-eclampsia and preterm labour are more common in women with pre-
existing diabetes70. Although the intrauterine environment will present challenges to the 
   




foetus in both DIP and GD, damage already caused by prolonged DIP results in higher risk 
pregnancies, compared to the acute onset of GD. Importantly, these differences between DIP 
and GD explained above, result in different alterations to a population of stem cells called 
endothelial progenitor cells (EPCs: Section 1:10) where EPCs isolated from GD umbilical cord 
blood (UCB) showed resistance to hyperglycaemic insult via decreased p38-MAPK activation, 
whilst EPCs from DIP UCB showed a reduction in colony formation, self-renewal capacity, and 
capillary-like tube formation71,72. As well as exposing clear differences between DIP and GD, 











Figure 1.13. The two main pathological components of T2DM 
Chronic β-cell dysfunction and insulin resistance combined result in the progression of T2DM. This can 
be caused by a complex interaction between lifestyle choice: obesity and physical inactivity, as well as 











     Peripheral insulin 
resistance  
  Hepatic glucose 
output 
   





Figure 1.14. Comparison of diabetes in pregnancy (DIP) and gestational diabetes (GD) 
Current definitions of DIP compared to GD using the 2-hour, 75-g oral glucose tolerance test threshold 
values for diagnosis68.  
 
 
1.6.3 PREVALENCE OF T2DM 
Since 1980, the number of people with diabetes worldwide has quadrupled, particularly in 
low/middle income countries and although the causes are complex, two major risk factors 
are rising trends in obesity and physical inactivity73. The World Health Organisation (WHO) 
reports that 422 million adults are currently living with diabetes, with 1.6 million deaths 
directly attributed to diabetes worldwide each year74. Figure 1.15 provides estimates of the 
projected prevalence of diabetes over the next two decades75. According to the American 
Diabetes Association, In 2015, 9.4% of the population in the USA had diabetes (30.3 million 
people), and 29 million of those had T2DM (95.8%)76. In the UK 1 in 15 people have diabetes, 
not including one million undiagnosed with T2DM66.  
1.6.4 OBESITY AND DIABETES 
Worldwide, 1 in 3 adults are overweight and 1 in 10 are obese77, and the relationship 
between obesity and premature insulin resistance/deficiency, has resulted in the term 
‘diabesity’ in the literature78,79. Being overweight or obese is one of the highest risk factors 
for developing T2DM, along with high blood pressure and high cholesterol, and genetic 
predisposition in 40-80% of cases65,80. Adipose tissue-derived factors known as adipokines, 
are involved in inflammation, mechanical organ protection and thermoregulation, and 
increased visceral deposits of white adipose tissue during obesity places individuals at risk of 
GD 
Typically 24-28 weeks 
Fasting plasma glucose  
5.1−6.9 mmol/L  
or 
1-hour post 75-g oral glucose load  
≥10 mmol/L 
2-hour post 75-g oral glucose load  
8.5–11.0 mmol/L 
DIP 
Any time during pregnancy 
Fasting plasma glucose  
≥7.0mmol/L 
and/or 
2-hour post 75-g oral glucose load 
 ≥11.1 mmol/L  
or 
Random plasma glucose  
≥11.1 mmol/L in the presence of 
diabetes symptoms. 
   




developing insulin resistance, T2DM and cardiovascular disorders81. Taken together, these 









Figure 1.15. Global prevalence of people with diabetes and diabetic retinopathy 
Adults with T2DM set to rise by over 200million (m), from ~415m in 2015 to 642m globally in 2040. DR 
set to remain at roughly 35%, and 11% being sight threatening. The social and economic burden of 
diabetes and its predicted increase is colossal, and along with an ageing population, will place huge 
burdens on healthcare facilities worldwide75.  
 
1.6.5 SOCIAL AND ECONOMIC BURDEN 
The social and economic burden of diabetes is colossal, and increasing each year due to a 
growing ageing population and higher proportion of obesity in modern society. In the UK, 
700 new cases of T2DM are diagnosed each day, which is presenting a huge challenge for the 
NHS to manage82. In the UK, over £14 billion/year is spent on treating diabetes and its 
complications, representing 10% of the NHS budget for England and Wales for 201983. As well 
as the economic burden, the social burden of diabetes needs to be addressed.  
A diagnosis of diabetes can be life changing to patients, who are advised to make major 
dietary and lifestyle adjustments, face the burden of multiple hospital/clinic visits, and come 
face-to-face with the realisation that they are living with a disease that will cause detrimental 
changes to their general health. Metabolic and nutrition-related conditions such as diabetes 
are also associated with neuropsychiatric disorders, through alteration in microbiota-related 
   




metabolites and signalling molecules, and can lead to mental illness, particularly depression 
if not managed correctly84. The devastating effects of unmanaged T2DM can ultimately 
involve limb amputation, with people with T2DM 15 times more likely to undergo an 
amputation85. This is due to multiple complications of T2DM including CVD, nephropathy and 
neuropathy, which in combination can result in wound non-closure, infections and ultimately 
limb amputation. Included in the myriad of cardiovascular issues, DR is the most common 
microvascular complication in T2DM which can ultimately lead to impaired vision or sight 
loss86. Overall, treatment and management of T2DM needs to be addressed urgently to 
provide best quality of life prospects to patients whilst considering the most effective and 
economically viable treatment options. 
1.6.6 DIAGNOSIS 
According to the WHO, diabetes can be diagnosed using the oral glucose or HbA1c testing87,88, 
and diagnostic criteria are outlined in Table 1.2 and Table 1.3 . HbA1c refers to average 
plasma glucose concentration of glycated haemoglobin (A1c).  
 















Oral glucose tolerance 
test 
Non-diabetic* 5.5 mmol/L <7.8 mmol/L 
Prediabetes 5.5 - 7 mmol/L 7.8-11.1mmol/L 
Diabetes > 7 mmol/L >11.1mmol/L 
HbA1c mmol/mol % 
Normal < 42 mmol/mol < 6.0% 
Prediabetes 42 - 47 mmol/mol 6.0% - 6.4% 
Diabetes > 47 mmol/mol > 6.4% 
   




1.6.7 OXIDATIVE STRESS & INFLAMMATION 
With the onset of insulin resistance and deficiency in the pre-diabetic condition, multiple cell 
signalling pathways become altered, due to the systemic hyperglycaemic environment.  In an 
attempt to maintain homeostasis and survive in the new, challenging, high glucose 
environment, ECs become activated. The cellular responses which follow are intrinsically 
linked with the activation of low-grade inflammation in multiple cell types, but in obese 
patients this is amplified by hyperglycaemia-induced adipocytes, which produce Tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and interferon-γ (IFNγ) 
primarily in visceral, and to a lesser extent, subcutaneous depots89. This pro-inflammatory 
switch and dysfunctional glucose metabolism leads to increased mitochondrial reactive 
oxygen species (ROS) production and endoplasmic reticulum (ER) stress. Upon activation 
many immune cells generate free radicals and, in a continuous pathogenic loop, the synthesis 
of ROS promotes an inflammatory status in the surrounding tissue. Cells have endogenous 
antioxidant mechanisms, such as superoxide dismutase (SOD), vitamin A, vitamin C, vitamin 
E and β-carotene, however due to the chronic nature of diabetes, these natural antioxidants 
become exhausted, leading to redox imbalance and further activation of stress-sensitive 
intracellular signalling pathways90–92. 
Unlike skeletal muscle cells, hepatocytes and adipocytes, ECs do not require insulin for 
glucose uptake and, therefore, are a target for glucose-dependent activation of intracellular 
signalling pathways, several of which have been implicated in EC apoptosis and the 
microvascular pathogenesis of T2DM93. Excess glucose increases the amount of ROS 
produced by the electron transfer chain during adenosine triphosphate (ATP) production, 
and this leads to activation of nuclear factor kappa-B (NF-κB) pro-inflammatory pathways and 
caspase-3-induced EC apoptosis94,95. ROS induce the further release of pro-inflammatory 
cytokines and upregulate expression of adhesion molecules and growth factors such as PDGF, 
connective tissue growth factor (CTGF), insulin-like growth factor-I (IGF-I), and vascular cell 
adhesion molecule-1 (VCAM-1), via upregulation of redox-sensitive transcription factors such 
as NF-κB and the NADPH oxidase pathway96. Others have found that subjecting HUVECs to 
intermittent ‘spikes’ of hyperglycaemia in vitro, mimicking the high blood glucose peaks after 
glucose intake during diabetes, resulted in increased intercellular adhesion molecule-1 
(ICAM-1), VCAM-1, endothelial selectin (E-selectin) and IL-6, through oxidative injuries 
induced by high glucose97. Superoxides are one type of ROS produced during the 
dysregulation of the biochemical pathways involved in the electron transport chain, and 
   




increased superoxide induces chronic inflammation by upregulation of chemokines and 
cytokines including IL-1β, ICAM-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), 
placental growth factor (PlGF) and VEGF98,99.  
1.6.8 ADVANCED GLYCATION END PRODUCTS  
As well as the insult caused by ROS, during long term hyperglycaemia and with increased age, 
glucose forms covalent adducts with the plasma proteins through a non-enzymatic glycation, 
resulting in advanced glycation end products (AGEs). AGEs are involved in the disease 
progression of diabetic neuropathy, nephropathy, retinopathy and cardiomyopathy. There is 
evidence that AGEs interact with their plasma membrane localized receptor (RAGE) to alter 
intracellular signalling, gene expression and release of pro-inflammatory molecules and free 
radicals100. Therefore, when investigating the disease progression of diabetes; oxidative 
stress, ROS, inflammation and AGEs add to the myriad of factors which need to be fully 
elucidated and considered when modelling the disease in vitro. 
1.7 DIABETIC RETINOPATHY 
1.7.1 PREVALENCE AND CLINICAL FEATURES OF DR 
DR is the leading cause of vision loss globally in working middle-aged adults101, and in line 
with the rising prevalence of T2DM worldwide, this causes huge economic and psychological 
burden globally. Among diabetic populations, the estimated prevalence of any form of DR is 
34.6% (93 million worldwide), and the prevalence of PDR and DME are 6.96% and 6.81%, 
respectively86. Duration of diabetes is a risk factor for developing DR and DR is present in 60% 
of people 20 years after onset of T2DM; sight-threatening retinopathy is found in 2.0% of 
people who have had diabetes for more than 5 years and in 15.5% of people who have had 
diabetes for more than 15 years102. DR can be divided into two main categories: the earlier 
non-proliferative stage (NPDR) and the advanced proliferative stage (PDR). An additional 
characterisation of DR is the presence of diabetic macular edema (DME), which can occur in 
both NPDR and PDR, and represents the most common cause of vision loss in patients19. 
Clinical features of NPDR include intra-retinal haemorrhages, microaneurysms, intra-retinal 
microvascular abnormalities, and cotton wool spots103. During PDR, new, leaky vessels form, 
leading to more microaneurisms which can begin to affect vision. Some of the clinical 
features of DR are highlighted in Figure 1.16. 
 
 
   














Figure 1.16. Fundus photography for diagnosis of diabetic retinopathy 
Diagram illustrating examples of vascular abnormalities which can be detected using fundus 
photography: abnormal neovascularization, haemorrhages, microaneurysms, and cotton wool spots. 
Untreated, these will eventually lead to vision loss104. 
 
1.7.2 SUSCEPTIBILITY TO OXIDATIVE AND HYPERGLYCAEMIC STRESS 
The retina is the most metabolically active tissue per weight in the body105, therefore, the 
tissue is particularly sensitive to chronic alterations in glucose and oxygen levels. Vascular 
ECs express high levels of the glucose transporter-1 (GLUT-1), rendering them particularly 
sensitive to sustained hyperglycaemic conditions, which accounts for the chronic 
microvascular complications which occur during diabetes100. As well as hyperglycaemia, cells 
of the retina are also insulted with reduced oxygen levels, increased oxidative stress and 
chronic inflammation, caused by a progressive imbalance of various growth factors such as 
VEGF and pigmented epithelium-derived growth factor (PEDF), which can ultimately lead to 
PDR5. The changes involved in retinal vascular decline and the order in which they occur is 
not clearly understood. Further understanding of the progressive decline of cells composing 
the blood vessels during ageing and diabetes will enable preventative and regenerative 
strategies to reduce or prevent vision loss. 
   




1.7.3 CHANGES TO THE VESSEL ARCHITECTURE 
Changes to the architecture of the retinal capillary include: BM thickening, pericyte loss, 
endothelial dysfunction and degeneration, leaky blood vessels and loss of barrier function 
and thus, controlled nutrient exchange. As the capillary bed degenerates, the underlying 
tissue experiences hypoxia due to insufficient oxygen exchange from the bloodstream to the 
surrounding cells. As EC death and BM thickening continues, along with increased production 
of AGEs, BRB breakdown enables water and albumin to pass unregulated into the retinal 
interstitium. This can lead to edema and build-up of exudates in the retinal tissue that adds 
to the decline in visual acuity. The choriocapillaris also incurs progressive degeneration under 
chronic diabetic insult, resulting in thinning of the capillary bed, inflammatory cell invasion 
and microaneurisms, all of which severely disrupt the underlying RPE and photoreceptors, 
further exacerbating sight loss19. As more vessels of the inner and outer-BRB degenerate, 
vessel occlusion leads to tissue ischemia, and over time the area of affected retina becomes 
larger. Vision loss occurs when photoreceptors begin to die, due to the multitude of defects 
described above. 
1.7.4 PERICYTE DROP-OUT 
Many studies report pericyte drop-out as an early phenomenon of DR, but it is not clear if 
this is a cause (or trigger) of disease progression, or a symptom. It is hypothesised that 
pericyte drop-out leaves the ECs more unstable, leading to leaky blood vessels, and the lack 
of pericytes could be part of the advance to PDR. ECs secrete PDGF-B, whilst pericytes express 
the receptor PDGFR-β, and Hammes et al. proved that heterozygous knock-out of PDGF-B in 
mice resulted in 30% reduction in retinal pericyte number compared to wild-type mice and a 
small but significant increase in acellular capillaries and microaneurysms106. In another study, 
Ang-2 was found to be upregulated 30-fold in the diabetic rat retina, and injection of Ang-2 
into healthy retinae caused Ang-2-induced pericyte drop-out in rat retinae, resulting in 
avascular capillaries53, providing evidence that Ang-2/Tie-2 signalling is also involved in 
pericyte loss and vessel destabilisation. Accumulation of AGEs, polyols and other toxic 
compounds by pericytes was confirmed in a streptozotocin-induced model of diabetes in 
rats, where AGEs accumulated first within the shared EC:pericyte BM, and then 
intracellularly, co-localising with cellular AGE-receptors107. Therefore, due to the high 
coverage of pericytes in the retina, there could be a major hyperglycemia-induced build-up 
of AGEs in the retinal vasculature throughout progression of diabetes, driving EC and pericyte 
   




cell dysfunction and death. An outline of the involvement of pericyte drop-out in NPDR 
leading to the progression to PDR is illustrated in Figure 1.1752. 
Pericytes and ECs have different secretomes, and aid one another in maintaining normal 
vascular function. If pericytes are lost early in diabetes, ECs may lose important pro-survival 
signals. Taking this into account, it is important to explore the effects of diabetes in a model 
similar to the in vivo environment, which would be ECs and pericytes in close contact. 
Therefore, an optimised co-culture model of the human retinal microvasculature could 




Figure 1.17. Progression of vascular abnormalities in diabetic retinopathy 
The diabetic milieu causes pericyte drop-out from retinal blood vessels. Loss of pericytes and diabetic 
insult causes EC dysfunction. This leads to NPDR with changes to the vessel architecture including: BM 
thickening, microaneurysms, haemorrhages, and eventually capillary occlusion. This compromises the 
blood flow in the retina and leads to local hypoxia. Hypoxia induces upregulation of angiogenic factors 
such as VEGF. As blood vessels with reduced pericyte coverage are more susceptible to angiogenic 
factors, neovascularization (PDR) is initiated52. 
 
   




1.8 CURRENT TREATMENT 
1.8.1 TREATMENT OF TYPE II DIABETES 
Early detection and lifestyle modification, including diet and exercise management are 
essential to slow disease progression, and aid in preventing sight loss108. According to NICE 
guidelines 2019, an individualised care approach is recommended, in order to account for 
multi-morbidities, individual preferences and circumstances. Systemic drugs to lower 
cholesterol and reduce blood pressure are introduced if a patient remains above NICE 
guideline levels for over 2 months109. Figure 1.18 outlines some of the treatment options for 
T2DM and its complications. Systemic drugs such as metformin are prescribed to manage 
blood glucose levels, and these are taken daily, before meals, and combined with lifestyle 
management have successfully reduced the mean fasting plasma glucose values of T2DM 
patients110. Fenofibrate or simvastatin can be prescribed to lower cholesterol levels and 
improve the cardiovascular health of patients with T2DM111,112.  
Studies have shown a decrease/disruption to the natural enzymatic and non-enzymatic 
antioxidant defence mechanism during diabetes, increasing the risk of cellular injury via free-
radical damage, therefore, there is scope for antioxidant therapy to slow disease 
progression113,114. Antioxidants such as vitamin C and E have long been investigated as 
treatment options for various human diseases and overall improvement to general health 
using animal models115, however long-term human in vivo studies on antioxidants are limited, 
particularly with regards to the effects seen in diabetes. 
1.8.2 CURRENT TREATMENT OF DIABETIC RETINOPATHY 
Everyone over the age of 12 years old with diabetes has their eyes screened annually in the 
UK, using fundus photography116. As cameras and software advance each year, the resolution 
of these images improves and disease can be detected at an earlier stage. Public Health 
England updates the ‘Eye Screening Programme’, in line with current grading definitions for 
referable disease and graders use a feature-based grading form to assess fundus images117. 
Figure 1.16 demonstrates some of the changes occurring in the retinal vasculature during DR, 
which can be detected using fundus photography104. The current treatments for DR are laser 
photocoagulation, anti-VEGF intravitreal agents, intravitreal corticosteroids, and 
vitreoretinal surgery, however, these are only offered at late stage of disease, once 
symptoms have arisen118. All these treatments are expensive, require a vitreoretinal 
specialist and have a number of secondary, or undesirable effects. Other than improvements 
   




to lifestyle and glycaemic control, there remains to be discovered an early stage 










Figure 1.18. Current and future treatments for diabetes and its associated 
complications 
Current treatments (red) and potential treatments (black). Tight control of blood glucose, 
hypertension and cholesterol are for improved systemic health and they should be achieved in all the 
stages of the disease, but they have a crucial role in early prevention of progression119. 
 
1.8.2.1 PAN-RETINAL LASER PHOTOCOAGULATION 
Pan-retinal laser photocoagulation (PRP) involves creating thermal burns across the 
peripheral retina, destroying the retinal tissue, with the overall consequence of improved 
retinal oxygenation. PRP is performed during late-stage PDR, where uncontrolled growth of 
new, ill-formed, leaky vessels puts a patient's sight at risk. PRP is generally implemented to 
target leaky vessels in the periphery of the retina and successfully reduces bleeds, although 
this therapy is inherently destructive17. Due to the importance of the structure of the macula 
to provide central, colour vision and contrast sensitivity, PRP cannot be used in that area, and 
macular laser techniques are instead performed, although the success rate in preventing 
vision loss is reduced to 60-70%120.  
1.8.2.2 ANTI-VEGF INJECTIONS 
The three main anti-VEGF drugs for treatment of sight-threatening DR with associated DME 
are ranibizumab (trade name Lucentis), bevacizumab (Avastin) and aflibercept (Eylea) all of 
which are antibodies against VEGF, but differ in size and structure. Prices range considerably: 
ranibizumab at ~£742/injection vial, aflibercept at ~£816/injection vial and bevacizumab at 
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~£12/injection vial, although bevacizumab is not currently licenced for use in the eye in the 
UK and US and is therefore ‘off label’121. Often patients require 3-7 injections/year (although 
this varies markedly according to disease progression), and so these treatments are hugely 
costly for the NHS122,123. Anti-VEGF therapy is also ineffective for ~50% of people, who are 
unresponsive to treatment124, therefore exploration of new pharmacological interventions is 
required. 
1.8.2.3 CORTICOSTEROID INJECTIONS 
Intravitreal injection of corticosteroids such as triamcinolone have been used off-label and 
have shown beneficial effects on reducing retinal swelling and vascular leakage, and although 
the mechanisms involved are not fully understood, steroids may act indirectly by inhibiting 
inflammatory cells and cytokine function, and directly by inhibiting VEGF, overall reducing 
BRB breakdown and vascular leakage125. However corticosteroids have severe side effects 
and their benefit is limited when compared to anti-VEGF treatment57. Common 
complications of intravitreal injection of corticosteroids include raised intraocular pressure 
and cataract formation, therefore long-term studies need to be implemented on the use of 
corticosteroids in the eye because current data provides mainly 1 year follow up results and 
the long-term use is underreported119. 
1.9 IN VITRO DISEASE MODELLING 
1.9.1 MODELLING DIABETES IN VITRO 
As described previously, diabetes is a multifactorial disease, which leads to hyperglycaemia 
(due to insulin resistance or impaired production), hypoxia, inflammation and oxidative 
stress. The first two are casual, whilst the latter are symptoms of the high glucose, low oxygen 
environment. When investigating cellular responses to diabetes, common in vitro conditions 
include high [D+] glucose, combined with low oxygen. Different groups use various ranges of 
glucose (15-33mM) and oxygen levels (1-5%) to mimic diabetes, often dependent on the 
timeframe of experiments and variation in experimental outputs126,127. This simple high 
glucose, low oxygen model can be developed further by introducing flow to mimic the 
haemodynamic stimulus of circulating blood16,63, or modifying the properties of the surface 
which the cells adhere (i.e. mimicking ECM remodelling and BM thickening)31.  
1.9.2 CURRENT CO-CULTURE MODELS 
In order to explore changes to the vasculature in vitro, studying ECs in isolation, on TC plastic, 
has been the traditional technique. However, this does not take into account the close 
   




structural and functional relationship of ECs and pericytes in vivo. As cell culture techniques 
have vastly improved over time, it is now possible to grow multiple cell-types together in co- 
or tri-cultures on transwell inserts, in order to provide data more relevant to the in vivo 
environment. Microporous membranes, attached to cell culture plate inserts (transwell 
inserts) have been developed over decades by pharmaceuticals companies, in order to offer 
researchers the opportunity to grow cells together (co/tri-culture) to better mimic the in vivo 
anatomy of e.g. blood vessels, kidney nephrons or germ cell production128. Investigating the 
complex cell-cell interactions involved in co-culture systems will improve knowledge of 
disease progression at the multicellular or tissue level129. 
Co-culture models to mimic the blood vessel environment have been developed by several 
groups interested specifically in the pathogenesis of DR62,130–132, which have greatly 
contributed to understanding the physiology of the retinal capillaries in healthy and disease. 
Previous groups have used various combinations of immortalised (cell-line)131,133, animal62,132, 
large vessel130, or non-site-specific cells in co-culture. It is likely these models made use of 
these particular cell-types due to accessibility and unlimited expansion rate. Human primary 
cells can be more challenging to culture, but may be more appropriate as, for example, when 
immortalized vs. primary hepatocyte cell proteome was analysed, many proteins were 
downregulated in the immortalised cell-line134. Such diversity in the currently published in 
vitro BRB models leads to set-ups with different characteristics, which makes the comparison 
of results difficult135. Similarly, it is well documented that the retina is particularly sensitive 
to changes in blood glucose and oxygen levels, due to its high metabolic demand104, 
therefore, using human, primary cells from the retinal microvasculature would provide data 
that are species and tissue-specific.  
As well as selection of appropriate cell-types, the appropriate layout of the co-culture model 
and timescale of experiments needs to be considered. Models can be: mono/co/tri-cultures, 
contact, non-contact, conditioned medium, shared medium etc., as demonstrated in the 
schematic (Figure 1.19). In order to successfully grow different cell types together in one 
system, conditioned medium is often used, subjecting cells on either side of the membrane 
to different growth conditions131,133. Considering DR is a progressive disease and patients 
often present at late stage, it is therefore, important to develop long-term in vitro studies, 
rather than the short time points often used in co-culture studies, such as 8-48H. Developing 
a 21 day experimental timeframe, with multiple data collection points and repeated 
measures would enable monitoring of cell behaviour and proteins of interest over time. 
   




These long-term, multiple time point, co-culture model data would fill a gap in the literature, 











Figure 1.19. Examples of experimental set-up of various mono/co/tri-culture models 
Cells were seeded on 24 w/p, polyethylene terephthalate (PET) transwell inserts with 1µm pores. Cells 
were seeded on either side of the PET membranes, according to the different model configurations 
(A-E).  (A) hREC monoculture, (B) hRP monoculture, (C) contact co-culture, (D) non-contact co-culture 
and (E) tri-culture. Spatial aspects of cell seeding are dependent on the most appropriate organisation 
to mimic the tissue. For the retinal capillaries, hREC and hRP are in contact through a shared BM, 
therefore the contact co-culture (C) is most appropriate. If considering the effect of astrocytes, option 
(E) would be appropriate. Monocultures enable study of individual cell-types as controls. (D) Non-
contact co-culture model allows investigation of the paracrine effect of each cell-type without physical 
contact. 
 
1.9.3 BARRIER TESTING 
When analysing BRB models, it is important to study the barrier function of the ECs, in order 
to confirm they behave in a similar way to a continuous type capillary in vivo. Barrier function 
can be analysed using simple functional assays. Trans-endothelial electric resistance (TEER) 
measures the integrity of TJ dynamics in cell culture models of EC layers. TEER is a strong 
indicator of the integrity of cell-cell barriers and because measurements can be performed 
in real-time without cell damage, TEER is often assessed before models are evaluated for 
transport of drugs or chemicals136. Dextran permeability assesses the ability of solutes of a 
particular size to escape through the endothelial layer, considering that selectively 
   




permeable mature capillaries are known to be impermeable to dextrans over a molecular 
weight of 65 kDa137. TJ and adherens junction expression can be assessed using 
immunofluorescence (IF) labelling of ZO-1 and VE-cadherin proteins, where a functional 
barrier can be confirmed by continuous expression of junctional proteins at cell-cell borders. 
1.10 ENDOTHELIAL PROGENITOR CELLS 
1.10.1 HISTORY AND DISCOVERY 
For normal maintenance and repair of adult vasculature, ECs need to be available for 
recruitment to sites of wear and tear and injury. Therefore, it has been postulated that there 
may be a source of stem cells involved in adult angiogenesis. Following the hypothesis that 
adult peripheral blood (APB) may contain progenitor cells that can become endothelial upon 
stimulation, a population of cells with vasoreparative capabilities was first reported in 1997 
by Asahara et al.138. This groundbreaking study described a CD34 positive subset of putative 
endothelial progenitor cells (EPCs) which were isolated from human APB, offering the 
potential of autologous cell therapy for blood vessel repair in adulthood. Over 20 years later 
these putative EPCs have been investigated by hundreds of researchers, with over 10,766 
papers under the search term ‘endothelial progenitor cell’ in PubMed as of April 2019.  
Initially, these cells were called EPCs and as the name suggests, were defined as early stage 
ECs, with higher reparative capabilities than their mature endothelial counterpart139. 
Extensive research has been undertaken to characterise these cells and test their ability to 
repair vessels damaged by numerous acute and chronic conditions, including; diabetes, 
retinopathy, peripheral arterial disease, ischemic heart disease and wound healing140.  
The source of EPCs has been debated, questioning if they are resident in the blood vessel 
wall, or are released from a bone marrow niche. In a study where bone marrow recipient 
blood was analysed, it was reported that donor genotype was detected in late outgrowth, 
highly proliferative EC populations, which suggests bone marrow may have an enriched 
population of EPCs, compared to APB141. Using whole animal tritiated thymidine labelling, 
researchers discovered that EPCs are not uniformly distributed throughout the vasculature, 
and are higher in number at areas were endothelial turnover is higher, to meet repair 
demand142. EPCs have been isolated from various sites in the body including adipose tissue, 
foetal liver tissue and adult bone marrow, and their organ-specific vasoreparative capability 
has been assessed in order to address organ-specific diseases140,143.  
   




It has been widely reported and is universally accepted that more EPCs can be isolated from 
same volume of umbilical cord blood (UCB) compared to APB, and also that UCB-EPCs possess 
a much higher proliferative capacity than APB-EPCs144. In fact, Ingram et al. reported a 
complete hierarchy of EPCs from APB and UCB, suggesting a heterogeneous population of 
cells involved in EC repair. In order to clarify many contradictory reports from different 
groups, using different criteria to identify EPCs, several recent reviews have focused on 
outlining more specific EPC markers and rigorous standards for their in vitro expansion and 
functional testing145,146. Efforts in this area should reduce ambiguity when assessing the use 
of EPCs for human cell therapy in the future. 
1.10.2 CURRENT DEFINITION OF ENDOTHELIAL COLONY FORMING CELLS (ECFCs)  
The first report of EPCs used cell surface markers for identifying desired cells, and defined 
the EPC population as: CD34, VEGFR-2, Tie-2 and CD31 positive cells, although these were 
not CD45 negative, suggesting they were possibly a heterogeneous population of 
progenitors, some of which had a haematopoietic lineage138. Various techniques have been 
described to isolate EPCs from blood. All include collecting blood and separating and 
collecting the mononuclear layer using fractionation techniques, but some of the many 
differences include the use of collagen I coated plates, fibronectin coated plates, re-plating 
non-adherent cells, disposing of non-adherent cells, culturing for 7 days or culturing for over 
21 days, or collecting ‘early outgrowth’ or ‘late outgrowth’ endothelial populations. In 2003, 
Hill et al. attributed the level of circulating EPCs to cardiovascular risk, and from this study, 
rather than using the earlier ambiguous cell surface markers to identify EPCs, a new assay 
called the colony forming unit-Hill (CFU-Hill) assay was developed to assess the colony 
forming capabilities of putative EPCs expanded in vitro147. EPCs were also reported to have a 
hierarchy based on their clonogenic and proliferative potential, comparing APB- and UCB-
derived EPCs148.  
Concise reviews of the different and evolving techniques to isolate and identify EPCs over 
time has been provided by Ingram et al. and more recently by Yoder149,150. It is now 
recognised that in early studies, researchers described cells isolated from blood as EPCs, 
when in fact a heterogeneous population of haematopoietic stem cells as well as putative 
EPCs were present, and recent advances in monoclonal antibody specificity and flow 
cytometry have now enabled a much more stringent characterisation of these putative 
EPCs150. Therefore, over time, the requirements to specify EPCs from contaminating cells of 
a haematopoietic lineage have evolved151.  
   




1.10.2.1 MYELOID ANGIOGENIC CELLS (MACs) AND ENDOTHELIAL COLONY FORMING 
CELLS (ECFCs) 
Shortly after their discovery in 1997, two distinct populations were recognised when EPCs 
were expanded in vitro: a population which appeared early (less than 7 days), called early 
EPCs, and a population which appeared late (2-4 weeks) called late EPCs or outgrowth 
endothelial cells152,153. In vitro testing of the two sub-populations found the early EPCs were 
of haematopoietic lineage, did not directly incorporate into damaged vasculature, and were 
involved in releasing paracrine signalling to encourage the outgrowth population to migrate 
to sites of vascular damage, where the outgrowth EPCs physically incorporated into the 
endothelial layer154. In line with improvements in flow cytometry, clonogenic assaying and 
genetic phenotyping, a very recent review by Medina et al. provided clarification on the 
correct nomenclature regarding the two distinct cell-types present during in vitro expansion 
of the mononuclear fraction of human blood; myeloid angiogenic cells (MACs) and 
endothelial colony forming cells (ECFCs; outlined in Figure 1.20)155. In the review, they explain 
the term EPC is now outdated and is too vague, and therefore to avoid confusion should no 
longer be used. This paper was published in a collaboration between three major research 
groups involved in EPC research, highlighting the recent combined efforts to standardise 
nomenclature and identification of cells isolated from the mononuclear fraction of human 
blood. Therefore, following guidelines from Medina et al., ECFCs are defined as CD34 
positive/negative, CD31, CD105, and CD146 positive, CD90 negative to confirm they are not 
fibroblastic, and importantly CD45 and CD14 negative to distinguish them from a 
haematopoietic lineage. ECFCs appear late in culture (14 days onwards), compared to MACs, 
which appear early in culture and play an important role in paracrine signalling during 








   















Figure 1.20. Two distinct groups of EPCs according to phenotypic lineage 
Nomenclature and minimal criteria for defining MACs (haematopoietic) and ECFCs (endothelial), based 
on immunophenotype, and function, assessed as a potency assay. Abbreviations: BOECs=blood 
outgrowth endothelial cells, CAC= circulating angiogenic cells, CFU=colony forming unit, 
ECFCs=endothelial colony forming cells, EOCs=endothelial outgrowth cells, EPC=endothelial 
progenitor cell, MACs=myeloid angiogenic cells, PACs=pro-angiogenic hematopoietic cells155.  
 
1.10.3 ECFCs IN VASCULAR DISEASE 
Normal steady-state endothelial turnover is relatively slow, however, in response to injury, 
EC proliferation rates increase and it is postulated that tissue or vascular wall resident ECFCs 
may contribute to vascular repair142. ECFCs could be a useful tool to repopulate damaged 
vasculature and ischemic tissues, however, the number and/or function of ECFCs has been 
reported to be reduced in chronic disease states such as diabetes and CVD139,156,157. EPC 
number has been assessed in various stages of CVD, and have been reported as increased in 
the early phase of acute myocardial infarction158, whilst both circulating and bone marrow-
derived EPCs were reduced in patients with chronic ischemic heart disease159, and more CVD 
EPC studies are summarised in a review by Shantsila et al.139. This review highlights the 
hypothesis that ECFCs are highly dynamic, and respond acutely to environmental changes. 
This means that depending on disease stage it is very difficult to fully understand the role of 
   




ECFCs in tissue-specific responses to different diseases. The aforementioned studies highlight 
that, similar to the debate surrounding identification of ECFCs, number and function of ECFCs 
during disease is also yet to be definitively determined.  
1.10.4 ECFCs AS A CELL THERAPY 
In order to be useful in human cell therapy, ECFCs isolated from either APB or UCB could be 
used. APB-ECFCs are easily obtainable from simple venipuncture blood samples, providing an 
autologous cell therapy. However, as previously mentioned (Section 1.10.1), APB-ECFCs have 
lower proliferative potential than UCB-sourced ECFCs. UCB-ECFCs could also be utilised and 
easily expanded in vitro due to their higher proliferative potential144, although they would 
have to be recipient HLA matched. Several small-scale phase 1 trials transplanting EPCs from 
peripheral blood and bone marrow into patients to treat acute myocardial infarction and 
severe ischemic legs, provided preliminary evidence of feasibility and safety139. Due to the 
limited therapeutic options for severe heart failure, bone marrow mononuclear cells and 
umbilical cord derived mesenchymal stem cells have been used to treat ischemic 
cardiomyopathy, acute myocardial infarction and non-ischemic cardiomyopathy, although 
their efficacy remains controversial mainly due to the design of the clinical trials and the need 
to standardise cell isolation techniques160. Due to their superior proliferative potential, UCB-
ECFCs could be more useful for engineering of vascularised tissue grafts, and to aid in 
triggering neovascular events in ischemic disease145. ECFCs have also been investigated for 
tumour targeting, via adenoviral-mediated EPC delivery of soluble CD115, which suppressed 
growth of prostate tumours in vitro, taking advantage of ECFC ability to migrate to areas of 
ischemia and responsiveness to viral manipulation161. ECFCs have also been investigated in 
tissue engineering, to repair large skin defects, and the highly hypoxic environment of a 
wound is a major driving force for activating ECFC migration and growth factor cross-talk in 
vitro162. Irrespective of which disease ECFCs may be useful to treat, in order for ECFCs to be 
useful in human trials, their in vitro expansion must be xeno-free and compliant with GMP 
standards163. This has been achieved, during a large scale, animal protein free, humanised 
expansion techniques described by Schallmoser et al., suggesting translation to human trials 
is possible, although xeno-free cultures are not always used during in vitro studies due to the 
cost implications164.  
1.10.5 ECFCs FOR CELL THERAPY IN DIABETIC RETINOPATHY 
The progression of DR involves alteration to a plethora of growth factors, cytokines and 
chemokines, induced by chronic hyperglycaemia, leading to EC and pericyte dysfunction, cell 
   




loss, loss of BRB integrity, increased permeability and eventually leaky blood vessels. 
Capillary repair via an exogenous source of endothelial stem cells delivered to the retina via 
intravitreal injection, may offer a cell-based therapy to repopulate the depleted retinal 
vasculature in DR. ECFCs are a good candidate, due to the ability to isolate them in sufficient 
numbers from UCB and healthy APB165, their high proliferative potential during in vitro 
expansion149, and their ability to withstand oxidative stress, through high intrinsic expression 
of SOD-2166. This idea of ECFC cell-based therapy has been explored in in vitro and animal 
models of various aspects of CVD, wound healing and DR140,167.  
Focusing on ECFC cell-therapy targeted specifically for treating DR, Stitt, Medina and 
colleagues have published techniques for isolation and characterisation of ECFC populations 
from human UCB and APB, and recently clarified the correct nomenclature in an attempt to 
standardise ECFC use with the aim of progressing along the translational pipeline to human 
trials153,155,157,168,169. Using an oxygen-induced retinopathy (OIR) mouse model170, an 
ischaemic hindlimb mouse model171, and rigorous individual cell analysis, scratch wound and 
incorporation experiments172, this group has produced robust data which strongly imply 
ECFCs are an appealing candidate for treating early stage DR.  Currently, rat tail collagen I 
coated plates are used to isolate and expand ECFCs from the heterogeneous population of 
cells in the mononuclear layer of blood, as well as fetal bovine serum (FBS) as a source of 
growth factors during cell culture153,173. However, in order to move ECFC cell-therapy to a 
translational stage, xeno-free or GMP-compliant culture conditions must be developed163. 
Production of ECM-like synthetic or modified culture surfaces may provide the solution. 
1.11 POLY-ε-LYSINE (pεK) HYDROGEL APPLICATIONS 
1.11.1 pεK POLYMER 
Poly-ε-lysine (pεK) is a naturally occurring biomaterial that is biodegradable, edible, water 
soluble and non-toxic to humans and the environment. pεK is a cationic homopolyamide 
made of lysine, formed by amide linkage between ε-amino and α-carboxyl groups (Figure 
1.21)174. pεK was fortuitously discovered as an ECM produced by filamentous bacterium 
Streptomyces albulus ssp. Lysinopolymerus strain 346 over 3 decades ago175, and has more 
recently been found to be secreted by various Streptomycetaceae bacteria and a few 
filamentous fungi176. Apart from its predominant use as a preservative in the food industry, 
derivatives of pεK are used in a wide range of applications including as: emulsifying agents, 
dietary agents, biodegradable fibres, drug carriers, anticancer agent enhancer, biochip 
coatings and hydrogels177. 
   










Figure 1.21. Outline of the chemical structure of poly-ε-lysine (pεK) 
 
 
1.11.2 pεK HYDROGELS 
Natural hydrogels are receiving attention as cell culture substrates and scaffolds, due to their 
mimicry of the in vivo ECM composition, inherent biocompatibility and cell adhesiveness and 
because they possess specific amino acid domains that are recognised by cells178. Peptide 
hydrogels can be synthesised using pεK and cast into gels with handleability and transparency 
properties similar to contact lenses, when cross-linked with carboxylic acids using 
carbodiimide chemistry (Figure 1.22, Figure 1.23). The mechanical properties of each gel can 
be tailored by changing the bis-carboxylic acid (length of carbon chain), density of pεK and 
the % of cross-linking. Free amine groups allow attachment of bioactive molecules to alter 
the surface properties of the gel for purposes such as drug carrying, antimicrobial properties 
and cell attachment (Figure 1.21, Figure 1.23). During gel production, aqueous synthesis 
allows creation of a porous gel for cell growth, or encapsulation of cells and bioactive 








   











Figure 1.22. Chemistry used for producing pεK 
Outline of chemistry used to form an amide bond between pεK and bis-carboxylic acids, using 
an 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (ECDI) and N-hydroxysuccinimide (NHS)-












Figure 1.23. Structure of pεK hydrogels cross-linked with carboxylic acid 
Outline of pεK cross-linking using carboxylic acids of different chain lengths, where free amine groups 
react with the carboxylic acid, using EDCI and NHS, via  carbodiimide chemistry (red circles). The 




   




1.11.3 PEPTIDE MODIFICATION OF HYDROGELS 
The arginine-glycine-aspartic acid (RGD) cell adhesion sequence was discovered in 
fibronectin in 1984180. The RGD motif is not restricted to fibronectin, because it occurs within 
more than 100 proteins, although its function as a cell adhesion motif is sometimes silent181. 
The RGD sequence is the cell attachment site for a large number of adhesive ECM, blood, and 
cell surface proteins, and nearly half of the known integrins recognize this sequence in their 
adhesion protein ligands182. Following this discovery, numerous materials have been RGD-
functionalised to enhance cell adhesion to otherwise non-adherent surfaces. Traditionally, 
biomedical devices were coated in proteins such as fibronectin, laminin or collagen, but these 
had several disadvantages: the proteins have to be isolated from organisms and purified, 
they may elicit undesirable immune responses, they can be continuously degraded, and may 
not have proper orientation to elicit cell adhesion. In addition, the properties of the surface, 
determined by topography, charge and wettability, may influence the orientation or 
conformation of the protein183. Using a small immobilised peptide such as RGD for cell 
attachment to biomaterials, rather than full length proteins, diminishes all of the 
aforementioned issues. The coverage and availability of RGD on any material is an important 
consideration, and ≥1 pmol/mm2 RGD enabled, for example, human primary saphenous vein 
cells to establish focal adhesion on RGD modified PET, compared to cells on unmodified 
PET184. Due to the free amine group on pεK hydrogels, RGD can be covalently bound to the 
surface, with the aim of improving cell adhesion (Figure 1.24). 
1.11.4 pεK FOR STEM CELL EXPANSION 
To date, expansion of ECFCs has been optimised using rat tail collagen I coated TC 
plastic153,173, however there has been minimal focus on the potential influence of the 
substrate on experimental outcomes, or the fate of the pluripotent nature of the cells129. In 
a study focusing on EPCs as a cell therapy for endothelialising small-diameter vascular grafts 
to repair areas of the vasculature damaged by atherosclerosis, PEG–peptide grafted 
poly(ethylene glycol) diacrylate (PEGDA) hydrogels were assessed for their ability to support 
adherence and expansion of ECFCs185. Unmodified gels did not support ECFC adherence, only 
PEG–REDV, PEG–YIGSRG or PEG–RGDS grafted hydrogels enabled ECFC adhesion, although 
this study did provide important information on ECFC-specific rolling adhesion. It is well 
known that biomaterial surfaces directly influence cell attachment, proliferation, phenotype 
and interaction with the immediate microenvironment186. Therefore, when aiming to expand 
   




ECFCs for multiple passages in order to expand numbers for autologous or allogeneic cell 















Figure 1.24 RGD binding to free amine group on pεK hydrogel 
RGD can bind covalently to the free amine groups available on the surface of the crosslinked pεK gels 
(blue circles). The RGD motif improves cell attachment via integrin binding. 
 
 
1.11.5 pεK IN THE EYE 
In a review focusing on biomaterials for ocular transplantation, Lace et al. give a concise 
description of different types of synthetic materials which have been tested for their 
suitability to delivery cells to the retina187. However, it is clear that the focus in this area has 
been replenishing the specialised cells composing the neural retina and not the retinal 
microvasculature itself. Biomaterial production and optimisation to deliver cells to the inner 
BRB to repopulate damaged vasculature remains a major area for development. pεK gels are 
suitable candidates for delivery of cells to the back of the eye, due to their transparency, non-
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toxicity and high water content, which ensures excellent oxygen transmission to any 
underlying tissues188. pεK contact lenses have been investigated for their antimicrobial 
properties in the cornea, and a study by Gallagher et al. showed the pεK gels supported 
growth of human corneal epithelial cell line (HCE-T cells) for up to 8 days in vitro, with no 
significant differences in scratch wound closure, compared to TC plastic. The HCE-T cells 
formed ZO-1 junctions  with neighbouring cells, suggesting the pεK gel surface is suitable for 
epithelial cells to form a functional barrier179. As well as casting the gel into lenses, pεK can 
be formed into microparticles via emulsification polymerisation, providing microparticles 
ranging in diameter from 1000µm to <150µm189. Potentially, these microparticles could be 
loaded with cells and delivered to the back of the eye via intravitreal injection, although they 









   




2 CHAPTER 2 
Developing a primary co-culture model of the human retinal 
microvasculature for use in the development of regenerative medicine 
strategies for diabetic retinopathy 
2.1 OVERVIEW 
To investigate the effect of diabetes on the retinal capillaries, co-culture models of ECs and 
pericytes grown together can be used to examine changes in cell behaviour. Considering their 
close interaction in vivo, through a shared BM, these two cell-types have major structural 
and paracrine influence on one another. Current co-culture models investigating the retinal 
capillaries use either non-human, immortalised, or large vessel ECs. This chapter focuses on 
optimising a human, retina-specific co-culture model using human retinal microvascular 
endothelial cells (hREC) and  human retinal pericytes (hRP) grown together on either side of 
polyethylene terephthalate (PET) membranes, for an extended period of time (21days). High 
glucose and low oxygen were used to induce a diabetic phenotype, and cell phenotype, 
proliferation, metabolic activity, protein expression and angiogenic protein secretion were 
analysed. 
 
2.2 AIMS & OBJECTIVES 
To develop a novel, human, primary, co-culture model of the retinal vasculature to 
mimic diabetic retinopathy in vitro 
1. Grow and characterise hREC and hRP in mono- and co-cultures in optimised 
physiologically healthy or diabetic conditions 
2. Explore changes in cell behaviour and protein secretion in healthy compared to 
diabetic conditions 
3. Explore differences in cell behaviour and protein secretion when cells are grown as 
monoculture compared to co-culture models  
 
 
   





2.3.1 hREC CULTURE 
Human retinal microvascular ECs (hREC) were purchased from Cell systems (Cell Systems, 
ACBRI 181V). Cells arrived at passage 3 (P3) and were used in experiments up to P10. hREC 
were cultured in PromoCell MV medium (PromoCell, C22020), containing 5% fetal bovine 
serum (FBS), further supplemented with heat inactivated FBS (Labtech, batch 013BS145)  to 
final concentration of 10%. Cells were cultured in a T75 flask (Greiner, 658-175) with fresh 
media supplied every 48 hours (H). hREC were sub-cultured at ~90% confluency. A full T75 
flask provided approximately 5-6x106 cells. 
2.3.2 hRP CULTURE 
Human retinal pericytes (hRP) were purchased from Cell Systems (Cell Systems, ACBRI 183V). 
Cells arrived at P3 and were used in experiments at up to P10. hRP were cultured in DMEM 
(Life Technologies, 11966-025) supplemented with 1mM sodium pyruvate (Life Technologies, 
11360-070), physiological (5.5mM) [D+] glucose (Life Technologies, A24940-01) and 10% FBS. 
Cells were cultured in a T75 flask with fresh media supplied every 3 days. Allowing cells to 
become >70% confluence initiated a phenotypic switch to larger, more elongated cells, so to 
avoid cells transitioning, hRP were sub-cultured at 70-80% confluency. At ~70% confluence, 
a T75 flask provided approximately 3-4x106 cells. Using light microscopy, cell shape, size and 
number were monitored regularly to ensure cells did not transition during cell culture, over 
time. At each passage, images were obtained and compared to earlier passage cells. 
2.3.3 SUB-CULTURING hREC AND hRP 
Once flasks reached appropriate confluence, culture medium was removed and cells were 
washed with warmed Dulbecco’s phosphate buffered saline (dPBS) (Sigma, D8537). dPBS was 
removed and 1X Trypsin-EDTA (Sigma, T4174) was added and incubated at 37°C with cells 
for 2-4 minutes (mins) or until >90% of the cells had detached. Complete medium was added 
at double the volume of trypsin, to neutralise the action of the trypsin. Cells suspended in 
media were spun in a centrifuge at 400xg for 5 mins to form a pellet. For further sub-culture 
flasks were split 1:3, or for seeding at specific densities, a haemocytometer was used to count 
cells.  
For freezing, cell pellets were re-suspended in 900µl FBS and 100µl of Dimethyl sulfoxide 
(DMSO) (Sigma, D2650) in a 1.8ml cryovial (STARLAB, E3090-6222) and transferred into -80°C 
in a Mr. Frosty (ThermoFisher, 5100-0001) containing isopropanol, for freezing at a rate of -
   




1°C/minute. For long term storage, cells were transferred to liquid nitrogen. To bring cells 
out of liquid nitrogen, vials were defrosted quickly at 37°C in a water bath over 2-4 mins. The 
defrosted cell suspension was dispersed into a T75 flask of warmed complete medium and 
left to adhere overnight. The next morning medium was completely changed to remove 
remnants of DMSO from the culture flask.   
2.3.4 IMMUNOFLUORESCENCE IMAGING 
Using human primary cells requires regular testing to ensure cell phenotype remains 
consistent throughout passaging. To do this, immunofluorescence (IF) imaging of 
fluorescently labelled antibodies against phenotype-specific proteins and receptors was 
carried out on hRP and hREC at different passages. Cells were washed 3x 5 mins in warm 
dPBS to remove remnants of cell culture medium. dPBS was removed and, working inside a 
fume hood, 10% neutral buffered formalin (NBF) (Sigma, HT501128) was added for 9 mins, 
at room temperature (RT) on a slow rocking platform. NBF was removed and cells were 
washed 3x 5 mins in dPBS. 0.5% Triton-X (Sigma, 45H0481) in dPBS was added for 4 mins at 
RT on a rocker, to permeabilise the cells. Cells were then washed 3x 5 mins with dPBS. 5% 
normal goat serum (NGS) (Sigma, G9023) in dPBS was added to cells for 1H, at RT on a rocker, 
to block non-specific binding sites. NGS was removed and primary antibodies, diluted to 
optimised working concentration in dPBS (Table 2.1), were added to cells and left on a slow 
rocking platform overnight at 4°C. 3x 5 min 0.1% Tween-20 (Sigma, P1379) in dPBS (wash 
buffer), at RT on a rocker removed any unbound primary antibody. 
Secondary antibodies (Table 2.2), were added at 5µg/ml in dPBS for 45 mins at RT on a slow 
rocking platform, in the dark. Cells were washed 3x 5 mins in wash buffer at RT, in the dark, 
on a rocking platform, to remove any unbound secondary antibody. 300 nM 4′,6-diamidino-
2-phenylindole (DAPI) (Life Technologies, D3571) in dPBS was added for 20 mins at RT on a 
slow rocking platform. 1x 5 min wash with wash buffer removed any unbound DAPI. 1x 5 min 
dPBS wash removed any remnants of Tween-20. 1x 2 min double-distilled water (ddH₂O) 
wash removed any salt crystals from the cells. When using the 8-well EZ- glass slides (MERCK, 
PEZGS0816), the plastic frame clips were removed and 1 drop of mounting media (Agilent, 
S3023) was added to each well, and a 22x50mm glass cover slip (ThermoFisher Scientific, 
BB02200500AC13MNT0) gently placed on top. Mounting media was left to set at RT, in the 
dark for 45 mins before imaging. 
 
 
   













Primary Antibody hRP Species Code Concentration 




















Primary Antibody hREC Species Code Concentration 























Conjugated Phallotoxin    





Secondary Antibody Species Conjugate Code Concentration 
Goat anti- Rabbit 488 Invitrogen A11008 5µg/ml 
Goat anti- Mouse 488 Invitrogen A11029 5µg/ml 
Goat anti- Rabbit 594 Invitrogen A11012 5µg/ml 
Goat anti- Mouse 594 Invitrogen A11005 5µg/ml 
Goat anti- Rabbit 647 Invitrogen A21244 5µg/ml 
Goat anti- Mouse 647 Invitrogen A21235 5µg/ml 
   




2.3.5 FLOW CYTOMETRY  
Flow cytometry was performed to explore the different cell surface receptors expressed by 
hRP and hREC. A panel of cell-surface antigens was selected to distinguish EPCs from mature 
ECs or cells of haematopoietic origin153. Cells from T75 flasks were trypsinised (See section 
2.3.3), neutralised using double the amount of complete media, and then spun at 1,200RPM 
for 8 mins. The cell pellet was re-suspended in 1ml of warmed Fluorescence-activated cell 
sorting (FACS) buffer (dPBS + 1% FBS) for counting using a haemocytometer. 1x105 cells/tube 
were re-suspended into 1.5ml Eppendorf tubes (Starstedt, 72.690.001) in a total volume of 
100µl FACS buffer. Fluorescent conjugated antibodies against 7 proteins of interest and 3 
Isotype controls (Table 2.3) were added at 5µl/tube, or 6µl/tube for CD34. Tubes were 
agitated for 5 seconds using a vortex on high speed, to consistently mix cells into solution 
with the conjugated antibodies. Cells were incubated with antibodies at 4°C in the dark for 
30 mins. FACS buffer was added at 500µl/tube to wash the cells of excess antibody and tubes 
were spun at 400RCF for 8 mins. Supernatant was gently removed, avoiding disturbing the 
cell pellet. 300µl FACS buffer was added and each tube was mixed thoroughly by pipetting 
up and down several times, to disperse cell pellet. Before sampling in the flow cytometer, 
the contents of each tube was thoroughly mixed again using a high speed vortex. 
Flow Cytometry was performed using a BD Accuri 6 machine and Accuri C6 software. 
Parameters for running flow were 1x104 events, on slow fluidics. Un-labelled cells were used 
to exclude dead cells/cell debris by gating the population of interest, and all samples were 
measured against corresponding fluorescent IgG controls for fluorescein isothiocyanate 
(FITC), phycoerythrin (PE) and allophycocyanin (APC). Steric hindrance was first checked if 
two antibodies were analysed in the same sample. Results were reported as % of cells 








   




Table 2.3. CONJUGATED PRIMARY ANTIBODIES FOR FLOW CYTOMETRY  
 
2.3.6 GROWTH CURVES  
To determine the growth rates of hREC and hRP, growth curves were set up for 21 days. Cells 
were seeded at 5x103, 1x104, 2x104 and 4x104 cells/well on 24 well plates (w/p) (Corning, 
3524) , to determine the effect of seeding density and time on cell growth rate. At day 1, 3, 
5, 7, 14 and 21 cells were washed and fixed in 10% NBF, permeabilised using 0.5% Triton-X 
and DAPI stained, and washed in preparation for microscopy (See section 2.3.4). To calculate 
an average cell number for each well, 5 images/well were captured at x10 magnification; 
centre, bottom, top, left and right, using the Nikon E-Ti fluorescent microscope. These 
coordinates were programmed into the Nikon E-Ti NIS Elements AR4.51.01 software to 
enable consistent imaging of each well across plates. Using ImageJ 1.51K software, a macro 
was recorded to enable automated counting of DAPI stained cell nuclei in each image (Figure 
2.1). In brief, using ImageJ software the raw image was set to auto threshold, using ‘Li’. The 
image was then inverted to black particles on white background, and black nuclei were 
counted using the ‘analyse particles’ option with size set to 50-800, to prevent any debris 
being counted as false positives. An average cell number/well was calculated using Prism 6 
software, followed by average cells/cm2, using cell count divided by the area of the image. 






Primary antibody Conjugate Supplier/Code Volume 
IgG 1 kappa FITC Fisher Scientific, 15104218 5µl 
IgG 1 kappa PE Fisher Scientific, 12611959 5µl 
IgG 1 kappa APC Fisher Scientific, 12642059 5µl 
CD34 FITC Fisher Scientific, 12372223 6µl 
CD31 APC Fisher Scientific, 15577906 5µl 
CD146 PE Fisher Scientific, 15546896 5µl 
CD14 APC Fisher Scientific, 15517886 5µl 
CD45 FITC Fisher Scientific, 15556406 5µl 
CD105 PE Fisher Scientific, 15576846 5µl 
CD90 APC Fisher Scientific,17090942 5µl 
   
















Figure 2.1. Automated cell counting 
Screenshots of the process of writing a macro using ImageJ, to run automated cell counting. Images 
from 5 consistent points/well were taken using a Nikon E-Ti fluorescent microscope, and images were 
processed using ImageJ 1.51K software. 
 
 
2.3.7 HEALTHY AND DIABETIC CONDITIONS 
For all experiments, healthy conditions were defined as media containing 5.5mM glucose, 
and incubators set to 37°C, atmospheric oxygen (20%) and 5% CO₂. In order to optimise 
culture conditions to mimic healthy and diabetic glucose ranges, hRP were grown in 0-35mM 
[D+] glucose over 14 days, with 35mM mannitol included as an osmotic control. Diabetic 
conditions were defined as media containing 33mM glucose, and incubators with oxygen 
reduced to 2%. The diabetic conditions provided a double insult of high glucose with low 
oxygen, mimicking the in vivo environment in DR. However, during early stage disease, the 
tissue may be subjected to more subtle changes in either glucose and/or oxygen levels, so 
each parameter was tested individually during optimisation. Therefore, hREC and hRP were 
also grown in low O₂ (5%) with 5.5mM glucose, and atmospheric O₂ (20%) with 33mM 
glucose. It was established during optimisation that 5% O2 had little effect on cell growth and 
morphology within the experimental time frame, therefore 2% O2 was chosen for all 
subsequent diabetic conditions using the transwell inserts. Antibodies used to explore 
cellular changes in healthy and diabetic conditions are outlined in Table 2.4. 
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2.3.8 METABOLIC ACTIVITY 
Cell metabolic activity was measured using resazurin sodium salt (Sigma, R7017-5G). A 
filtered stock solution of resazurin was made to 0.1mg/ml with dPBS and stored at 4˚C in the 
dark. For use in assays, stock solution was diluted 1:10 with serum-free culture medium to 
working concentration of 0.01mg/ml. Growth medium was aspirated from cells and serum-
free resazurin medium was added. This procedure was performed in the dark in a sterile 
hood. Cells were placed back into the incubator, in the dark for 2H for the assay to develop. 
The incubation time was optimised by initially testing 1-4H for both hREC and hRP. After 2H, 
100µl of resazurin media from each well was transferred to a black 96 w/p (Greiner, 655079) 
in duplicate, to account for technical error. Plates were analysed immediately or sealed using 
para-film and stored at 4˚C in the dark for up to 7 days. Plates were read using a FLUOstar 
Optima plate reader (Optima, Serial 413-3363) with BMG Lab Tech (Optima, 2.20) plate 
reader software, set to excitation 560nm and emission 590nm to measure fluorescence, 
using endpoint settings with 10 flashes/well. Resazurin media only (blanks) were included on 
each plate and the average of the blanks was deducted from each reading. Gain was adjusted 
for each plate to allow comparisons between plates, using a standard curve (Figure 2.2). 
Assay results were assessed using Optima Data Analysis MARS software and transferred to 





Primary antibody EPC Species Code Concentration 
SOD-1 mouse MABC684 1:200 
SOD-2 mouse A21990 5µg/ml 
HIF1-α mouse ab199004 1µg/ml 
Ang-2 rabbit ab153934 7.2µg/ml 
VEGF-R2 mouse ab9530 1:200 
VEGFA mouse ab1316 5µg/ml 
   














Figure 2.2. Standard curve to adjust for gain  
Graph to show how a standard curve was used to allow results from resazurin assays to be adjusted 
for different gains. This enabled each plate to be read at its optimal range, depending on weak/strong 
signal, whilst still allowing comparisons across plates. The curve was produced by using the ‘fit non-




Transwell inserts with semi-permeable membranes made from polyethylene terephthalate 
(PET) and polyester, with 0.4µm or 1µm pores were sampled for their suitability for use in 
the co-culture model. hRP and hREC were seeded individually to assess cell attachment and 
viability. The inserts which provided superior imaging capabilities, to enable long term 
monitoring under the light microscope, and sufficient cell attachment and viability were 24 
w/p hanging PET transwell membranes with 1µm pores (MERCK, MCRP24H48) (Figure 2.3). 
During optimisation, transwell inserts were coated with collagen IV and laminin III to provide 
an ECM to aid in initial cell attachment, although this was determined to be unnecessary 
because cells attached well without protein coating. 
A simplified example of the hRP:hREC interaction is shown in Figure 2.4. hRP and hREC were 
seeded as mono- and co-cultures to enable direct comparisons between cells grown in 
isolation versus co-cultures. To mimic the ratio of coverage of EC:pericytes in the retina, hRP 
and hREC were seeded at 1:1 ratio. Inserts were placed upside-down in the inside surface of 
60ml pot lids (Scilabware, 360104) (Figure 2.5). 2x104 hRP were seeded on the upside-down 
transwell inserts, in a 50µl bubble of complete DMEM with 10% FBS. A large drop of dPBS 
was added to each 60ml pot lid for humidity. Pots were loosely screwed on to lids to ensure 
   




sterility when transferring the upside-down inserts into the incubator, at 37°C for 1H to allow 
hRP to adhere to the PET membrane. Transwell inserts were then gently inverted and placed 
into 24 w/p’s. Each well in the plate was filled with 900µl of MV medium with 10% FBS. hREC 
were seeded at 2x104 cells/insert in 200µl MV with 10% FBS medium on to the apical surface 
on the inserts, and plates were moved to the incubator overnight. 
Figure 2.3. Selecting appropriate transwell insert material 
Imaging quality of hRP, P10 on underside of different transwell inserts. A) 0.4µm pore, MERCK PET 24 
w/p transwell insert was opaque, therefore not possible to monitor cells. B) 1µm pore, MERCK PET 24 
w/p transwell insert provided sufficient cell attachment and was translucent, enabling cell monitoring. 
C) 0.4um pore, Corning Polyester 12 w/p transwell insert provided sufficient cell attachment and was 
translucent, enabling cell monitoring. A and B were seeded with 3x103 hRP and grown for 24H. C was 

















Figure 2.4. Basic anatomy of retinal capillary and mono-/co-culture design 
A) Schematic of the basic anatomy of a retinal blood capillary, with hRP wrapping around hREC, sharing 
a BM. B) Co-Culture: 2x104 hRP seeded on underside, 2x104 hREC seeded on apical surface of PET 
membrane. C) hREC only: 2x104 hREC seeded on the apical surface of the PET membrane. D) hRP only: 
2x104 hRP seeded on the underside of the PET membrane. All models were in MV medium with 5% 
FBS and either 5.5mM or 33mM glucose for healthy or diabetic conditions. 
A B C 
   










Figure 2.5. Seeding hRP on to the underside of the PET transwell inserts 
Transwells were placed upside down in sterile 60ml pot lids with small volume of dPBS on lid. hRP 
were seeded on upside-down transwell inserts in a 50µl bubble of complete DMEM (A). Transwells 
were transferred to incubator in 60ml pot lids, with 60ml pots loosely secured, on a sterile tray (B). 
hRP required 45 mins to 1H to adhere, before inserts were inverted and hREC were seeded at the 
same density on the apical side. 
 
The experimental timescale of the mono-/co-culture models is outlined in (Figure 2.6). In 
brief, after 12-24H, inserts were transferred to a new 24 w/p to prevent any detached hRP 
(which may re-attach to the TC plastic well) from interfering with the co-culture model. At 
this point, the whole model was switched to MV medium with 5% FBS. 72H after seeding, 
inserts either remained in physiological healthy conditions or were transferred to 2% oxygen 
and 33mM glucose, mimicking a diabetic condition. Cells were cultured for up to 21 days in 
healthy or diabetic conditions. 
A B 
   




































































































































































































































































































































































































































































































































































































































   




2.3.10 CELLTRACKER LABELLING  
To enable monitoring of attachment and growth of hRP and hREC on the PET membranes, 
CellTracker dye was used. To aid visualisation of both cell-types in co-culture, two different 
coloured cell trackers were used. According to manufacturer’s instructions, 50µg CellTracker 
Red (CTR) (Invitrogen, C34552) was dissolved in 7.2µl DMSO to make stock concentration of 
10mM. 1mg CellTracker Green (CTG) (Invitrogen, C2925) was dissolved in 215.1µl DMSO to 
make stock concentration of 10mM. Confluent cells were trypsinised and spun to form a cell 
pellet (See section 2.3.3) of ~1x106. The cell pellet was re-suspended in 1ml serum-free 
medium. 1µl CTG stock was added to hREC suspension and 1µl CTR stock was added to hRP 
suspension. After thorough mixing, tubes were placed in the incubator for 30-45 mins for 
trackers to incorporate into cells. Tubes were spun at 1,200PRM for 5 mins and CellTracker 
working solution was removed. Cells were re-suspended in complete medium and counted 
using a haemocytometer for required seeding density. CellTracker dyes allow for optimal cell 
monitoring for up to 72H. Beyond that time frame, dye becomes weaker, due to its transfer 
to daughter cells during proliferation.  
2.3.11 BARRIER TESTING (TEER) 
To determine if hREC formed a monolayer with functional barrier properties on the apical 
surface of the transwell inserts, trans-endothelial electrical resistance (TEER) measurements 
were performed using a Millicell® ERS-2 Voltohmmeter. This measures membrane potential 
and resistance of ECs in culture. TEER measurements of mono- and co-cultures were taken 
from 0-21 days. Briefly, electrodes were washed in 70% ethanol for 30 mins, to sterilise. 
Electrodes were removed from ethanol and left to dry within sterile hood, on sterile surface. 
To record readings, electrodes were attached to Millicell® ERS-2 Voltohmmeter and switch 
was set to measure Ohms. The silver/silver chloride (Ag/AgCl) pellet on each electrode tip sat 
below culture media level when introduced to the insert, but not touching. Duplicate 
readings were taken for: media only, empty transwell insert in media, and mono/co-cultures. 
This method is temperature sensitive, so measurements were taken quickly, or for large 
sample numbers, one set of readings was taken followed by an incubation period to 
equilibrate to 37°C before continuing with remaining readings. For reporting results, all 
readings were normalised against an empty insert, and divided by the surface area of the 
transwell insert to report Ohms/cm2. This reduced the error associated with increasing 
surface area, as previously reported for this technique136. 
 
   




2.3.12 HUMAN ANGIOGENESIS MULTIPLEX ARRAY 
 









All components to perform the assay were supplied in the kit. Oxford Biosystems kindly 
loaned a rotational rocker, for slow rotational washes, an automated plate washer (TECAN- 
Columbus Washer) to enable consistent and gentle washes, and the Q-Plex TM Imager LS 
with PC (Quansys, 104250GR), to perform image analysis on the 96-w/p’s. To optimise 
dilution of samples to fit within the calibrator range, one plate was used with sample added 
at varying concentrations. 1:3 was chosen as optimal sample concentration. A multichannel 
pipette was used for all measurements to reduce technical error and pipette tips were pre-
wetted before use, to prevent any liquid retention. According to the manufacturer’s 
instructions, an 8-point calibration curve was prepared using the calibrator (Quansys, 
102655HU) and the human sample diluent (Quansys, 110957HU), and added to each plate to 
enable direct quantification of each analyte (Figure 2.7). Samples were defrosted, spun for 5 
mins at 400xg then diluted 1:3 with human sample diluent e.g. mix 30µl sample with 90µl 
To explore changes in secreted proteins in the healthy and diabetic models over time, cell 
culture medium was collected from both the mono- and co-culture model at multiple time 
points (Figure 2.6). The Q-Plex Human Angiogenesis Array (Quansys, 150249HU) uses 
multiplex technology to measure 9 angiogenic proteins of interest. 100µl of media was 
collected from the apical, and 100µl from the outer compartments of the mono and co-
culture models at 7 time points (Figure 2.4). The 200µl total volume was stored immediately 
in -80°C to prevent degradation of proteins of interest within the media and also to allow 
samples to be analysed collectively. The 9 proteins included in the Q-Plex Human 
Angiogenesis array, and their concentration range are outlined in (Table 2.5).  
Analayte Calibrator Range LLD 
Ang-2 10000 - 13.72 pg/ml 3.9 
FGF basic 5000 - 6.86 pg/ml 12.7 
HGF 14000 - 19.2 pg/ml 7.2 
IL-8 2000 - 2.74 pg/ml 2.7 
PDGF-BB 4000 - 5.49 pg/ml 2.2 
TIMP-1 10000 - 13.72 pg/ml 10.2 
TIMP-2 20000 - 27.43 pg/ml 15.9 
TNFα 4000 - 5.49 pg/ml 5.2 
VEGF 2000 - 2.74 pg/ml 2.74 
   




diluent. 50µl/well of the calibration curve and all samples were loaded on to the Q-Plex Array 
96-w/p (Quansys, 150252HU), in duplicate, within 10 mins of preparation. The plate was 
covered with the seal provided, and placed on the rotational shaker at 500RPM, at RT for 1H. 
20X Wash Buffer (Quansys, 101158GR) was used at 1X working concentration with ddH2O for 
all washes. Table 2.6 outlines the settings used to programme the coordinates into the 
automated plate washer. Plates were washed 3x using the automated plate washer. 50µl of 
Detection Mix (Quansys, 150256HU) was added to each well and the plate was covered with 
a new seal and returned to the rotational shaker at 500RPM, at RT for 1H. The plate was 
washed 3x as described above. 50µl of Streptavidin-HRP 1X (Quansys, 101173GR) was added 
to each well, the plate was covered with a new seal and returned to the rotational shaker at 
500RPM, at RT for 15 mins. Plates were washed 6x to remove any unbound Streptavidin-HRP. 
RT Substrate was prepared 15 mins prior to use, by combining 3ml of Substrate A (Quansys, 
101159GR) with 3ml of Substrate B+ (Quansys, 101120GR), gently mixed and kept at RT in 
the dark. 50µl of previously prepared substrate was added to each well and imaging was 
commenced within 15 mins. 
 
Figure 2.7. 8-point calibration curve for direct quantification 
Instructions sourced from Quansys Q-Plex Human Angiogenesis instruction manual. Diagram showing 
how to create 8-point calibration curve, which must be plated in duplicate on each 96 w/p to enable 
direct quantification of analytes. 
 
For imaging, the 96 w/p was placed into the Q-Plex TM Imager LS and Q-View Imager Pro 
Software was used. Exposure time was set to 270 seconds, with standard image processing. 
Ensuring correct well alignment on the software, images were captured and stored at 
multiple exposure times. For image analysis, by following software manual instructions to 
label samples with dilution factor, Q-View Imager Pro provided automated concentration 
calculations which were exported to GraphPad Prism 6 for statistical analysis. 
   


















2.3.13 HUMAN ANGIOGENESIS ANTIBODY BLOT ARRAY 
The Human Angiogenesis Antibody Blot Array (Abcam, ab134000) enabled detection of 20 
cytokines in one blot, which is less labour intensive, uses fewer resources, and is more 
economically viable than the more traditional methods such as 2D SDS-PAGE or mass 
spectrometry. However unlike the multiplex data, these blot arrays do not provide 
concentrations, only amount relative to positive control. Therefore these data provide a 
more economical technique to further validate the results from the expensive Quansys 
multiplex array data. The 20 cytokines in this blot array and a summary of their biological 








Plate 96 well, Greiner, clear flat bottom 
Dispense Position 20 
Dispense Rate 1 
Aspiration Position 1:-36  2:-35 
Aspiration Rate 2mm/sec for 2 seconds 
Height 128 
Wash Bottom 20 
Wash Overflow -6 
Run 3x for 3x washes 
   




Table 2.7. ANALYTES IN Q-PLEX HUMAN ANGIOGENESIS ARRAY 
ANALYTE FUNCTION 
Angiogenin 
Interacts with the actin in ECs resulting in cell migration, 
proliferation, invasion, and formation of tubular structure via 
upregulation of proteases and plasmin that degrade the 




Binds to its receptor EGF-R, resulting in cell proliferation, 





Is produced following stimulation of cells with the inflammatory 
cytokines IL-1 or TNF-α and has been implicated in connective 




Has broad mitogenic and cell survival properties and is involved 
in a variety of biological processes, including; cell growth, 
morphogenesis and tissue repair. During wound healing 
heparan sulfate degrading enzymes activate bFGF, resulting in 




Involved in the processes of angiogenesis, wound healing, 
inflammation and tumorigenesis via signaling through the 
chemokine receptor CXCR2. 
Interferon Gamma 
IFN-ƴ 
Vital in innate and adaptive immunity against viral, some 
bacterial and protozoal infections. IFNγ has immunostimulatory 
and immunomodulatory effects and abnormal IFNγ expression 





Works downstream of growth hormone, has growth-promoting 
effects on most cell-types, showing insulin-like effects via the 




Acts as both pro- and anti-inflammatory cytokine. IL-6 is 
produced by adipocytes, therefore obese individuals have 
higher endogenous levels. Its’ anti-inflammatory action is 
mediated through inhibitory effects on TNF-α and IL-1 and 
activation of IL-1Ra and IL-10. 
Interleukin-8 
IL-8 
A potent promoter of angiogenesis. In target cells IL-8 induces a 
series of physiological responses required for migration and 
phagocytosis. 
   





Outside its main function of promoting satiety in the brain, in 
the periphery, leptin modulates energy expenditure and 





Is anchored in the plasma membrane of ECs and recruits 
monocytes, memory T-cells, and dendritic cells to the sites of 




A potent mitogen for mesenchymal cells; fibroblasts, smooth 
muscle and glial cells. Produced primarily by platelets but also 




A member of the VEGF sub-family, with key roles in 
angiogenesis and vasculogenesis, mainly during embryogenesis. 
Increase in PIGF has been associated with increased 
inflammation and neovascularisation. 
RANTES 
A chemotactic cyto/chemokine for T-cells, eosinophils and 




A secreted protein involved in: control of cell growth, 
proliferation, differentiation and apoptosis. Dysregulation of 
TGF-β signalling can result in apoptosis. Has different effects on 
different cells, at different stages of maturity. 
Tissue Inhibitor of 
Metalloproteinases-1 
TIMP-1 
A natural inhibitor of the matrix metalloproteinases (MMPs), 
can promote proliferation in numerous cell-types, and may have 
an anti-apoptotic function. 
Tissue Inhibitor of 
Metalloproteinases-2 
TIMP-2 
A natural inhibitor of MMPs, and can directly suppress the 
proliferation of ECs, therefore has role in maintaining 
homeostasis by suppressing proliferation of quiescent cells in 
response to angiogenic factors, and by inhibiting protease 
activity during remodelling of ECM. 
Thrombopoietin 
Produced in the liver by parenchymal cells and sinusoidal ECs, 
as well as in the kidney by proximal convoluted tubule cells and 
involved in differentiation of bone marrow cells into 
megakaryocytes, and further maturation of these cells. 
Vascular Endothelial 
Growth Factor  
VEGF 
In adulthood, produced by cells to create new blood vessels 
after injury, muscle following exercise, and new vessels to 




Is active in angiogenesis, lymphangiogenesis, and EC growth via 
activation of VEGFR-2 and VEGFR-3 receptors. 
 
   





The Nikon DIAPHOT microscope with Top View 3.7 software was used to capture phase 
contrast images of cells in culture. The Nikon E-TI microscope, with NIS Elements AR 4.51.01 
software was used to perform cell counts, for live cell imaging and to image cells that were 
fixed and prepared for IF staining on 24 w/p’s. The Zeiss Confocal M800 microscope with ZEN 
Blue 2.3 software was used for imaging cells grown on glass slides, and cells grown on PET 
membranes, mounted on glass slides. For co-culture PET membranes, after IF procedure 
described above, membranes were very delicately cut away from transwell frames using a 
scalpel. For mono-cultures, membranes were transferred directly on to glass slides, cells 
facing upwards, using mounting media underneath and on top, and covered with a glass 
coverslip. For co-cultures, membranes were transferred on to a thin glass coverslip using 
mounting media underneath and on top, and sandwiched with another glass coverslip on 
top. For imaging co-cultures, this sandwiching technique allowed the membrane to be flipped 
over on to glass slides, to provide best quality images of both sides during confocal 
microscopy. 
2.3.15 STATISTICAL ANALYSIS 
All statistics were analysed using GaphPad Prism 6 software. Significance level of p<0.05 was 
set for all experiments. Data were reported as mean, with standard deviation (SD). Two-Way 
AVONA with Sidak's multiple comparisons post-hoc test was used to report multiplexing data. 




   





2.4.1 hRP AND hREC RETAINED THEIR PHENOTYPE THROUGHOUT PASSAGING UP 
TO P10 IN VITRO 
hRP and hREC were cultured in vitro and used in experiments from P3-10. No change in cell 
morphology of hRP and hREC from P3-10 suggests cells did not transition within experimental 
timeframe (Figure 2.8 A and B). hRP retained a large, irregular-shape, with finger-like 
projections (Figure 2.8 A). hREC retained a smaller, cuboidal and more uniform size and 
shape, and formed a monolayer sheet when confluent (Figure 2.8 B). hRP narrowed and 
elongated as the cells became more confluent.  
2.4.2 IF ANALYSIS CONFIRMED hRP AND hREC EXPRESSED PHENOTYPE-SPECIFIC 
PROTEINS  
IF analysis of hRP and hREC validated that both cell-types retained their phenotype in vitro, 
during normal cell culture conditions (Figure 2.9, Figure 2.10). IgG isotype controls were 
included to exclude non-specific staining. hRP in this study expressed NG2, Desmin and 
PDGFR-β, antibodies commonly used to confirm pericyte phenotype in culture48 (Figure 2.9). 
hRP showed positive/negative expression for α-SMA and this a common phenomenon, 
described in the literature50. hRP also expressed CD90/Thy-1, which has been previously 
described by others190. Phalloidin was used to visualise the F-actin filaments to show 
organisation of components of the cytoskeleton. Some hRP expressed Ang-2. 
hREC expressed CD31, vWF and Cx43 (Figure 2.10). vWF expression was localised to storage 
vesicles (Weibel-Palade bodies) in the cytoplasm of ECs and vWF is expressed constitutively 
by all ECs. CD31 is expressed by all mature ECs and is present at the border of cell membranes 
as an integral part of the cell junction. Typical pattern of CD31 expression on ECs can be 
observed in Figure 2.10. Positive expression of ZO-1 confirms TJs and VE-Cad confirms 
presence of adherens junctions, suggesting hRECs form cell-cell contacts with their 
neighbours, resulting in a monolayer with barrier function. Cx43 is a GJ protein and is present 
on hREC and is used in this study to monitor changes to the GJ complex during healthy or 





   




























Figure 2.8. Light microscopy of hRP and hRP passage 3-10 
Micrographs show both cell-types maintained their cell morphology from passage 3-10. A) hRP were 
large cells with non-uniform shape, with cytoplasmic finger-like projections. B) hREC were smaller, 
uniform, cuboidal-shaped cells which formed contact with neighbouring ECs. Phase contrast images 
were captured using Nikon DIAPHOT microscope, x10 objective. Scale bar =200µm. 
 










A hRP  
B hREC 
   





























Figure 2.9. IF characterisation of hRP 
Using double or triple labelling confocal microscopy, IF characterisation of hRP was performed using 
antibodies against common markers of hRP phenotype. hRP expressed  NG-2, PDGFR-β, CD90/Thy-1 
and desmin. hRP were +/- for αSMA. Phalloidin was used to explore the F-actin arrangement of the 
hRP cytoskeleton. IgG isotype controls were performed as negative controls for non-specific staining. 
Images were obtained using the Zeiss M800 confocal microscope, x40 oil objective. Scale= 50µm. 
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Figure 2.10. IF characterisation of hREC 
Using double or triple labelling confocal microscopy, IF characterisation of hREC was performed using 
antibodies against common markers of hREC phenotype. hREC expressed CD31, vWF, VE-Cad, ZO-1 
and Cx43. Phalloidin was used to explore the F-actin arrangement of the cytoskeleton. hREC were 
negative for αSMA. IgG isotype controls were performed as negative controls for non-specific staining. 
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2.4.3 FLOW CYTOMETRY ANALYSIS VALIDATED THE EXPRESSION OF CELL 
SURFACE MARKERS EXPECTED OF hRP AND hREC 
CD31 and CD90 were used to confirm if hREC or hRP respectively were present in culture and 
also to determine the homogeneity of the in vitro cell populations. Cultures of hRP at P7 and 
hREC at P9 retained their expected morphology and reached 70-95% confluence before 
analysis.  hRP were CD34 –ve, CD14 –ve, CD45 –ve, CD31 –ve, CD90 +ve (99.9%), CD105 +ve 
(98.9%) and CD146 +/-ve (26.3%) (Figure 2.11). 26.3% of hRP expressed CD146, which could 
in part be due to a heterogeneous population, considering the pluripotent nature of hRP. hRP 
were negative for both CD31 and CD34, validating they were not of EC-lineage.  hREC were 
CD34 –ve, CD14 –ve, CD45 –ve, CD90 -ve, CD31 +ve (96%), CD105 +ve (100%) and CD146 +ve 
(99.9%) (Figure 2.12). CD31 is endothelial specific and 96% of hREC at P9 were CD31 positive, 
suggesting the primary hREC used in this model retained a strong EC phenotype throughout 
passaging. hREC were CD34 –ve, verifying they were a mature EC type, because more 
primitive or progenitor ECs, such as ECFCs, express the CD34 transmembrane protein. Both 
hREC and hRP were CD14 and CD45 negative, distinguishing them from hematopoietic cells. 



















   






























Figure 2.11. Flow cytometry analysis of hRP 
Flow cytometry analysis of hRP at P7. Results were expressed as % positive expression of cell surface 
receptor (magenta) compared to IgG isotype control (black), for each corresponding fluorophore. hRP 
were CD34 –ve, CD14 –ve, CD45 –ve, CD31 –ve, CD90 +ve (99.9%), CD105 +ve (98.9%) and CD146 +/-
ve (26.3%). Analysis was performed using BD Acuri C6. Phase image was captured using the Nikon 









hRP P7 CD34 0.1% 
CD31 CD146 26.3% 0.1% 
CD14 0% CD45 0.1% 
CD105 98.9% 
CD90 99.9% 
   






















Figure 2.12. Flow cytometry analysis of hREC 
Flow cytometry of hREC at P9. Results were expressed as % positive expression of cell surface receptor 
(magenta) compared to IgG control (black), for each corresponding fluorophore. hREC were CD34 –ve, 
CD14 –ve, CD45 –ve, CD90 -ve, CD31 +ve (96%), CD105 +ve (100%) and CD146 +ve (99.9%) Analysis 
was performed using BD Acuri C6. Phase image was captured using the Nikon Eclipse TS100 light 
microscope, x10 objective. Scale =200µm. 
 
 






Cell Surface ‘Marker’ hRP hREC 
CD34 X X 
CD146 X/  
CD31 X  
CD105   
CD14 X X 
CD45 X X 
CD90  X 
hREC P9 
CD34 0% 
CD31 96% CD146 99.9% 
CD14 0% CD45 0% 
CD105 100% 
CD90 0% 
   




2.4.4 SEEDING DENSITY AND LENGTH OF CULTURE IMPACTED GROWTH RATES OF 
THE TWO CELL-TYPES DIFFERENTLY 
hREC and hRP grew at different rates, with hRP continuing to expand in number up to day 
21, whereas hREC numbers increased until day 7, followed by a sharp decline from day 7-21 
(Figure 2.13). Neither hREC nor hRP followed the typical sigmoid growth curve for cultured 
cells. When grown as monocultures, hRP continued to expand in number over the extended 
culture time period and depending on cell seeding density, did not reach a clear plateau even 
by day 21 (Figure 2.13A). This continued growth over an extended time may be in part due 
to their ability to become elongated and therefore take up less space on the culture dish, 
allowing continual expansion of cell numbers. The four seeding densities had very similar 
growth trends, suggesting seeding density between 5x103-4x104 cells/well had little effect on 
the growth rates of hRP. 
In contrast, the growth curves of hREC showed an initial small increase in cell number when 
seeded at ≤2x104 cells/well, followed by a sharp decline in cell number for all seeding 
densities after 7 days (Figure 2.13B). When seeded at 4x104 cells/well, hREC exhibited cell 
loss at all time points. Overall this suggests there was less cell loss over time when cells were 
initially seeded at lower density (≤2x104 cells/well in a 24w/p). Seeding hREC at 5x103, 1x104 
or 2x104 cells/well resulted in gradual increase in cell number until day 7. Reporting the 
average, seeding density of 5x103 cells/well surpassed cell number of those seeded at 
1x104/well, although there was no statistically significant differences between all seeding 
densities by day 7. These data suggest hREC seeded at a lower density grow at a faster rate 
in days 1-7 than those seeded at higher densities. During cell culture, hREC culture medium 
turned yellow indicating a drop in pH every 2-3 days. Therefore hREC metabolic activity may 
have caused toxic build-up of metabolites as well as lack of physical space for cell expansion. 
hREC reached the death phase by day 7 whereas pericytes did not appear to reach the death 
phase within the 21 day experimental timeframe. 
 
 
   





























Figure 2.13. Growth curves of hRP and hREC at different seeding densities 
hRP (A) and hREC (B) were seeded at 5x103, 1x104, 2x104 and 4x104cells/well on col. I coated 24 w/p’s, 
to determine the effect of seeding density and time on cell growth rate. At time points day 1, 3, 5, 7, 
14 and 21 cells were washed, fixed in 10% NBF, permeabilised using 0.5% Triton-X and DAPI stained, 
in preparation for cell counting using the Nikon E-Tie fluorescence microscope, x10 objective. ImageJ 
software was used to write a micro to perform automated cell counting. n=3 and lines represent 
average for each seeding density. 
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2.4.5 hRP METABOLIC ACTIVITY WAS NOT AFFECTED BY ADDITION OF FBS >5%  
Images captured at days 2 and 12 show the effect of FBS on cell number (Figure 2.14A). At 
day 2 there were no significant differences in cell metabolic activity in hRP grown in 0-20% 
FBS (Figure 2.14B). From day 7-12 hRP grown in 0% FBS were significantly less metabolically 
active than those grown in 5-20% (p<0.001). Images captured at days 2 and 12 also show 
little/no increase in cell number in the hRP grown in 0% FBS (Figure 2.14A). hRP grown in 5-
20% FBS all show increased in cell number, which all look comparable in the day 12 images. 
There was no statistically significant difference in the metabolic activity of hRP in 5, 10, 15 or 
20% FBS at any time point (Figure 2.14B). Therefore, these data lead to the decision to use 
5% FBS in culture medium for hRP for all future experiments. General observations from the 
resazurin sodium salt metabolic activity assay suggested that, overall, hRP had relatively low 
























Figure 2.14. The effect of FBS concentration on hRP growth and metabolic activity 
hRP P12, seeded at 2x104 cells/well in 24 w/p’s in 0-20% FBS, grown in physiologically healthy 
conditions (5.5mM Glucose with 20% oxygen) (A). Images were captured using the Nikon DIAPHOT 
microscope, x10 objective. Scale=200µm. Resazurin sodium salt was used to determine metabolic 
activity of hRP over 2Hs, in 0-20% FBS (B). 100µl resazurin of 0.01mg/ml media was analysed using a 
FLUOstar Optima plate reader at excitation 560nm and emission 590nm. Technical duplicates were 
read to account for error and n=4. Lines represent average fluorescence for each FBS concentration. 
For statistical analysis, one-way ANOVA with Tukey’s post hoc test was performed. ***p<0.001. 
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2.4.6 GLUCOSE CONCENTRATION SIGNIFICANTLY AFFECTED hRP METABOLISM  
hRP survived in all conditions up to day 14, and hRP in 5-35mM glucose appeared to increase 
in number over time(Figure 2.15A and B). Mannitol control and 0mM glucose had the lowest 
metabolic activity over 14 days, (Figure 2.15B), whilst the metabolic activity of hRP in 5-
35mM glucose gradually increased from day 3 onwards. 5mM glucose was highlighted in red, 
as this is the average physiological glucose levels in humans, and 5.5mM glucose was used in 
healthy conditions for all following experiments. From day 5, the metabolic activity of hRP in 
the mannitol control and 0mM glucose were significantly different from all other conditions 
(p<0.001), and combined with images captured (Figure 2.15A), suggests the hRP survived but 
did not continue to expand in number when there was no glucose present.  
Interestingly there were significant differences in the metabolic activity of 5mM glucose 
compared to 25mM (p=0.0145) and 30mM (p=0.00330) at day 5, but no difference compared 
with the highest glucose concentration 35mM (Figure 2.15C). By day 14 the metabolic activity 
of hRP in 15mM glucose was significant reduced compared to physiological 5mM (p=0.0005) 
and compared to the highest (35Mm) glucose concentrations (p<0.0001). 10mM (p=0.0170), 
20mM (p=0.0106), 25mM (p=0.0097) and 30mM (p=0.0041) glucose all caused significant 
reduction in metabolic activity by hRP compared to 35mM glucose, but were not different 
from hRP  grown in 5mM glucose. However, although not quantified, there appeared to be a 
similar number of hRP in 5mM-35mM glucose by day 14 (Figure 2.15A). Taken together these 
data support the hypothesis that at 35mM glucose levels there may be disruption to normal 
metabolic activity, which was not observed in the hRP grown in lower glucose concentrations. 
These data supported the decision to optimise future experiments to beyond 14 days and to 
use between 30-35mM glucose for diabetic conditions. Following reports from the literature, 














   

































Figure 2.15. The effect of glucose concentration on hRP growth and metabolism 
hRP P6, seeded at 2x104 cells/well in 24 w/p’s, were grown in 20% oxygen, 10% FBS and 0-35mM 
glucose for 14 days. A) Images captured at D1, 7 and 14 using, the Nikon DIAPHOT microscope, x10 
objective, scale=200µm. B-D Resazurin sodium salt was used to determine metabolic activity of hRP 
cultured in 0-35mM glucose. 100µl resazurin of 0.01mg/ml media was analysed using a FLUOstar 
Optima plate reader, at excitation 560nm and emission 590nm. Technical duplicates were read to 
account for error. B) Metabolic activity of hRP grown in 0-35mM glucose for 14 days. Lines represent 
average fluorescence for each glucose concentration. Red line highlights physiological glucose levels 
in humans. C) Day 5, where hRP grown in mannitol and 0mM glucose had significantly lower metabolic 
activity that those in 30 and 35mM, and there was no difference in hRP grown in 5mM and 35mM 
glucose. D) Day 14, where hRP grown in 35mM glucose had significantly higher metabolic activity than 
in all other concentrations. For statistical analysis, one-way ANOVA with Tukey’s post hoc test was 
performed. n=3 or 4. *p<0.05, ** p<0.01, ***p<0.001. 
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2.4.7 hREC GROWN IN 5% OXYGEN AND 33mM GLUCOSE SHOWED ONLY MINOR 
DIFFERENCES IN PROTEIN EXPRESSION AT DAY 7 
20% oxygen with 5.5mM glucose represented healthy conditions (Figure 2.16A) and 20% 
oxygen with 33mM glucose represented early stage diabetes, with hyperglycaemia present 
(Figure 2.16B). 5% oxygen with 5.5mM glucose represented disruption to blood supply, 
therefore reduced oxygen, but with normal physiological glucose levels (Figure 2.17A) and 
5% oxygen with 33mM glucose represents the environment of damaged vessels with 
insufficient blood supply (reduced oxygen) and hyperglycaemia, i.e. a diabetic model (Figure 
2.17B).  
There was no noticeable difference in expression of SOD-1 and SOD-2 (Figure 2.16 and Figure 
2.17). HIF1α becomes active once translocated to the nucleus, however it did not translocate 
to the nucleus in any of the experimental conditions. Therefore, oxygen levels were reduced 
to 2% for future experiments. VEGFR-2 binds soluble VEGF and is activated upon ligand-
mediated dimerization. VEGFR-2 appeared to be upregulated in 5% oxygen with 33mM 
glucose, which represented the most diabetic-like conditions in this experiment (Figure 
2.17B). ZO-1 was present across all conditions, which implied the hREC formed a functional 
barrier with their neighbouring cells, however in 5% oxygen (Figure 2.17) most of the ZO-1 
was at the cell junctions, whereas in 20% oxygen (Figure 2.16) a higher proportion of ZO-1 
was dispersed in the cell cytoplasm. In the right hand panel, vWF appeared unchanged across 
the four conditions and validated that hREC retain their endothelial phenotype in vitro. CD31 
is expressed by all mature endothelium, and on the left panel CD31 was present in all 
conditions. In 20% oxygen with 33mM glucose, CD31 appeared to have more gaps in its 
expression on the hREC membrane. This suggests high glucose may have caused disruption 
to normal CD31 expression. Ang-2 becomes active when ECs undergo angiogenesis. The 
second panel shows Ang-2 expression was increased in 5% oxygen (Figure 2.17) compared to 
20% oxygen conditions (Figure 2.16),. This suggests low oxgen appeared to drive an 
angiogenic response in hREC.  
Overall, these data suggest the hREC cells were robust enough to withstand low oxgen and 
high glucose, and with the aim of inducing a more severe diabetic phenotype, oxygen levels 
for subsequesnt experiments were reduced to 2% and experiments were carried out for up 
to 21 days. 
 
 
   











































Figure 2.16. Assessing the effect of high glucose on hREC 
hREC P8 were seeded on 8-well glass slides and left to adhere for 24H in healthy physiological 
conditions (20% oxygen and 5.5mM glucose). At 24H, hREC were either kept in healthy conditions (A) 
or moved to high glucose (33mM) conditions (B), and cultured for a further 7 days. CD31, ZO-1, vWF, 
SOD-1, SOD-2, Ang-2, VEGFR-2 and HIF1α expression were assessed to determine hREC phenotype, 
oxidative, angiogenic and hyperglycaemic stress response. Phase images were captured using Nikon 
DIAPHOT microscope, x10 objective, black scale bars =200µm. IF images were captured using the Zeiss 
M800 confocal microscope, x40 oil objective, white scale bars =20µm.  
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Figure 2.17. Assessing the effect of low oxygen and high glucose on hREC 
hREC P8 were seeded on 8-well glass slides and left to adhere for 24H in healthy physiological 
conditions (20% oxygen and 5.5mM glucose). At 24H, hREC were transferred to low oxygen conditions 
(5%) (A), or low oxygen and high glucose (33mM) conditions (B), and cultured for a further 7 days. 
CD31, ZO-1, vWF, SOD-1, SOD-2, Ang-2, VEGFR-2 and HIF1α expression were assessed to determine 
hREC phenotype, oxidative, angiogenic and hyperglycaemic stress response. Phase images were 
captured using Nikon DIAPHOT microscope, x10 objective, black scale bars =200µm. IF images were 
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2.4.8 hRP GROWN IN 5% OXYGEN AND 33mM GLUCOSE RETAINED THEIR 
PHEONTYPE AND SHOWED OXIDATIVE STRESS RESPONSE AT DAY 7 
PDGFR-β, NG2, Desmin and αSMA remained unchanged in the four conditions studied, and 
were used to confirm hRP phenotype (Figure 2.18 and Figure 2.19). There was no clear 
difference in Ang-2 expression in any conditions, suggesting hRP did not undergo the 
angiogenic switch that was observed in the hREC in the same conditions. Also, HIF1α had 
cytoplasmic distribution, except for in 5% oxygen with 33mM glucose (Figure 2.19B), where 
it appeared HIF1α was clustered on the nuclear border. This translocation of HIF1α towards 
the nuclear compartment suggests the most diabetic-like conditions induced a major 
regulatory hypoxic response in the hRP by day 7. SOD-1 expression changed dramatically 
from a dispersed nuclear location in 20% oxygen (Figure 2.18) to distinctly perinuclear in both 
5% oxygen conditions (Figure 2.19). This perinuclear pattern follows that of the ER, 
suggesting the low oxygen caused SOD-1 activity in the ER, as an oxidative stress response. 
There were no noticeable differences in SOD-2 expression across the different cell culture 
conditions. Due to artefacts, VEGFR-2 staining was inconclusive. Overall, these data confirm 
hRP can withstand low oxygen and high glucose insult over time, but undergo oxidative stress 

























   











































Figure 2.18. Assessing the effect of high glucose on hRP 
hRP, P7, were seeded on 8-well glass slides and left to adhere for 24H in healthy physiological 
conditions (20% oxygen and 5.5mM glucose). At 24H, hRP were either left in healthy conditions (A) or 
moved to high glucose (33mM) conditions (B), and cultured for a further 7 days. PDGFR-β, NG2, αSMA, 
Desmin, SOD-1, SOD-2, Ang-2, VEGFR-2 and HIF1α expression were assessed to determine hRP 
phenotype, oxidative, angiogenic and hyperglycaemic stress response. Phase images were captured 
using Nikon DIAPHOT microscope, x10 objective, black scale bars =200µm. IF images were captured 
using the Zeiss M800 confocal microscope, x40 oil objective, white scale bars =20µm.  



































   











































Figure 2.19. Assessing the effect of low oxygen and high glucose on hRP 
hRP, P7, were seeded on 8-well glass slides and left to adhere for 24H in healthy physiological 
conditions (20% oxygen and 5.5mM glucose). At 24H, hRP were transferred to low oxygen conditions 
(5%) (A), or low oxygen and high glucose (33mM) conditions (B), and cultured for a further 7 days. 
PDGFR-β, NG2, αSMA, SOD-1, SOD-2, Ang-2, VEGFR-2 and HIF1α expression were assessed to 
determine hRP phenotype, oxidative, angiogenic and hyperglycaemic stress response.  Phase images 
were captured using Nikon DIAPHOT microscope, x10 objective, black scale bars =200µm. IF images 



































   




2.4.9 SERUM WAS ESSENTIAL FOR ATTACHMENT AND GROWTH OF hRP ON THE 
UNDER SIDE OF PET MEMBRANES  
There is limited data outlining the ability of human primary, retina-specific pericytes to 
adhere and expand on the underside of PET transwell membranes. When no serum was 
present, hRP did attach, but they had a rounded shape, and did not appear to increase in 
number from days 3-7 (Figure 2.20A). When 10% FBS was present in the growth medium, 
hRP attached and had characteristic elongated, non-uniform cell shape with finger-like 
projections from the cell cytoplasm. There was also an increase in cell number from day 3-7 
in the cells seeded with 10% FBS in the growth medium (Figure 2.20B). However, even in the 
absence of FBS, hRP displayed significant increase in metabolic activity from Day 5-7 (p< 
0.0001), increasing from 686 a.u. to 9301 a.u, a 13.5x increase, whereas on TC plastic, the 
data from the FBS % optimising (Figure 2.14) showed no significant increase in hRP metabolic 
activity across all time points in 0% FBS. Therefore, hRP in 0% FBS on PET membranes 
displayed increasing metabolic rate, but no increase in number of cells, whereas those in 0% 
FBS on TC plastic did not show any increase in metabolic activity (Figure 2.20 vs Figure 2.14). 
Directly comparing 0% FBS with 10% FBS conditions for hRP on PET membranes, metabolic 
activity was over 20 times higher in 10% FBS hRP cultures at day 5. But by day 7, the 
difference was only 3.6x higher in the 10% FBS cultures, even though cell number was much 
lower in 0% FBS. This means the hRP in 0% FBS were exhibiting a higher metabolic rate/cell 















   

















Figure 2.20. FBS is required for hRP to adhere to underside of PET membranes 
hRP P10 were seeded on the underside of PET transwell membranes with 10% FBS, or no FBS, in DMEM 
for 1 hour to allow cells to adhere. hRP were then moved into DMEM with 10% FBS for up to 7 days. 
Images were captured at 3, 5 and 7 day after seeding cells (A), scale bar=200µm. Metabolic activity of 
cells seeded with or without FBS was assessed at day 5 and day 7 (B). Lines represent mean metabolic 
activity, which was higher at both time point in hRP seeded with 10% FBS. n=8. Data was analysed 
using un-paired T-test with Welch’s correction. ***p<0.001. 
 
 
2.4.10 hRP AND hREC GREW TOGETHER ON EITHER SIDE OF PET TRANSWELL 
MEMBRANES  
During optimisation of the hREC-hRP co-culture model, MV medium only, DMEM only and 
1:1 MV:DMEM media were tested. hRP were robust in all conditions, but hREC attachment 
and survival over long culture periods was only successful in MV medium in the co-culture. 
hREC:hRP seeding density was 1:1 ratio, as is described in the cerebral and retinal 
microvasculature in vivo46. hRP and hREC were monitored on the bottom and apical surface 
of PET membranes when grown as monocultures, using simple light microscopy (Figure 
2.21A). When hRP and hREC were grown together on either side of the PET membranes, it 
was difficult to monitor the individual cell-types. Red arrows highlight hREC on the apical 
surface, with hRP underneath (Figure 2.21A). Therefore, to confirm successful attachment 
and monitor short term growth of the hRP and hREC in co-culture, CTR and CTG dyes were 
used, with IF microscopy. The cell trackers had no detrimental effect on proliferative of hRP 
or hREC monocultures, on TC plastic (Figure 2.21B).  
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Figure 2.21. CellTracker red and green were used to distinguish hREC and hRP from 
one another in co-culture 
A) Light microscope micrographs of hRP and hREC alone and together on PET transwell inserts. It was 
difficult to see hREC on co-culture images, but red arrow heads indicate possible hREC. B) CTR and 
CTG were used to enable cell tracking of hRP and hREC.  Fluorescence images were captured using 
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2.4.11 CELL TRACKER DYE ENABLED LIVE CELL IMAGING OF BOTH CELL-TYPES IN CO-
CULTURE 
CellTacker dye was retained well for up to 48H (Figure 2.22) and cells could be distinguished 
in both mono-cultures (Figure 2.22A) and co-cultures (Figure 2.22B) on the PET inserts. 
Beyond 48H, the CellTracker dye decreased in intensity overall, and was also passed on to 
any daughter cells, therefore although very useful short term, CellTracker dye was not 





















Figure 2.22. CellTracker was a useful tool for short term cell monitoring in co-cultures  
CTG and CTR were added to hREC and hRP to enable cell tracking on the PET membranes. It was 
possible to see hRP on the underside and hREC on the top side, when each cell-type were grown as in 
monocultures (A). CTG-hREC could be distinguished from CTR-hRP when grow as a co-culture (B), for 
24 and 48H. Fluorescence images were captured using the Nikon E-Ti Live Cell Microscope, x10 
objective. Scale bars= 100 or 200µm. 






































































































   




2.4.12 TEER RESULTS WERE INCONCLUSIVE DUE TO LARGE VARIABILITY  
TEER measurements are a quick, inexpensive and repeatable method used to test the barrier 
properties of the endothelial layer. However, the method is notorious for its error and high 
sensitivity to e.g. culture medium temperature and rod placement. Overall results were 
inconclusive, with generally very low TEER Ω/cm2 compared to those reported in the 
literature (Figure 2.23A). This time point break down of the data highlights the inconsistent 
variation in the differences between different culture models. There were no significant 
differences between models on day 3 and day 21 (Figure 2.23B and C), however at all other 
time points, the TEER data showed significant differences between the groups, particularly 
differences compared to hREC only, which generally had lower TEER than the other groups. 
Overall there was no clear trend. TEER was performed on multiple occasions, however data 
















Figure 2.23. TEER provided inconclusive results  
TEER was measured at 5 time points over 21 days (A). Reading were generally very low and error was 
large. Although barrier proteins were present (confirmed by IF imaging), TEER did not change over 
time or in any conditions. At day 3 there was no difference in TEER in healthy or diabetic, mono- or co-
cultures (B), and the same results at day 21 (C). n=6, error bars show SD and all TEER measurements 
were performed in duplicate. One-Way ANOVA with Tukey’s post hoc test was used to perform 
statistical analysis, although P-values are not reported. 
T E E R  o f C o / M o n o -C u ltu r e  M o d e l In
H e a lth y  o r  D ia b e t ic  C o n d ito n s













h R E C  H e a lt h y
h R E C  D ia b e t ic
B o t h  H e a lt h y





















































































































   




2.4.13 hREC FORMED TJs UP TO DAY 14 WHEN GROWN ON PET AS 
MONOCULTURES 
hREC attached and formed TJs (ZO-1) and adherens junctions (VE-Cad)  which were present 
at days 7 (Figure 2.24) and 14 (Figure 2.25) in both healthy and diabetic conditions, when 
grown as monocultures. By day 21 hREC were still present, but there are fewer cells 
remaining in both healthy and diabetic conditions (Figure 2.26). This suggests after day 14 
there is some cell loss, which is supported by the growth curve data (Figure 2.13B). By day 21 
the adherent hREC were either remaining as patches, with neighbouring cell-cell contact, or 
more sparse, with large gaps between cells. This was variable from insert to insert when 
imaging hREC grown in healthy monoculture conditions. This may be due to the IF staining 
process, such as multiple washes and cutting out the PET membranes from their frames, 
resulting in cell detachment or peeling.  Consequently, VE-Cad and ZO-1 were visible at the 
cell membrane border of hREC grown as monoculture by day 21, in both healthy and diabetic 
conditions, but the large gaps between the cells means there was no physical or functional 
barrier, unlike at earlier time points (Figure 2.26). Overall there was little difference between 
ZO-1 and VE-Cad expression in healthy compared to diabetic conditions at all three time 
points. The main differences were fewer cells in the diabetic conditions by day 21 (Figure 
2.26) although this was variable from insert to insert, so would require further investigation. 
2.4.14 CX43 WAS EXPRESSED AT CELL-CELL JUNCTIONS IN DIABETIC BUT NOT 
HEALTHY MONOCULTURE CONDITIONS 
Cx43 is a component of the GJ complex and there are differences in its expression pattern in 
hREC grown as monoculture across days 14-21 and also differences when comparing healthy 
with diabetic. At day 7 in hREC monocultures, Cx43 looks distributed across the cytoplasm, 
with some concentrations at the cell membranes, i.e. where the gap junctions would be 
found, with little differences between healthy and diabetic conditions (Figure 2.24). By day 
14, in diabetic conditions the Cx43 was prominently concentrated at the lateral border of the 
cell membranes, indicating the presence of GJs (Figure 2.25).  However at day 14 healthy 
conditions, the Cx43 remains evenly distributed across the cytoplasm, similar to day 7.  
By day 21 of hREC monoculture, there was noticeable reduction in cell number, and co-
staining of Cx43 and F-actin highlights major differences in cytoskeletal organisation between 
healthy and diabetic conditions (Figure 2.26). hREC in healthy conditions have similar Cx43 
distribution as day 7 and 14, but with more of a Cx43 concentration at the perinuclear area. 
F-actin filaments are clearly visible in the hREC grown in healthy conditions at day 21, 
whereas both Cx43 and F-actin distribution in the hREC in diabetic conditions for 21 days 
   




show major changes. Overall the hREC in diabetic conditions for 21 days look very small in 
size, lacking normal cytoskeletal structure. This suggests hREC the attachment to the PET 
membrane may be compromised in the long term diabetic conditions. F-actin filaments were 
no longer visible, Cx43 was visible at the cell membrane although there were large gaps 
between the cells, so cell-cell contacts were not functional.  
2.4.15 NO MAJOR DIFFERENCES IN HYPOXIC AND ANGOIGENIC RESPONSE FROM 
hREC MONOCULTURE ON PET 
HIF1α and VEGFR-2 expression were assessed, to explore oxidative stress and angiogenic 
changes. There were no noticeable differences across time and in healthy or diabetic 





















   

























Figure 2.24. hREC form a monolayer with GJ protein expression in both healthy and 
diabetic conditions at day 7 
hREC monocultures, P6, seeded at 2x104 cells/well on the apical surface of PET transwell inserts with 
1µm pores. Cells were grown in healthy conditions for 72H to allow hREC to become a monolayer. 
Cells were then kept in physiologically healthy conditions (20% O2 and 5.5mM glucose) or moved to 
diabetic conditions (2% O2 and 33mM glucose) for a further 7 days. Media was changed every 24-72H. 
Cells were fixed at day 7 and processed for IF analysis of ZO-1, VE-Cad and CX43 expression, to explore 
GJ and adherens junction formation, and for VEGFR-2 and HIF1α to analyses hREC response to hypoxia 
and angiogenesis. Images were captured using the Zeiss M800 confocal microscope, x40 oil 





























































































   

























Figure 2.25. Cx43 was expressed at cell-cell borders only in diabetic conditions in hREC 
monocultures at day 14 
hREC monocultures, P6, seeded at 2x104 cells/well on the apical surface of PET transwell inserts with 
1µm pores. Cells were grown in healthy conditions for 72H to allow hREC to become a monolayer. 
Cells were then kept in physiologically healthy conditions (20% O2 and 5.5mM glucose) or moved to 
diabetic conditions (2% O2 and 33mM glucose) for a further 14 days. Media was changed every 24-
72H. Cells were fixed at day 14 and processed for IF analysis of ZO-1, VE-Cad and Cx43 expression, to 
explore GJ and adherens junction formation, and for VEGFR-2 and HIF1α to analyses hREC response 
to hypoxia and angiogenesis. Images were captured using the Zeiss M800 confocal microscope, x40 oil 





























































































Day 14-hREC monocultures on PET insert 
   


























Figure 2.26. By day 21 there was cell loss in both healthy and diabetic conditions and 
cytoskeletal alterations in the diabetic hREC monocultures 
hREC monocultures, P6, seeded at 2x104 cells/well on the apical surface of PET transwell inserts with 
1µm pores. Cells were grown in healthy conditions for 72H to allow hREC to become a monolayer. 
Cells were then kept in physiologically healthy conditions (20% O2 and 5.5mM glucose) or moved to 
diabetic conditions (2% O2 and 33mM glucose) for a further 21 days. Media was changed every 24-
72H. Cells were fixed at day 21 and processed for IF analysis of ZO-1, VE-Cad and Cx43 expression, to 
explore GJ and adherens junction formation, and for VEGFR-2 and HIF1α to analyses hREC response 
to hypoxia and angiogenesis. Images were captured using the Zeiss M800 confocal microscope, x40 oil 






























































































Day 21-hREC monocultures on PET inserts 
   




2.4.16 hRP RETAINED PHENOTYPE MARKERS WHEN GROWN ON THE UNDER 
SURFACE OF PET MEMBRANES 
hRP were grown as monocultures during optimisation of the model to confirm hRP could 
attachment and growth on the underside of the PET material, whilst retaining their 
phenotype markers NG2, Desmin and +/- αSMA (Figure 2.27). αSMA was expressed in some 
hRP, which was a common feature of the hRP in all experiments, suggesting the hRP behaved 










Figure 2.27. hRP retained their phenotype when cultured on the bottom of PET 
membranes at day 14 
hRP monocultures, P6, seeded at 2x104 cells/well on the under surface of PET transwell inserts with 
1µm pores. Cells were grown in healthy conditions for 72H. Cells were then kept in physiologically 
healthy conditions) for a further 14 days. Media was changed every 24-72H. Cells were fixed at day 14 
and processed for IF analysis of NG2, αSMA, Desmin and VEGFR-2 to analyse cell phenotype and 
response to culture conditions. Images were captured using the Zeiss M800 confocal microscope, x40 

























   




2.4.17 JUNCTIONAL PROTEIN EXPRESSION WAS NO DIFFERENT IN CO-CULTURED 
hREC COMPARED TO MONOCULTRED hREC 
To provide in vitro data of vascular changes during diabetic conditions, hREC were grown on 
PET membranes, with hRP on the under surface; a model mimicking the human retinal 
capillary structure. Apical view, under surface view and z-stack projections were included to 
confirm the presence of both cell-types in the different models over time. VE-Cad and ZO-1 
were present on the membrane at cell-cell junctions of hREC in both healthy and diabetic 
conditions at day 7, when cells were grown in co-culture with hRP (Figure 2.28). This shows 
hREC grown in co-culture form similar barrier properties to those grown as monocultures 
(Figure 2.24), by day 7 in both healthy and diabetic conditions. Cx43 distribution in hREC in 
the co-culture model is no different from Cx43 in monocultured hREC at day 7, with Cx43 
present throughout the cytoplasm.  
By day 21, there was a reduction in hREC number in both healthy and diabetic co-culture 
models. However, there is much more hREC cell loss in diabetic conditions, with only clusters 
of shrunken hREC remaining. hREC co-cultured in healthy conditions for 21 days retain similar 
cell size and VE-Cad and ZO-1 expression as day 7 time point, with physical cell-cell contacts 
and only a small (variable) reduction in cell number (Figure 2.28, Figure 2.29). These data 
suggest when hREC are grown in healthy co-culture with hRP, they remain attached to the 
PET (ECM mimic) with functioning cell-cell contacts by day 21, whereas when grown as mono-
cultures, hREC appear to lose their cell-cell contacts when grown in the same conditions for 
the same period of time (Figure 2.26). In contrast, diabetic co-culture conditions have caused 
major hREC cell loss, shrinkage, clustering and possibly cells peeling off the PET membrane 
during the IF washing process (Figure 2.29). Similar to the monocultured hREC, the hREC co-
cultured in diabetic conditions lose cell-cell contact and the cell size is noticeably reduced 
when compared to healthy co-cultured hREC. hRP remained attached to the under surface 
of the PET in all conditions, suggesting they can withstand diabetic conditions for long periods 
of time. Unfortunately Day 14 data are missing due to damage to the cells on the PET inserts 
during processing for IF. 
 
   

























Figure 2.28. hREC co-cultured for 7 days expressed similar GJ proteins to 
monocultured hREC 
hREC P6, and hRP P8 were seeded  at a 1:1 ratio, with 2x104 hREC/well on the apical surface and 2x104 
hRP/well on the under surface of PET transwell inserts with 1µm pores. Cells were grown in healthy 
conditions for 72H to allow hREC to become a monolayer. Cells were then kept in physiologically 
healthy conditions (20% O2 and 5.5mM glucose) or moved to diabetic conditions (2% O2 and 33mM 
glucose) for a further 7 days. Media was changed every 24-72H. Cells were fixed at day 7 and processed 
for IF analysis of ZO-1, VE-Cad and Cx43 expression, to explore GJ and adherens junction formation, 
and for VEGFR-2 and HIF1α to analyses hREC response to hypoxia and angiogenesis. Images were 
captured using the Zeiss M800 confocal microscope, x40 oil magnification. Z-stack projections were 
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Day 7- Co-culture: hREC P6 + hRP P8 
   
























Figure 2.29. Co-cultured hREC retain healthy morphology and cell-cell contacts in 
healthy conditions at day 21  
hREC P6, and hRP P8 seeded  at a 1:1 ratio, with 2x104 hREC/well on the apical surface and 2x104 
hRP/well on the under surface of PET transwell inserts with 1µm pores. Cells were grown in healthy 
conditions for 72H to allow hREC to become a monolayer. Cells were then kept in physiologically 
healthy conditions (20% O2 and 5.5mM glucose) or moved to diabetic conditions (2% O2 and 33mM 
glucose) for a further 7 days. Media was changed every 24-72H. Cells were fixed at day 7 and processed 
for IF analysis of ZO-1, VE-Cad and Cx43 expression, to explore GJ and adherens junction formation, 
and for VEGFR-2 and HIF1α to analyses hREC response to hypoxia and angiogenesis. Images were 
captured using the Zeiss M800 confocal microscope, x40 oil magnification. Z-stack projections were 
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Day 21- Co-culture: hREC P6 + hRP P8 
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2.4.18 HIF1α AND VEGFR-2 EXPRESSION WAS INCONCLUSIVE AT DAY 7 AND DAY 
21 DUE TO CELL LOSS IN DIABETIC CONDTIONS 
HIF1α is a major transcriptional regulator of a cells’ response to hypoxia and should 
translocate to the nucleus when active. At day 7 in co-culture, there was no difference 
between HIF1α expression in healthy and diabetic conditions, displaying broad cytoplasmic 
distribution in both conditions (Figure 2.28). By day 21 of co-culture the HIF1α expression in 
hREC in healthy conditions remained unchanged from day 7. It was not possible to determine 
HIFα expression of hREC in co-culture diabetic conditions by day 21, due to the cytoplasmic 
shrinkage and clustering of the possibly partly detached hREC (Figure 2.29). Further imaging 
at earlier time points between day 7 and 21 may provide conclusive data on HIF1α activity.  
VEGFR-2 is a receptor for VEGF and can be up/down regulated on the cell surface in different 
microenvironments, with a major role in angiogenesis. At day 7 of co-culture, VEGFR-2 
appeared upregulated in hREC grown in diabetic conditions, compared with healthy 
conditions (Figure 2.28). Only one cell in the field of view appears to be expressing high levels 
of VEGFR-2 in day 7 healthy conditions, and that cell has 2 nuclei, suggesting it is undergoing 
mitosis. By day 21 of co-culture conditions, due to cell loss, clumping and shrinkage in 
diabetic conditions, similar to HIF1α, it was not possible to determine VEGFR-2 expression 
(Figure 2.29). Using the z-stack projection it is possible to see VEGFR-2 (magenta) was present 
in the healthy co-culture at day 21, in the perinuclear location, although it was not possible 
to compare these levels against the diabetic model.  
2.4.19 hRP SHOWED DIFFERENTIAL EXPRESSION OF αSMA IN ALL CULTURE 
CONDITIONS AND THROUGHOUT PASSAGING 
On TC plastic, TC treated glass and PET transwell membranes, hRP purchased from Cell 
Systems used throughout these experiments had positive/negative expression of αSMA. hRP 
grown on TC treated glass slides (Figure 2.30) highlights that some hRP were negative for 
αSMA and some were positive (green staining). There was no clear cause for this 
phenomenon, as hRP positive for αSMA had no obviously different morphology, and there 
was positive/negative αSMA expression in hRP in both healthy and diabetic conditions and 
in mono- and co-cultured hRP (Figure 2.27, Figure 2.29). hRP retained expression of PDGFR-





   









Figure 2.30. Some hRP expressed αSMA whilst others did not 
hRP P6, grown on TC treated glass slides for 7 days in healthy conditions. Some hRP expressed αSMA 
and some didn’t. This positive/negative αSMA expression did not appear to be influenced by the 
material the cells were grown on or the culture conditions. Images were captured using the Zeiss M800 
confocal microscope, x40 oil magnification. Scale bars= 50µm.  
 
 
2.4.20 hRP CYTOPLASMIC αSMA PROJECTIONS GREW THROUGH PET MEMBRANE 
PORES RESULTING IN AREAS OF DIRECT PHYSICAL CONTACT BETWEEN hRP 
AND hREC IN CO-CULTURE 
Using IF confocal microscopy z-stacking applications, it was possible to build z-projections of 
the hREC and hRP on either side of the PET membrane, at high resolution. These data were 
used to confirm the presence of hREC on the apical surface and hRP on the underside of the 
PET membrane at multiple time points and in healthy or diabetic conditions, to aid in 
validating the use of a retina-specific, human primary co-culture model. By day 14 hRP grown 
on the underside of PET membranes sent finger-like projections from the cytoplasm through 
the 1µm pore up to the apical surface, if they were grown on their own (monoculture) (Figure 
2.31 A) or grown in the presence of hREC on the apical surface (co-culture) (Figure 2.31B and 
C). The orange on the right panel highlights the projections which migrated to the apical 
surface of the membrane. This observation was important to take in to consideration as it 
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Figure 2.31. Cytoplasmic projection from hRP through PET membrane in both mono 
and co-cultures 
hRP P8, cultured in healthy conditions for 14 (A and B) and 21 days (C) on the bottom of PET 
membranes. A) hRP monoculture at day 14, B) co-culture at day 14, and C) co-culture at day 21. CD31 
and VE-cad confirmed the presence of hREC on apical surface of PET. Antibodies against αSMA were 
used to image cytoplasmic projections through PET membranes. Images were captured using the Zeiss 
M800 confocal microscope, x40 oil magnification. Z-stack imaging was sued to capture images of hRP 
projections passing through PET 1µm pores. Scale bars= 50µm. 
 
 
2.4.21 ANG-2 WAS SIGNIFICANTLY INCREASED IN DIABETIC CONDITIONS BUT IN 
CO-CULTURES THE DIFFERENCE WAS SMALLER 
Multiplex technology enabled quantification of 9 secreted proteins collected from cell 
supernatants at multiple time points, for mono and co-cultures, in healthy and diabetic 
conditions. Four out of nine proteins fell within range for quantification. Ang-2 is a soluble 
proangiogenic vascular growth factor, involved in adult angiogenesis. In monoculture, hRP 
did not secrete Ang-2. In monoculture, hREC secreted Ang-2 in low levels at all time points 
when in healthy conditions (Figure 2.32A). From day 7-21 hREC in monoculture in diabetic 
conditions secreted significantly more Ang-2 than those in healthy conditions (P<0.01). Ang-
2 levels spiked at 12149.1pg/ml by day 7 in diabetic mono-cultured hREC conditions, 
compared to healthy 2998.86pg/ml (p<0.001). When hREC were co-cultured with hRP, Ang-
2 levels remained higher in diabetic conditions, although this level only reached significant 
difference from healthy conditions at day 7 (p<0.001) and day 17 (p<0.01). Similar to 














   




monocultured hREC, Ang-2 levels again peak at day 7 at 8813.86pg/ml in the diabetic co-
culture model, compared to healthy 3490.6pg/ml, although the diabetic co-culture peak is 
over 3000pg/ml lower than in the hREC monocultured in diabetic conditions at day 7. When 
hREC and hRP were grown in co-culture in healthy conditions, Ang-2 levels reached a peak at 
day 14 at 5565.29pg/ml and levels were overall higher than those in healthy monocultured 
hREC, where Ang-2 levels peaked earlier and at day 7 and at lower concentration 
(2998.86pg/ml). By day 21 Ang-2 levels in the healthy co-culture model were almost three 
times (2.88) the levels of Ang-2 in hREC monocultures. By day 21 Ang-2 levels in the diabetic 
co-culture model were almost 1.5 times (1.48) the levels of Ang-2 in hREC monocultures.  
Taken together, these three graphs show that Ang-2 secretion was increased in diabetic 
conditions and also secretion levels were altered when hREC and hRP are grown in co-culture, 
more closely mimicking the environment of the retinal microvasculature. The presence of 
hRP appears to reduce the difference between Ang-2 secretion in healthy and diabetic 
models, by increasing the Ang-2 levels secreted in healthy conditions 
2.4.22 hRP CONTINUALLY SECRETED HGF OVERTIME ALTHOUGH DIABETIC 
CONDITONS AND PRESENCE OF hREC CAUSED A REDUCTION IN SECRETION 
LEVELS 
Hepatocyte growth factor (HGF) or scatter factor, is a paracrine cellular growth, motility and 
morphogenic factor which acts primarily on ECs and is involved in adult wound healing and 
organ regeneration. HGF was not secreted by hREC grown on their own (Figure 2.32B). HGF 
was secreted by monocultured hRP, in both healthy and diabetic conditions, with an 
increasing amount secreted over time. By day 14 hRP monocultured in diabetic conditions 
secreted significantly less HGF than hRP grown in healthy conditions, 804.4pg/ml vs 
1770.6pg/ml (p<0.001). HGF remained significantly reduced in hRP in diabetic conditions up 
to day 21, reaching peak in hRP monocultured in healthy conditions, at 3151.3pg/ml vs 
1578.2pg/ml in diabetic conditions at day 21 (p<0.001). However, when hREC and hRP were 
grown in co-culture, HGF secretion was reduced overall, to levels below 700pg/ml, with no 
significant differences between healthy and diabetic co-culture conditions. Taken together, 
these three graphs suggest HGF is not secreted at all by hREC, HGF secretion was reduced in 
diabetic conditions and that in the presence of hREC, hRP secretion of HGF was reduced to 
very low, stable levels compared to a much higher, rising trend when hRP were grown in 
isolation.  
   




2.4.23 BOTH hREC and hRP SECRETED IL-8 AND WHEN THE CELLS ARE CO-
CULTURED, THE EFFECT ON IL-8 SECRETION APPEARED ADDITIVE 
Interleukin-8 (IL-8) has two primary functions: induces chemotaxis in target cells, causing 
immune cells to migrate towards sites of injury/infection, and induced phagocytosis at sites 
of injury/infection. IL-8 is also a potent promoter of angiogenesis. When hREC were 
monocultured, IL-8 secretion was significantly increased at day 3 (p<0.01) at 2241.7pg/ml in 
diabetic conditions, compared to 1223.8pg/ml in healthy conditions (Figure 2.32C). However, 
at all other time points there were no significant differences in IL-8 secretion by 
monocultured hREC in healthy or diabetic conditions. There was a small dip in IL-8 secretion 
at day 10, but otherwise, levels remained relatively consistent over time. IL-8 secretion levels 
in hRP grown on their own, increase over time from day 10 onwards reaching 3217.6pg/ml 
by day 21, with no significant differences between healthy and diabetic conditions at any 
time point. When hREC and hRP were grown in co-culture, there appears to be an additive 
effect on IL-8 secretion. In co-cultures, IL-8 secretion remained relatively stable from day 0-
10 (similar to hREC monocultures), with a sharp rise from day 10-21 in both healthy and 
diabetic co-cultures, peaking at 5927.2pg/ml in healthy and 5020pg/ml in diabetic co-culture 
conditions. IL-8 secretion was higher in the healthy co-culture model from day 10-21, but this 
difference only reached significance on day 17 (p<0.05) with 5408.5pg/ml in healthy 
conditions compared to 4025pg/ml in diabetic conditions. Overall, the differences between 
IL-8 secretion in healthy and diabetic conditions was small. Although, in the co-culture model 
by day 21, IL-8 secretion increased to double the level in hRP monocultures and triple the 
level of hREC monocultures. These data suggest both hREC and hRP can secrete IL-8, and 
when cultured together, IL-8 secretion is affected in additive manner.  
2.4.24 DIABETIC CONDITIONS SIGNIFICANTLY REDUCED TIMP-2 SECRETION IN ALL 
MODELS 
TIMP-2 is an inhibitor of MMPs. MMPs degrade numerous ECM proteins during cell 
proliferation, tissue rearrangement and wound healing, therefore TIMP-2’s action inhibiting 
MMPs could be critical to the maintenance of tissue homeostasis and quiescence. When 
hREC were grown on their own, TIMP-2 secretion remained stable over time, although by day 
7-10 TIMP-2 was significantly reduced in hREC grown in diabetic conditions (p<0.01) and from 
day 14-21 the difference between healthy and diabetic is more significant (p<0.001) (Figure 
2.32D). Overall however, in monocultured hREC, levels of secreted TIMP-2 remained 
relatively low and did not surpass 6,264.1pg/ml in healthy conditions, or 4,765.2pg/ml in 
diabetic conditions. hRP secretion of TIMP-2 was much higher than hREC at all time points. 
   




hRP displayed a rising trend of TIMP-2 secretion over time, with levels significantly lower in 
hRP grown in diabetic conditions compared to healthy, from day 7-21 (p<0.001). The highest 
levels of TIMP-2 were observed at day 14 in hRP monocultured in healthy conditions 
24,878pg/ml, whereas in diabetic conditions, significantly lower TIMP-2 was secreted 
15,345.1pg/ml. When hREC and hRP were co-cultured, a similar trend of increasing TIMP-2 
secretion over time was observed. Likewise, TIMP-2 secretion was significantly reduced in 
diabetic co-culture conditions, from day 10 (p<0.05) to day 21 (p<0.01) compared to healthy 
conditions, although the difference between healthy and diabetic TIMP-2 levels was smaller 
than when hRP are grown on their own. Overall, when hREC and hRP were grown in co-
culture, their interaction appears to have a small suppressive action on TIMP-2 secretion, 
because by day 21 both healthy and diabetic co-culture conditions show lower TIMP-2 levels 















   




























Figure 2.32. Different secretion profiles of hREC and hRP in mono- and co-cultures and 
the effect of diabetic culture conditions over time 
hREC and hRP were cultured on PET membranes at 1:1 ratio, as mono- or co-cultures over 21 days. At 
seven time points media was collected and analysed for secreted Ang-2 (A), HGF (B), IL-8 (C) and TIMP-
2 (D). All samples were tested in duplicate and corrected against a sample of media with no cells. Data 
presented is an average, n=3 and error bars represent SD. Two-way ANOVA with Sidak’s multiple 
comparison test to account for errors from repeated measures was used to perform statistical analysis, 
using GraphPad Prism 6 software. *p<0.05, **p<0.01 and ***p<0.001. 
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2.4.25 VEGF RESULTS FROM ANGIOGENESIS BLOT CORROBORATE THAT MINIMAL 
VEGF WAS PRESENT 
Results from the multiplexing data suggested VEGF levels at day 7 were overall very low (0-
75pg/ml) (data not shown), with a large number of samples across all time points incalculably 
low, therefore it was not possible to analyse those results. In agreement with the 
multiplexing data, the VEGF and VEGF-D levels reported from the human angiogenesis 
antibody array at day 7 were also very low (0.06-0.28 relative to positive control) (Figure 2.32, 
Figure 2.33). 
2.4.26 DIABETIC CO-CULTURE CONDITIONS CAUSED REDUCED LEVELS OF SECRETED 
ENA-78 AND IL-6 BY DAY 7 
By day 7, Epithelial neutrophil-activating peptide 78 (ENA-78) levels were higher in the 
healthy co-culture model (1.5) compared to the diabetic co-culture model (0.84) (Figure 
2.33). Both healthy and diabetic co-culture models displayed higher ENA-78 secretion than 
healthy and diabetic hREC monoculture models (0.06 and 0.1 respectively). Interleuikin-6 (IL-
6) levels were highest in the healthy co-culture model (5.8), with one result reading as 
undetectably high (above the line), and at 2.15 in the diabetic co-culture model. Overall IL-6 
levels were lower in the hREC monoculture model. Healthy hREC monoculture IL-6 secretion 
levels were 1.08 whilst diabetic IL-6 levels were almost half the levels at 0.59. Therefore, IL-
6 levels were reduced in both mono- and co-culture diabetic models compared to healthy. 
2.4.27 LEVELS OF SECRETED PDGF-BB AND TIMP-1 WERE REDUCED IN DIABETIC CO-
CULTURE BUT NOT IN THE DIABETIC hREC MONOCULTURE CONDTIONS 
Platelet derived growth factor-BB (PDGF-BB) levels were higher in the healthy co-culture 
model (1.01) than the diabetic co-culture model (0.34) at day 7 (Figure 2.33). PDGF-BB levels 
were the same in healthy hREC monoculture (1.51) as the healthy co-culture model (1.01). 
PDGF-BB levels in diabetic hREC monoculture (0.67) were double those of the diabetic co-
culture model (0.34), although due to low n (2) this difference may not be significant. Overall, 
the diabetic co-culture model shows the lowest PDGF-BB expression. Both TIMP-1 and TIMP-
2 density were relatively high, which corroborates multiplex day 7 data (Figure 2.32), where 
TIMP-1 levels were too high to quantify. For the angiogenesis antibody array, TIMP-2 levels 
were too high to quantify and therefore analyse, but TIMP-1 results fell within quantifiable 
range.  TIMP-1 levels were lowest in diabetic co-culture (1.56) and highest in diabetic hREC 
monoculture (3.66), similar to but lower than the  pattern of secreted PDGF-BB levels, 
suggesting the presence of hRP and diabetic conditions reduced the secretion of both 
proteins.  
   




Overall, the angiogenesis blot data highlights differences in the secretome of angiogenic 
factors when ECs were grown on their own (circles) or as co-cultures (triangles) (Figure 2.33), 
which along with compelling evidence from the multiplex analysis data (Figure 2.32) supports 
the use of co-cultures to provide models closer to the in vivo environment when exploring 
















Figure 2.33. Different secretion profiles of hREC in mono- and co-cultures and the effect 
of diabetic culture conditions at day 7 
Human Angiogenesis Antibody Array was used to analyse the same media used for the multiplex array 
(Figure 2.32). Data is from day 7 only, using multiple repeats pooled to make 1ml of supernatant, the 
volume required for the blot protocol. Models sampled were: hREC only healthy, hREC only diabetic, 
co-culture healthy and co-culture diabetic. 20 angiogenic proteins were analysed. Results above the 
red dotted line were too dense to be quantified. Results at 0 were not present in neat supernatant. 
Italics indicate when a result from one of the four models was too high or low to quantify. All blots 
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2.5 DISCUSSION  
2.5.1 OVERVIEW 
The aim of this chapter was to develop and optimise a human primary, retina-specific, 
microvascular co-culture model to provide an in vitro environment to study; cellular changes, 
disease progression and future cellular or pharmacological intervention for conditions such 
as DR. Current treatment of DR only targets late stage disease, where dysfunction of the 
retinal capillary ECs and pericytes leads to microaneurisms, plasma exudates and edema and 
after an initial non-proliferative stage, new, leaky vessels form during PDR, further 
exacerbating the condition when large bleeds can lead to vision impairment or loss. This 
study aimed to explore the early changes in cell behaviour when cells comprising the retinal 
capillary (hREC and hRP) were subjected to either physiologically healthy or diabetic 
conditions. Traditional cell culture involves assessing the behaviour of cells grown on TC-
treated plastic or glass, however, growing cells in isolation does not take in to consideration 
the effect of neighbouring cells, which would interact with each other in vivo. Therefore, 
growing hREC and hRP together with a shared BM mimic, in conditions optimised to maintain 
the phenotype/function of both cells would provide valuable data on the early cellular 
changes in T2DM. 
This chapter provides data which confirm that hREC and hRP retained their phenotype in 
vitro, and can, therefore, provide human, tissue-specific data relating to changes between 
diabetic and healthy conditions, over time, unlike previous animal, immortalised or large 
vessel co-culture models reported in the literature. Differences in the cellular response to 
oxidative stress, angiogenesis and inflammation in healthy compared to diabetic conditions 
provided evidence that low oxygen (2%) and high glucose (33mM) insult induced a diabetic-
like state in both hREC and hRP. The hREC and hRP response to oxidative stress, angiogenesis 
and inflammation were different when cells were grown as mono-culture compared to co-
culture models, highlighting the importance of using co-culture models to elucidate 
modifications to the perivascular pericyte cells as well as the underlying EC layer during 
progression of DR.  
 
 
   




2.5.2 hREC AND hRP ARE SUITABLE HUMAN PRIMARY CELLS TO STUDY THE 
CELLULAR RESPONSE DURING DIABETIC RETINOPATHY  
In order to improve current treatment options for DR, investigation of early changes in the 
cells comprising the retinal microvasculature (hREC and hRP) would provide insight for 
potential new cellular or pharmaceutical therapies, to either slow or prevent progression to 
sight threatening stage of disease. Once taken from their in vivo tissue-specific environment, 
human primary cells grown for multiple passages in vitro can de-differentiate and become 
fibroblastic or senescent overtime, which is why many groups opt to genetically alter their 
primary cells to provide a stabilised cell line191. In particular, due to the pluripotent nature of 
the pericytes192, it was important to ensure that there were no substantial changes in cell size 
and shape; which could indicate de-differentiation and provide irrelevant data. De-
differentiation can be recognised using light microscopy by increased cell size and elongation 
when cells become fibroblastic, and also increase in size of the cell cytoplasm when cells 
become senescent30,193. In the present study, hREC and hRP maintained their characteristic 
morphology up to P10 without genetic modification, confirmed by regular light microscopy 
(Figure 2.8), IF staining (Figure 2.9, Figure 2.10) and flow cytometry analysis (Figure 2.11, 
Figure 2.12). 
When investigating diseases of the vasculature, many groups exploring EC behaviour use 
macro-vascular sourced ECs such as HUVECs or aortic ECs in vitro, often from mouse or 
bovine tissue, simply due to ease of isolation from larger vessels and/or commercial 
availability194, and validate their in vitro findings using an animal model. Human primary 
vascular ECs are commercially available sourced from pancreas or brain for example, 
however, there are differences reported between ECs isolated from different organs14, and 
also between cells sourced from larger vessels compared to the microvasculature42,195. For 
example, long-term culture of capillary ECs requires specific protein coating of culture 
surfaces and specialised growth medium, compared to their large vessel counterparts196. 
These studies underline the importance of using human, primary, microvascular-sourced 
cells when investigating the retina, and also highlight some of the challenges faced when 
growing these cells in vitro. 
To ensure the data reported were tissue-specific, hREC were regularly analysed to confirm 
endothelial functionality and ensure no endothelial to mesenchymal transition and hRP were 
assessed for cell-specific protein expression to ensure they had not de-differentiated to a 
fibroblastic phenotype, issues which have been reported by other groups when modelling 
   




disease in vitro48,197. By day 21, hREC grown as monocultures retained expression of VE-Cad 
and ZO-1 (Figure 2.10, Figure 2.16, Figure 2.17, Figure 2.24, Figure 2.25), both of which are 
involved in the barrier function of ECs. At various time points hREC were tested for expression 
of CD31 and vWF, which are endothelial-specific, and hREC used in these experiments were 
always positive for both markers (Figure 2.10, Figure 2.12, Figure 2.16). Presence of αSMA in 
hREC would suggest trans-differentiation to smooth muscle cells or a fibroblast cell-type, due 
to the flexibility of primary cell fate in vitro198, however hREC remained negative for αSMA 
expression throughout passaging (Figure 2.10, Figure 2.24, Figure 2.25, Figure 2.26).    
In the present study, TEER was measured at multiple time points from experimental time 0 
to day 21 and results were generally very low (6-18 Ω.cm2) (Figure 2.23), when compared to 
similar contact co-culture experiments by other groups; Hayashi et al. reported up to 98 
Ω.cm2 and Wisniewska-Kruk et al. reported up to 380 Ω.cm2 62,199. There was also no overall 
significant difference between mono- and co-cultured hREC TEER over the 21 days in our in 
vitro model, compared to the large differences reported in the study by Hayashi et al. In vivo, 
retinal ECs form a barrier between blood and the underlying tissue (BRB), with highly 
regulated permeability to allow nutrient exchange, and it is conjectured that this barrier 
regulation is disrupted in the early stages of DR104. TEER is often reported in EC studies as an 
indicator of the barrier function of an EC monolayer. Although it is a useful and relatively 
simple, high throughput method, several factors can influence TEER readings including but 
not confined to; temperature, surface area, passage number, culture period, cell culture 
medium components and shear stress136. In a tri-culture model of rat brain ECs, pericytes and 
astrocytes, TEER was reported as ~380 Ω.cm2 by day 5, although the EC:Pericyte:Astrocyte 
seeding ratio was 10:1:1, quite different from my 1:1 ratio and cells were seeded on to 12 
w/p transwell inserts with 0.4µm pores, all potential contributing factors in the discrepancies 
between our TEER results and other published groups200. Although every effort was made to 
ensure consistent temperature, appropriate transwell insert surface area and low cell 
passage number, it was not possible to draw any conclusions from the TEER data collected 
for this study. 
Due to the pluripotency of the pericytes and dynamic expression of various markers, different 
groups use different antibodies to confirm phenotype. It is generally agreed that a panel 
consisting of antibodies against; PDGFR-β, NG2, desmin, αSMA and CD90 can be used to 
confirm hRP phenotype47,201. Throughout passaging, the hRP used in these experiments 
expressed these markers (Figure 2.9, Figure 2.18, Figure 2.19, Figure 2.30), albeit there was 
   




a degree of heterogeneity within hRP cultures. Some hRP expressed αSMA, whilst some did 
not (Figure 2.30). This phenomenon has been reported in the literature190,202, although the 
reason is not fully understood, and the positive/negative expression did not appear to be 
influenced by different culture conditions. CD146 was expressed by 26.3% of hRP (Figure 
2.11) and this can be explained by the reported ‘dynamic’ expression of CD146 by pericytes, 
dependent upon specific in vitro environments203,204. hREC were CD31 positive and CD90 
negative, in direct comparison with hRP which were CD31 negative, CD90 positive (Figure 
2.12, Figure 2.11). CD90/THY-1 function is not yet fully understood but it is believed to be 
involved in adhesion and cell communication in numerous cell types, with highest expression 
in the neurovasculature in brain tissue of humans190. Interestingly, Park et al. found two 
distinct populations of human brain pericytes, one was CD90+ and 57% CD146+, one CD90- 
and 26.2% CD146+. However, the pericytes sourced from the human retina used in the 
present study appeared to be >99.9% CD90 positive (Figure 2.11), but also 26.3% CD146+, 
highlighting a broad similarity, whilst also emphasising differences in pericyte phenotype 
reported between different studies, and from brain as opposed to retinal tissue. 
hRP function by wrapping around the perivascular surface of ECs, sharing physical contact 
through a shared BM and communicating via paracrine signalling (Figure 2.4)205. In the 
present study, hRP extended finger-like cytoplasmic projections through the 1µm pores 
when grown on the underside of the PET membrane, when cultured on their own or in co-
culture, with hREC on the apical side (Figure 2.31). This happened in both healthy and 
diabetic conditions and was discovered using z-stack confocal imaging of anti-αSMA antibody 
staining, which labelled the actin cytoskeleton within the hRP cytoplasm. hRP morphology 
relates to function, enabling them to wrap around other cells, a function that has been 
observed in vitro when ECs and pericytes form structured tubules when cultured together in 
3D gels206–208. Hence, the ability of hRP to send cytoplasmic projections through 1µm pores 
is not surprising, although this behaviour has not been reported in the literature before. The 
high resolution of the z-stack confocal images clearly showed the extension of the 
cytoplasmic αSMA projections through the pores and on to the top surface of the PET 
membrane. This altered the configuration of the co-culture in some areas, because the hREC 
and hRP were in direct physical contact rather than separated by the PET (ECM-substitute) 
membrane, and this finding should be taken into consideration when interpreting these data 
and designing future experiments. 
   




As mentioned above, the phenomenon of some hRP expressing αSMA whilst others do not 
is not fully understood, but has been investigated by a number of groups to further elucidate 
the role of pericytes in vascular disease progression190,202,209. In the present study, there were 
no noticeable difference between percentage of αSMA positive/negative cells in healthy 
versus diabetic conditions (Figure 2.27, Figure 2.29). Because this αSMA positive/negative 
expression pattern has been reported by numerous groups, this corroborates our findings 
that the hRP in both mono- and co-culture experiments did not transition in vitro within our 
experimental timeframe, therefore validating our novel co-culture setup.  
A combination of light microscopy, IF staining and flow cytometry has provided validation 
that hREC and hRP maintained their phenotype, confirming they could be grown together 
and were robust for long periods of time in vitro. Both hREC and hRP showed some degree 
of heterogeneity in vitro, however this is a common feature of human primary cells reported 
by other studies. hREC and hRP both grew in physiologically healthy conditions during growth 
optimisation and characterisation, and the next step was to assess their ability to withstand 
diabetic conditions mimicking DR.  
2.5.3 DOUBLE INSULT OF LOW OXYGEN (2%) AND HIGH GLUCOSE (33mM) 
INDUCED CHANGES IN ANGIOGENEISIS, OXIDATIVE STRESS AND 
INFLAMMATION-REALTED PROTEIN EXPRESSION 
Throughout onset and progression of T2DM, the ECs lining blood vessels and the perivascular 
pericytes progressively deteriorate due to the persistent, poorly controlled hyperglycaemic 
environment. Disruption to the EC capillary lining can lead to disrupted blood flow and 
ultimately vessel occlusion, which in turn causes ischemia, leading to hypoxia and subsequent 
non-perfusion of the underlying retina tissue. During T2DM, reduced insulin production or 
insulin resistance leads to an increase in blood glucose, and if poorly controlled or left 
untreated, causes a state of hyperglycaemia in the blood66. Therefore, in order to investigate 
cellular changes during T2DM, in vitro conditions were carefully optimised to mimic the in 
vivo glucose and oxygen concentrations reported in the healthy and diabetic retina. 
In a healthy human, blood glucose levels should be between 4.0 to 5.4 mmol/L (72 to 99 
mg/dL) when fasting and up to 7.8 mmol/L (140 mg/dL) 2 hours after eating210. For people 
with diabetes, the WHO defines hyperglycaemia as; blood glucose levels greater than 7.0 
mmol/L (126 mg/dl) when fasting and greater than 11.0 mmol/L (200 mg/dl) 2 hours after 
meals (Table 1.3)88. Diabetes is a long onset, progressive disease (often 10-20 years before 
symptoms arise), so to mimic that condition in vitro, generally much higher glucose 
   




concentrations are used. Several groups have used [D]+ glucose concentrations ranging from 
20-35mM to represent high glucose conditions relevant to human T2DM in vitro97,126,127,211–
215. Measurements of metabolic activity in hRP grown in 0-35mM glucose for over 14 days 
indicated a significant difference at 35mM, compared to 20-30mM (Figure 2.15), suggesting 
that this very high dose had an effect on cell function. 25mM or 30mM D-glucose is most 
commonly used to mimic diabetes in vitro, however following the trend of altered metabolic 
activity above 30mM glucose for hRP in the glucose concentration curve, I chose 33mM as 
this has previously been reported in the literature126. 
Modelling a disease in vitro is often a compromise between mimicking as closely as possible 
the in vivo disease, whilst working within the laboratory parameters. Choosing the 
appropriate oxygen tension presents a complicated issue for cell culture experiments. During 
optimisation, by day 7, hREC and hRP mono-cultures at high glucose and 5% oxygen were 
viable and showed only minor differences in angiogenic response compared with control, but 
no difference in junctional and oxidative stress protein expression (Figure 2.17, Figure 2.19), 
therefore, oxygen levels were reduced to 2% for subsequent co-culture experiments. This 
lack of difference between in vitro optimised ‘healthy’ and ‘diabetic’ conditions could in part 
be due to the use of sustained high glucose levels. Other groups report that intermittent high 
glucose has a more detrimental effect on both ECs and pericytes97,127,216. However, the 
multifactorial environment of diabetes progression makes it very difficult to account for 
every parameter, and sustained high glucose was used for my model. This prevented regular 
re-oxygenation of the cultures, which would have occurred if regular changes of medium 
were required to alter glucose levels. Intermittent glucose is, however, an important risk 
factor for disease progression and should, therefore, be considered for future work. 
Oxygen levels in vivo vary between tissues, from 12% to 1%, depending on distance from the 
arterial blood vessel supply and the metabolic requirements of the tissue12. Oxygen levels in 
the human eye have been reported as ranging from 1 to 5%217, and the tissue of the retina 
has the highest oxygen consumption in the body, due to the high metabolic activity and 
constant renewal of the photoreceptors in the neural retina218. Therefore, along with the 
brain, alterations in oxygen and nutrient supply caused by compromised blood flow, can have 
particularly profound effects on the cells of the retina, leading to vision loss219. It is widely 
accepted that human primary cells, and stem cells in particular, favour a low oxygen 
environment (<5%) similar to in vivo levels, to allow cell growth without de-differentiation220. 
This, therefore, is in opposition to the idea of growing human primary cells at ambient (20%) 
   




oxygen, as hyperoxia as well as hypoxia can cause oxidative stress damage to the cell via ROS 
production221,222. This suggests during the process of primary cell isolation and culture, 
ambient ‘physioxia’ (20%) may induce some unavoidable, undesirable changes to the human 
primary cells that would not be seen in vivo223. However, with consideration of these cell 
culture limitations, data from this model remains very useful in beginning to elucidate cell 
changes in diabetic conditions. 
In the present study, HIF1α expression in hRP subjected to 5% oxygen and 33mM glucose for 
7 days (during initial optimisation of diabetic conditions), appears perinuclear, suggesting the 
hRP in the double insult conditions underwent a major transcriptional alteration to adapt to 
hyperglycaemic, hypoxic conditions (Figure 2.19). Early pericyte drop-out is characteristic of 
DR, alongside EC dysfunction and ultimately vascular leakage108,157. Disrupted blood supply 
and/or insufficient gas exchange at the capillary bed can create a hypoxic environment, 
leading to activation of HIF-1α within the cell, which is at the centre of complex pathways 
that enable cell survival, including initiating angiogenesis by activating VEGF gene 
transcription224. SOD-1 (CuZn-SOD) is the soluble cytosolic form of SOD, and along with SOD-
2 (Mn-SOD, mitochondrial) and SOD-3 (EC-SOD, extracellular), are the primary anti-oxidant 
enzymes that protect cells from free radical damage225. SODs are highly conserved enzymes 
that catalyse the conversion of highly reactive superoxide anion into oxygen and hydrogen 
peroxide124. Decreased SOD-1 activity has been reported in obese humans91, and SOD activity 
is reduced and its expression down regulated in the diabetic retina226. SOD-1 was expressed 
specifically at the ER compartment in hRP grown in 5% O2 (Figure 2.19), suggesting the 
oxidative stress response was activated. However, unlike the hREC, hRP showed no 
difference in Ang-2 expression at 5% compared to 20% O2, therefore, an antioxidant 
response, but not an angiogenic response had been initiated by the hRP (Figure 2.17, Figure 
2.19). 
In the present study, Cx43 was expressed throughout the cytoplasm at all time points, except 
for on day 14 in diabetic conditions, where Cx43 appeared to cluster at the cell-cell junction 
more than at any other time or condition, perhaps representing a tight monolayer (Figure 
2.24, Figure 2.25, Figure 2.26, Figure 2.28, Figure 2.29). This suggests Cx43 expression is 
highly dynamic and is affected by oxidative and hyperglycaemic stress. Breakdown of the EC 
cell-cell junctions leads to leaky microvasculature, and during T2DM this EC barrier 
breakdown is insufficiently repaired for reasons not yet fully understood. Therefore, the 
expression of barrier proteins VE-Cad, ZO-1 and Cx43 was explored, due to their role in EC 
   




cell-cell communication. Cx43 is a component of EC GJs, reported to be involved in numerous 
processes such as cell-cell communication, cell migration and survival signalling as well as 
proliferation and wound healing227. Of the three connexins expressed in the retinal vascular 
ECs (Cx37, Cx40 and Cx43), Cx43 is the most abundant type228. Various groups have suggested 
Cx43 expression is affected in vitro by diabetic cell culture conditions229, which supports the 
change in Cx43 expression in the diabetic conditions observed in the present study. 
ZO-1 is a TJ protein which regulates tension by acting on VE-Cad and is involved in barrier 
formation, cell migration and angiogenesis of primary ECs60. In a study using bovine retinal 
microvascular ECs, conditioned medium from cultured rat brain astrocytes was found to 
increase ZO-1 expression compared to controls, suggesting factors released by astrocytes (a 
perivascular cell-type) contribute to EC barrier function in, for example,  the blood-brain 
barrier (BBB) and BRB230. This was more recently confirmed by Dohgu et al., who found 
increased BBB function with a significant decrease in the permeability to sodium fluorescein 
in a co-culture of immortalised mouse brain capillary ECs with primary rat brain pericytes, 
compared to mono-cultures, induced by Transforming growth factor-β (TGF-β) secretion 
from the pericytes231 . Although Dohgu et al. did not investigate ZO-1 expression, TGF-β has 
been attributed to upregulation of ZO-1 and, therefore, improved barrier properties when 
added to quiescent, but not proliferating human primary corneal ECs in vitro232. TGF-β has 
not been explored in our study, however, these findings highlight the importance of release 
of growth factors from neighbouring cells, which directly influence EC behaviour, hence 
underlining the benefit of using in vitro co-culture models as opposed to traditional mono-
cultures. These publications suggest co-culturing hRECs with a perivascular cell such as hRP 
may improve ZO-1 expression, however, ZO-1 was expressed equally in both mono- and co-
cultures and in both healthy and diabetic conditions at day 7 (Figure 2.24, Figure 2.28). By 
day 21 in co-cultures, hREC maintained a healthy morphology with ZO-1 expression at cell-
cell borders only in the healthy conditions, whereas in diabetic conditions there was cell 
rounding and shrinkage, creating large empty spaces on the PET membrane, suggesting 
dysfunctional hREC at this stage (Figure 2.29). In healthy mono-cultures, hREC number was 
reduced and there was loss of cell-cell contact, with large gaps between cells (Figure 2.26). 
This supports the hypothesis that co-culture with hRP in healthy conditions sustains hREC for 
extended culture periods (21 days) compared to mono-cultures and also that hREC do not 
survive as well in long term diabetic co-culture conditions compared to healthy. The effects 
of the diabetic insult were more noticeable in the co-culture compared to the mono-culture 
   




at day 21 (Figure 2.26, Figure 2.29), highlighting the necessity to co-culture hREC with hRP to 
achieve more relevant results, considering they are so closely associated in vivo.    
VE-Cad was expressed by hREC in both health and diabetic conditions and also in mono and 
co-cultures (Figure 2.10, Figure 2.24, Figure 2.25, Figure 2.28). By day 21, hREC in diabetic 
conditions in both mono- and co-cultures underwent cell rounding and shrinkage, creating 
large empty spaces on the PET membrane, suggesting dysfunctional hREC at this stage (Figure 
2.26, Figure 2.29). As with the observations of ZO-1 expression, there was more cell shrinkage 
in the diabetic co-culture model, although the number of cells remaining was similar 
compared to diabetic mono-culture at day 21, suggesting the double insult of sustained low 
oxygen and high glucose for 21 days led to EC dysfunction, and barrier failure in both mono- 
and co-cultures over time (Figure 2.26, Figure 2.29). VE-Cad is a member of the cadherin 
family, the vascular endothelial-specific transmembrane component of the adherens 
junction complex. In a recent comprehensive study by Tornavaca et al., it has been found to 
be upstream of ZO-1, which indicates VE-Cad is essential to recruit ZO-1 through regulation 
of the actin cytoskeleton60. VE-Cad is also involved in multiple regulatory and signalling 
mechanisms such as modulating growth factor receptors, intracellular messengers and 
proteins for gene transcription regulation59. In a study using primary ECs, pericytes, and 
perivascular resident macrophage-type melanocytes isolated from cochleae of mice, Neng et 
al. found conditioned media from pericytes and perivascular macrophage-type melanocytes 
caused increased expression of ZO-1 and VE-Cad by ECs at the mRNA and protein level, and 
found increased barrier function233. Therefore, exploring the presence of both VE-Cad and 
ZO-1 would confirm the presence of mature and functional barrier junctions between ECs as 
well as normal EC regulation and signalling.  
2.5.4 hREC AND hRP HAVE SIGNIFICANTLY DIFFERENT SECRETION PROFILES 
WHEN GROWN INDIVIDUALLY OR AS CO-CULTURES IN HEALTHY OR 
DIABETIC CONDITIONS 
Cells cultured in co- or tri- culture models are continuously being investigated and re-
developed, with the aim of developing highly reproducible, stable environments that can be 
used for applications such as disease modelling and drug testing234. To create environments 
as close as possible to in vivo human tissues, whilst reducing the complexity of multiple 
factors influencing results, simple but well characterised, species and tissue-specific co-
culture models can provide invaluable data on, for example,  toxicity reports, cell signalling 
pathways, cell growth etc., as a step before the use of animal models or clinical trials. To 
understand changes in the retinal microvasculature, where pericyte coverage is very high, 
   




optimising a co-culture of hRP and hREC provides more relevant data that may not be present 
in mono-cultures of either cell-type. Several signalling systems have been implicated in 
pericyte:EC function, therefore, the breakdown or dysfunction of these interactions is likely 
to add to the diabetic milieu, and may provide a target for intervention at early stage DR46. 
In the present study, cell culture medium was collected at 7 time points, over 21 days, 
providing data on cell behaviour over time rather than a few early, or one single time point 
(Figure 2.32). Cell culture medium from day 7 was analysed for secreted proteins via both 
multiplex and antibody array techniques. Published co-culture models range in time scale 
from: unreported, to 2, 3 and 8 days, providing data on relatively short-term disease 
models62,131,199. In an in vitro study of the effect of hyperglycaemia on human retinal ECs, 
hRECs responded to cytokines rather than high glucose235, suggesting diabetes–related EC 
injury in the retina may be caused by glucose-induced cytokine release by non-endothelial 
retinal cells, and hREC can in fact withstand high glucose insult alone. Therefore, we 
investigated the response of hREC grown alone and hREC co-cultured with hRP, and the 
results suggest the two cell-types do secrete different proteins when grown as mono- vs. co-
cultures. 
To improve understanding of the physiological changes occurring in a chronic disease such 
as T2DM, the secretion profile of 9 angiogenic proteins released from: hREC only, hRP only 
and co-cultures, in healthy and diabetic conditions was analysed at 7 time points, over 21 
days and directly compared and quantified, using multiplex technology (Figure 2.32). Four 
proteins were too low to quantify using these experimental parameters: TNFα, VEGF, PDGF 
and FGF. TIMP-1 levels were too high to quantify in all conditions. Ang-2, IL-8, TIMP-2 and 
HGF were all secreted at levels within range for direct quantification and significant 
differences in cell secretion profile of these four angiogenic proteins were found when hRP 
and hREC were grown individually compared to when grown as co-cultures. Cells grown in 
diabetic conditions also had significant changes to all four proteins, compared to those grown 





   






Table 2.9. SUMMARY OF SECRETED ANG-2 FROM EACH MODEL  
ANG-2 Day 7 Day 14 Day 21 
Model Healthy Diabetic Healthy Diabetic Healthy Diabetic 
hREC only + +++ + ++ + ++ 
hRP only - - - - - + 
Co-culture + ++ ++ ++ ++ ++ 
 
A summary of the results for Ang-2 expression is provided in Table 2.9. Under physiologically 
healthy conditions, Ang-1 binds to and activates the Tie-2 receptor, leading to increased; EC 
survival, vessel stability, TJ integrity and ultimately tissue homeostasis236. Under pathological 
conditions, such as T2DM, Ang-2 is upregulated and competes against Ang-1 for binging on 
the Tie-2 receptor, resulting in inactivation and ultimately destabilisation of the vasculature 
via an angiogenic shift in the target cells34. Current treatment for PDR involves a combination 
of laser therapy and anti-VEGF drugs, however new treatments based on targeting the effect 
of Ang-2 are currently at early clinical  trial stage99. Data from the present study suggest hRP 
grown as monoculture do not secrete Ang-2, until day 21 when very low levels are secreted 
in diabetic conditions (Figure 2.32A). hREC grown as monocultures secreted Ang-2 at 
consistently low levels in healthy conditions over time, whereas in diabetic conditions hREC 
Ang-2 levels were significantly higher from day 3 onwards. Ang-2 levels in the co-culture 
model were also higher in the diabetic conditions at all time points. Ang-2 levels in healthy 
co-cultures were overall higher than EC grown in healthy monoculture, which implies the 
presence of hRP results in higher ambient Ang-2 secretion by either hREC alone, or both hREC 
and hRP in healthy co-culture conditions. In diabetic co-culture conditions, the peak in Ang-
2 secretion at day 7 was 27.45% lower than the peak in the hREC only diabetic model. That 
being said, from days 10-21, Ang-2 levels remained higher in diabetic co-culture compared 
diabetic hREC monoculture conditions. By day 21 diabetic co-culture Ang-2 levels were 32.6% 
higher than levels in diabetic hREC monocultures. Taken together these data imply Ang-2 is 
highest in diabetic conditions. Ang-2 levels were generally higher in the co-culture model, 
except of a higher peak at day 7 in the diabetic hREC only model. This suggests the presence 
   




of hRP increased Ang-2 secretion in both healthy and diabetic co-culture models compared 
to hREC grown on their own. Many studies using both animal and human retinae suggest 
Ang-2/Tie signalling is critical for pericytes survival and interaction with underlying EC, where 
increased Ang-2 activity leads to unstable pericyte:EC contact points44,53. In a mouse study, 
Park et al. found high glucose conditions resulted in Ang-2 induced pericyte apoptosis via 
α3β1 integrin237. Overall, in agreement with reports from the literature, we found a 
significant, very high peak in Ang-2 in diabetic conditions. My results highlight the difference 
between hREC and hRP grown in monoculture compared to co-cultures and also the 
importance of the 21 days duration of cell culture, considering changes were observed over 
a long period of time e.g. hRP do not secrete detectable levels of Ang-2 until very low levels 
in diabetic conditions at day 21. 
 
Table 2.10. SUMMARY OF SECRETED HGF FROM EACH MODEL  
HGF Day 7 Day 14 Day 21 
Model Healthy Diabetic Healthy Diabetic Healthy Diabetic 
hREC only - - - - - - 
hRP only + + ++ + +++ ++ 
Co-culture + - + - + + 
 
A summary of the results for Hepatocyte growth factor (HGF) expression is provided in Table 
2.10. HGF, or scatter factor, has been described as both an adipocytokine and a 
hepatokine238, which has a role in metabolic flux of glucose in various insulin-sensitive cells, 
with growing evidence suggesting HGF plays a role in metabolic disorders such as T2DM239. 
A study using bovine retinal ECs concluded retinal ECs secrete HGF and it is involved in EC 
proliferation and migration, although the concentrations of [D+]glucose used during cell 
culture were not specified240. In the present study, HGF was not secreted by hREC in 
monoculture. HGF was secreted by hRP, increasing over time, with significantly more HGF 
secreted in healthy conditions compared to diabetic (Figure 2.32B). When hREC and hRP 
were grown in co-culture, HGF levels remained very low across the 21 days, in both healthy 
and diabetic conditions. HGF levels peaked in healthy hRP monocultures, reaching 
3151.3pg/ml by day 21, 4.7 fold higher than in healthy co-cultures. Taken together, these 
   




data suggest the presence of ECs in the co-culture model reduced the level of HGF secreted 
by hRP, which over time cultured alone secreted over 4 times more in healthy conditions. In 
a study of 1,474 patients, significant increase in HGF levels was correlated with multiple 
components of the metabolic syndrome241, however, this was a general disease-free 
population study, so these patients were not diagnosed with T2DM. A comprehensive study 
comparing human patients at various stages of eye disease, both diabetic and non-diabetic, 
found vitreous HGF levels significantly increase depending on severity of retinopathy242. This 
study suggests HGF levels vary depending on stage of retinopathy, and they focused on PDR. 
PDR has not been specifically pharmacologically induced in the present study, so although 
useful, Nishimura et al’s. data is not directly comparable to the reduced HGF observed in the 
present study. These results further highlight the differences in hREC and hRP behaviour 
when grown as monocultures compared to co-cultures, and again the importance of 
monitoring protein secretion over an extended period of time, because some changes only 
became significant after 14 days.  
 
Table 2.11. SUMMARY OF SECRETED IL-8 FROM EACH MODEL  
IL-8 Day 7 Day 14 Day 21 
Model Healthy Diabetic Healthy Diabetic Healthy Diabetic 
hREC only + + + + + + 
hRP only - - + + ++ ++ 
Co-culture + + ++ ++ +++ +++ 
 
Interleukin-8 (IL-8) is a chemokine involved in systemic immunity, wound healing, 
macrophage infiltration, inducing chemotaxis in target cells, and also a potent promoter of 
angiogenesis243. A summary of the results for IL-8 expression is provided in Table 2.11. Both 
hREC and hRP secreted IL-8 when grown in monoculture, in both healthy and diabetic 
conditions (Figure 2.32C). Except for a rise in IL-8 in at day 3 in hREC grown as monocultures 
in diabetic conditions, there was no significant difference between healthy and diabetic 
conditions over time. hRP initially secreted very low levels of IL-8 until day 10, where in both 
healthy and diabetic conditions IL-8 levels increased until day 21, although there was no 
significant difference between healthy and diabetic conditions. In the co-culture model, IL-8 
   




levels remained consistent from 0-10 days at roughly 2500pg/ml for both healthy and 
diabetic models, until day 10 where IL-8 levels increased over time, with higher levels in 
healthy conditions, although this only reached significance at day 17. Unfortunately no 
results could be extrapolated from the day 7 human antibody array IL-8 data, because IL-8 
levels exceeded the maximum density for quantification (Figure 2.33), however, this does 
support the presence of IL-8 at day 7, in both the hREC and co-cultures, as detected from the 
multiplex data. Circulating IL-8 is elevated in patients with T2DM244 and also elevated in 
Keratinocytes cultured in high glucose at both the mRNA and protein level245. Due to its role 
in the inflammatory pathway and because diabetes is a disease of chronic inflammation, IL-
8 levels were expected to be significantly raised in the diabetic conditions, however this was 
not the case within the timeframe of this experiment. Nevertheless, the contrast between 
the mono- and co-culture results and the change in IL-8 secretion over a long period of time 
again highlights the importance of both co-culturing and longer experimental time scales, 
extending beyond 14 days. 
 
Table 2.12. SUMMARY OF SECRETED TIMP-2 FROM EACH MODEL  
TIMP-2 Day 7 Day 14 Day 21 
Model Healthy Diabetic Healthy Diabetic Healthy Diabetic 
hREC only + + ++ + ++ + 
hRP only ++ ++ +++ ++ +++ ++ 
Co-culture ++ ++ ++ ++ +++ ++ 
 
TIMP-2 is constitutively expressed in most tissues and has highest affinity to inhibiting MMP-
2 activity, important for maintaining ECM homeostasis in healthy and pathological 
conditions246. TIMP-2 inhibition of MMP-2 leads to reduced ECM remodelling. Capillary BM 
thickening is reported in DR247. Dysregulated remodelling of the ECM can lead to BM 
thickening, due to increased deposition of BM proteins, resulting in disruption to normal cell 
signalling in the over or underlying cells248. The ratio between MMPs and TIMPs can be 
predictors in wound healing, which is impaired in T2DM249. TIMP-2 was found to inhibit the 
proliferation of human microvascular ECs in vitro250. A summary of the results for TIMP-2 
expression is provided in Table 2.12. In the present study, TIMP-2 was significantly reduced 
   




in diabetic conditions for all models, compared to healthy conditions, from day 7-10 onwards 
(Figure 2.32D). TIMP-2 was secreted at higher levels overall by hRP than hREC. hRP TIMP-2 
secretion increased over time, and was significantly higher in healthy than diabetic 
conditions. A similar trend but lower overall levels of TIMP-2 was secreted in the co-culture 
model. In my study, hREC cultured alone secreted relatively low, stable levels of TIMP-2. As 
observed with HGF and Ang-2, the presence of both cells in the co-culture appears to reduce 
the overall levels of TIMP-2 secretion. Unfortunately no results can be extrapolated from the 
day 7 human antibody array TIMP-2 data, because TIMP-2 levels exceeded the maximum 
density for quantification in all conditions (Figure 2.33).   
In the diabetic environment, reduced TIMP-2 levels may result in increased activity of MMP-
2, leading to ECM remodelling, and potentially interference with normal cell adhesion, 
function and cell:cell communication, mimicking an angiogenic switch, such as a progression 
towards PDR. MMP-2 levels in cultured HUVEC were reported as reduced over time, which 
conflicts somewhat with data from the present study, considering TIMP-2 secretion was 
stable over time in the healthy monoculture model39. MMP-2 and -9, along with their 
affiliated TIMPs; TIMP-1 and -2, were found to be elevated in the serum of diabetic patients 
compared to controls (p<0.0001)251. Our data does not agree with the report by Derosa et 
al., however they analysed human serum directly from patients whereas our TIMP-2 data 
were collected from conditioned cell culture medium. High levels of MMPs as well as their 
TIMPs may reflect abnormal ECM metabolism.  In agreement with our discovery of reduced 
TIMP-2 in diabetic conditions, Lobmann et al. reported reduced TIMP-2 in tissue biopsies 
taken from chronic foot ulcers on diabetic patients, compared to healthy controls252. One 
suggestion for the discrepancy in reported TIMP-2 levels between Lobmann et al. and Derosa 
et al. is the duration of T2DM. Patients from the Lobmann study were on average 10 years 
older, with diagnosed T2DM for on average 15 years, whereas patients from the Derosa study 
had T2DM diagnosis for only roughly 5 years, with no pharmaceutical intervention. These 
two groups represent entirely different patient populations, where foot ulcers analysed in 
the Lobmann group come from a more progressed stage of disease. Therefore, it is possible 
TIMP-2 levels vary depending on disease stage, possibly increasing at early stage, followed 
by a decrease at later stage. Our data follows that of a putative later stage of T2DM, similar 
to the findings by Lobmann et al. 
With regards to reporting human angiogenesis antibody array data, results were technical 
duplicates from two experiments (n=2), therefore statistical analysis was not performed, 
   




although trends and general observations have been reported. It was also not possible to 
directly quantify protein levels, therefore all data is reported normalised to positive controls.  
Human angiogenesis antibody blot data from day 7 shows diabetic co-culture conditions 
resulted in the lowest rates of TIMP-1 (Figure 2.33). However, TIMP-1 secretion was highest 
by hREC in diabetic monoculture conditions. These data further support the multiplex results, 
which suggest there are major differences between the secretion profiles of hREC in 
monoculture compared to co-culture. As described with TIMP-2, TIMP-1 has particular 
affinity to certain MMPs including MMPs 1, 3, 7 and 9, and binding leads to inactivation of 
ECM remodelling. In a study by Jayashree et al., where serum levels of TIMP-1 and MMP-9 
were compared between patients with T2DM, with or without retinopathy, there were no 
statistical differences in TIMP-1 levels, although MMP-9 was significantly higher in patients 
with DR (p=0.048), with positive correlation with severity of disease253. Therefore, with 
greater activity of MMP-9 and unaltered TIMP-1 levels, this could lead to MMP-9-driven 
dysregulated ECM remodelling, which could contribute to the weakening of the BRB at this 
stage of DR. 
Epithelial neutrophil activator (ENA-78)/CXCL5 is a proangiogenic chemokine which along 
with its family of CXCL proteins, promote vascular EC growth93. Levels of ENA-78 were very 
low in the hREC monocultures in both healthy and diabetic conditions. Interestingly ENA-78 
levels were increased in co-culture conditions, with the highest levels observed from the 
healthy co-culture models (Figure 2.33). Yuen et al. showed silent information regulator 
protein-1 (SIRT-1) activation led to increased secretion of proangiogenic chemokines 
including ENA-78, restoring EPC function in ex vivo diabetic rat outgrowth ECs254. This 
suggests ENA-78 may be downregulated in diabetes, and our data does suggest reduced ENA-
78 secretion from the diabetic co-culture model compared to the healthy co-culture at day 
7. In an analysis of serum from 93 patients, Meleth et al. investigated a panel of cytokines 
and chemokines to assess their involvement in severity of DR. RANTES (regulated on 
activation, normal T cell expressed and presumably secreted) is a chemokine for recruiting T-
cells, eosinophils, basophils, and leukocytes into inflammatory sites. They found significantly 
elevated levels of RANTES in severe NPDR and positive immunostaining for monocyte 
chemoattractant protein-1 (MCP-1) in the inner retina, but no significant differences 
between VEGF or ENA-78 levels when less severe DR samples were compared to severe DR 
samples255. The immunoblot data in the present study for MCP-1 secretion was too high to 
quantify in all conditions, whilst negligible levels of RANTES were detected in all conditions. 
   




However, the data from Meleth et al. was healthy controls, therefore is not directly 
comparable to our healthy mono- or co-culture data. 
IL-6 is a cytokine involved in the infection and inflammation immune response and also in 
regulation of metabolic, regenerative and neural processes256. IL-6 levels are raised in most 
inflammatory diseases and both obesity and T2DM are considered long term inflammatory 
diseases, where cytokines and chemokines such as IL-1β, IL-6 and C-reactive protein (CRP) 
are elevated257. Contrary to reports of elevated IL-6 in obesity and T2DM, data from the 
present in vitro models suggests IL-6 levels were highest in the healthy co-culture model, 
where levels unfortunately exceeded the maximum quantifiable density, so therefore could 
not be measured (Figure 2.33). This discrepancy could possibly be due to very long onset of 
DR in vivo compared to relatively short in vitro disease modelling, which will always be a 
limiting factor. IL-6 levels were much lower in the hREC monocultures compared to co-
cultures and lowest overall in diabetic monocultures, although this would need to be 
repeated to determine if the difference was significant. These results suggest that growing 
hRP and hREC together increases IL-6 secretion overall. 
PDGF-BB is an important growth factor for all phases of wound healing as well as a potent 
mitogen for mesenchymal cells258. In a study focused on diabetic nephropathy, urinary 
excretion rates of PDGF-BB from 65 cases of diabetes and 27 controls were analysed using 
ELISA and urinary PDGF-BB rates significantly increased congruent to urine albumin 
excretion259. This implies PDGF-BB may play a role in the onset of diabetes, linked with early 
microvascular changes. In a study comparing vitreous and serum levels of PDGF isoforms (-
AA, -AB and –BB) with VEGF levels in 31 patients with PDR and 15 non-diabetic controls, all 
isoforms of PDGF along with VEGF were significantly increased in the vitreous samples from 
PDR group compared to controls, although this was not evident from serum samples260, 
which may suggest a tissue-specific (posterior compartment of the eye) response. In contrast 
to the two aforementioned studies, in the present study, PDGF-BB levels were lowest in the 
diabetic co-culture model and highest in the healthy co-culture model (Figure 2.33). It is 
possible this data contrasts with data from human clinical samples due to different stage of 
disease, or because although co-culturing aims to improve the in vitro similarity to the in vivo 
environment, the retinal vasculature is a multifaceted environment, and it remains difficult 
to replicate all elements in a laboratory model .  
Surprisingly, data from the multiplex and blot arrays indicated that levels of secreted VEGF 
and VEGF-D were negligible (Figure 2.32, Figure 2.33). VEGF levels increase in the ocular fluid 
   




of patients with varying stages of DR, with a large increase particularly during PDR261. In a 
study of 65 patients, Baharivand et al. found serum (515.21 vs 343.58 pg/ml) and vitreous 
(383.1 vs 24.81 pg/ml) concentration of VEGF were significantly raised in patients with PDR 
compared to NPDR, and that vitreous and serum VEGF levels were correlated, although 
serum levels were always much higher102. However various groups have reported a wide 
range of VEGF levels in vitreous and serum, from both healthy and diabetic patients, 
suggesting VEGF levels may be quite variable on an individual basis and also highly dependent 
on stage of DR. That being said, all the concentrations reported in the literature fall within 
range for detection using the multiplex system used in the present study, therefore it is 
unclear why VEGF could not be detected. Individual variation and precise disease stage is 
very difficult to model in vitro, using primary human cells in a highly simplified environment. 
Kumar et al. detected secreted VEGF from their mono- and co-culture in vitro models made 
using human retinal progenitor cells and HUVEC, over a 48H period, where levels peaked at 
~90pg/ml/mg at 24H in the contacting co-culture model in 1% oxygen conditions130. For the 
multiplex analysis, VEGF detection range was 2.7-2000pg/ml, which would enable detection 
if VEGF levels were similar to those found by Kumar et al.. It is not fully understood why VEGF 
appears absent from all conditions, however some factors may include; cell type (HUVEC vs 
hREC), cell number (6-well inserts vs 24-well inserts), transwell insert material (polyester vs 
PET), smaller transwell pore size (0.4µm vs 1µm), 1% lower oxygen, duration of experiments 
(24H vs 7 days).  
2.6 LIMITATIONS & FUTURE WORK 
There are already multiple variables to the different mono-/co-culture, healthy/diabetic, 0-
21 day models discussed in this chapter, however further optimisation could include adding 
flow, fluctuating glucose levels and reducing oxygen tension to 1%, and should all be 
considered when taking this model forward. Taking into account multiple factors, these 
variables were adapted from previous successful co-culture models62, according to primary 
cell availability, time and financial constraints. Seeding density and ratio was optimised for 
initial 1:1 hREC:hRP coverage, however growth curve data suggests lower seeding density of 
hRP may be required to maintain that ~1:1 ratio at later time points. Blot data was analysed 
from only one time point; day 7. It would be interesting to see the change in secretion of 
angiogenic factors at multiple time points, as was performed in the multiplex array data, 
however this was beyond the scope of this study. Angiogenesis blot data reported was n=2 
and multiplex data was n=3, therefore to give greater power and confidence, repeats should 
   




be carried out. Fluctuating glucose has been reported to have more detrimental effect on 
both the ECs and pericytes97,216, therefore, in future experiments fluctuating glucose from 
low-mid range to high range may result in a more diabetic-like phenotype. Adding flow to 
the mono- and co-culture models may result in changes to the barrier function of the hREC63, 
and create a model closer to the BRB. That being said, overall this work has produced a 
human, primary co-culture model of the retinal vasculature, which can withstand long term 
diabetic insult. This model can be further adapted or modified to suit purpose by adding any 
of the variables mentioned above, and is a useful tool for modelling diabetes in vitro. 
2.7 CONCLUSIONS 
The major hurdles in optimising this human primary model of the retinal microvasculature 
involved first optimising growth conditions to maintain two different cell-types for multiple 
passages and extended periods of time, on both TC plastic and PET membranes, and second 
growing these cells together on either side of the same PET membrane for up to 21 days in 
culture. Data presented in this chapter confirms successful growth of human primary hREC 
and hRP and these cells have been stringently characterised. Introducing carefully optimised 
healthy and diabetic conditions to the mono- and co-culture models enabled data collection 
up to 21 days and the differences in the secretion profile of the healthy compared to diabetic 
models suggest the cells have undergone changes in the low oxygen, high glucose 
environment. Significant differences were discovered in the secretion profile of hREC grown 
as mono-culture compared to co-culture with hRP, highlighting the importance of studying 





   




3 CHAPTER 3 
Isolation and expansion of human ECFCs for incorporation into an in 
vitro model of DR 
3.1 OVERVIEW 
Since their discovery in 1997, ECFCs have been identified as a prospective autologous cell 
therapy for blood vessel repair. With developments in cell culture technology, identification 
and expansion of this small population of cells from human blood have improved and there 
has been a focus on standardising protocols. Animal studies using the OIR model have 
provided evidence that ECFCs can physically incorporate and contribute to repairing vessels 
damaged by ischemia in vivo. During T2DM, the microvasculature is damaged due to 
persistent hyperglycaemia, disrupted blood supply and, therefore, reduced oxygen delivery 
and due to the high metabolic activity of the photoreceptor cells, the retina is particularly 
sensitive to this damage. ECFCs were isolated from UCB and APB and characterised, before 
adding to the optimised co-culture model of DR described in chapter 2, to test their ability to 
integrate into a mature EC layer. 
3.2 AIMS & OBJECTIVES 
To isolate, characterise and expand ECFCs from human UCB and APB and test their 
capability to incorporate into healthy and diabetic human primary co-culture 
models of the retinal microvasculature 
1. Collect samples of APB and UCB and isolate and expand populations of ECFCs 
2. Characterise ECFC populations using cell-surface markers and proliferative potential 
3. Lentivirally transduce ECFCs to express green fluorescent protein (GFP) for 
monitoring of cells on various biomaterials over time 
4. Test incorporation potential of ECFCs into in vitro healthy and diabetic co-culture 
models or retinal microvasculature 
   





3.3.1 PERIPHERAL BLOOD ISOLATION 
Ethical approval for the collection of human adult peripheral blood and umbilical cord blood 
was obtained from North of Scotland Research Ethics Committee (17/NS/0071). Umbilical 
cord blood collection was carried out at Liverpool Women’s Hospital and peripheral blood 
collection at the University of Liverpool. Healthy adults were recruited to donate 50ml of 
peripheral blood. Donors were not taking vitamin or antioxidant supplements and were 
without diabetes. A trained blood extractor carried out the blood collection procedure. 
Briefly, adult peripheral blood was collected from the median cubital vein using a tourniquet 
(Greiner, 840050), a SAFETY Blood Collection Set + Holder, size 23G or 21G (Greiner, 450086, 
450085) and 9 ml K3EDTA VACUETTE® Tubes (Greiner, 455036). Extracted blood was 
processed immediately at RT.  
3.3.2 UMBILICAL CORD BLOOD ISOLATION 
Pregnant women undergoing planned caesarean section surgery were recruited at pre-
operative clinic by NHS staff at Liverpool Women’s Hospital. Consent was obtained to collect 
the umbilical cord with attached placenta immediately after surgery. Cords were clamped at 
either end by the surgery team to improve retention of blood within the umbilical cord. The 
umbilical cord blood (UCB) collection procedure was carried out as soon as possible after 
delivery of placenta, to prevent blood clotting and cell death. UCB collection was performed 
in a class II hood using aseptic technique. Placenta with attached cord was elevated using a 
clamp stand with modified platform, to enable gravitational flow (See Figure 3.1). Cord was 
cleaned using antiseptic wipes (Brosch, DW4220) and blood was extracted from the cut 
(distal) end of the cord, just above the clamp, using a 19G needle (NHS Supply Chain, 
AN1950R1) attached to a 10ml syringe (BD, 305959). Once blood from one region was 
extracted, the needle was re-inserted further towards the proximal end and the procedure 
was repeated until the umbilical vein and artery were empty of blood. Blood was also 
extracted in the same way from the large vessels of the placenta. The volume of blood 
extracted was variable from each donor depending on size of placenta, length of cord, 
delayed cord clamping at birth and time since placenta delivery (due to blood clotting), see 
Figure 3.1. According to the protocol described by Medina et al., fresh UCB was mixed with 
equal parts Alsever’s solution (Sigma, A3351) in sterile 50ml tubes, to prevent coagulation153. 
 
   
















Figure 3.1. Elevated extraction method for collecting umbilical cord blood 
Images showing modified clamp stand used to elevate placenta with clamped umbilical cords, and 
variation in cord lengths and placenta size. Table shows variation in total blood volume collected from 
a total of 17 umbilical cords and placenta. Volumes ranged from 5-62.5ml. 
 
3.3.3 ECFC CULTURE 
From this point on, both adult peripheral (APB) and UCB were processed in the same way, at 
RT, following the protocol described by Medina et al., outlined below153. Using non-skirted 
sterile 50ml tubes (Greiner, 227261), 30ml dPBS was added for every 20ml blood with 
anticoagulant and gently mixed, i.e. 3 parts dPBS to 2 parts blood solution. In fresh non-
skirted sterile 50ml tubes, 20ml blood-dPBS solution was very gently layered on top of 20ml 
Histopaque (Sigma, 10771), avoiding any mixing. The tubes of blood layered on Histopaque 
were centrifuged at 400rcf for 30 minutes, with slow break applied to separate blood via 
centrifugation fractionation. Using a sterile Pasteur pipette, the buffy coat layer of 
mononuclear cells was removed from each tube (red arrow, Figure 3.2) and transferred to a 
new non-skirted 50ml tube and topped up with 30ml dPBS. Buffy coat-dPBS mixture was 
centrifuged for 8 minutes at 330rcf using normal break, resulting in a large, loose, pink-
Donor No. Date Volume Collected 
17-002 23.11.17 17.5ml 
17-003 27.11.17 30ml 
17-004 04.12.17 10ml 
17-005 05.12.17 11ml 
17-006 11.12.17 35ml 
17-007 12.12.17 35ml 
17-008 13.12.17 62.5ml 
17-009 13.12.17 20ml 
18-001 09.01.18 5ml 
18-002 11.12.18 30ml 
18-003 15.01.18 5ml 
18-004 15.01.18 12ml 
18-005 15.01.18 18ml 
18-006 16.01.18 18.5ml 
18-007 16.01.18 10ml 
18-008 16.01.18 23.5ml 
18-009 17.01.18 43.5ml 
Modified Platform Average Cord Short Cord Long Cord 
   




coloured pellet of cells in the bottom of the tube. dPBS was removed, leaving a small volume  
covering the cell pellet. 3ml of 1X red blood cell (RBC) lysis buffer (Invitrogen, 00-4300-54) 
was added to the cell pellet and after gentle mixing, was left for 10 minutes to lyse any 
contaminating RBCs. The solution changed to a glossy/ less opaque colour. This solution was 
centrifuged at 330rcf for 10 minutes, to form a cell pellet. Using a sterile 1000µl tip, 
supernatant was removed, avoiding the large cell pellet. 1ml Endothelial Growth Medium-2 
(EGM-2) (PromoCell, C22011) with 20% FBS was added and gently but thoroughly mixed with 















Figure 3.2. Steps in the procedures of collecting ECFC from umbilical cords and adult 
peripheral blood 
Images of UCB and APB extraction and processing by density gradient centrifugation. Red arrows 
highlight the mononuclear layer of cells which was collected then seeded on to col I. coated TC plastic 
24 w/p. Peripheral no.3 and Umbilical no.4 Images demonstrate the difference in the quality of the 
separated blood from the two different sources.  
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Before adding mononuclear cells to 24 well plates(w/p), wells were coated with collagen I 
(col I.) solution (Corning, 354236) at 50µg/ml. Col I. solution was mixed with sterile ddH2O 
and sterile filtered using 0.2µm filter (Appleton Woods, 16532) and 10ml syringe. 200µl of 
col.I solution was added to each well in 24w/p and left in sterile hood at RT for 1H. Col I. 
solution was then removed and wells were washed once with sterile dPBS and once with 
EGM-2 media. One extra row of wells was col.I coated for cells to be re-seeded at 24H, and 
left covered with dPBS. Mononuclear cell pellet was thoroughly mixed with EGM-2 with 20% 
FBS then added to each well at 500µl/well at a density of ~5x106cells/well. Therefore, 1x 50ml 
tube of cells collected from UCB/APB was transferred to 2x wells in a 24w/p. EGM-2 was 
supplemented with 20% FBS until cells reached P2. Thereafter, EGM-2 was supplemented 
with 10% FBS for ECFC culture.  
At 24H after seeding, unattached cells in media from two wells were collected in to a 15ml 
centrifuge tube (Greiner, 188261) and spun for 5 minutes at 400rcf. Supernatant was 
removed and cell pellet was re-suspended in 500µl EGM-2 with 20% FBS and re-seeded in 
spare col I. coated well on 24w/p. Due to very high seeding density, this allowed a second 
chance for putative ECFCs to attach to TC plastic. All other wells had a complete media 
change, performed gently so as not to disrupt any loosely attached cells. Media was gently 
changed every day for the first 7 days, as there was a large number of cells and debris floating 
in the media. Cells were monitored and imaged daily, until over time cell debris decreased 
and cells could be seen attached to TC plastic from ~day 7 onwards. From day 7, media was 
changed every 48H. From day 10 (UCB) or 21 (APB) populations of cuboidal, colonies of ECFCs 
appeared in the culture (Figure 3.3). Once these cells filled each well, they were trypsinised 
(as described in 2.3.3) and transferred to col I. coated 6w/p’s, where they were cultured in 
2ml EGM-2 with 20% FBS/well and media was changed every 2-3 days. After 4-10 days (UCB) 
or 5-14 days (APB), passage 1 (P1) ECFCs filled the wells of a 6w/p. Cells were trypsinised and 
each well of ECFCs was transferred to a col I. coated T25 flask. At this stage (P2) EGM-2 serum 
content was reduced to 10% FBS.  
After 2-7 days, at 80% confluence ECFCs were either frozen for use at later date or used 
immediately in experiments. For freezing, after tryspinisation ECFCs were re-suspended in 
900µl +100µl DMSO at a density of ≥1x106 cells/ml, in a cryovial and transferred to -80°C in a 
Mr Frosty container containing isopropanol for freezing at a rate of -1°C/minute. For long 
term storage, cells were transferred to liquid nitrogen. To recover cells from liquid nitrogen, 
vials were defrosted quickly at 37°C in a water bath over 2-4 minutes. The defrosted cell 
   




suspension was dispersed into a col I. coated T75 flask of warmed EGM-2 with 10% FBS 
medium and left to adhere overnight. The next morning medium was completely changed to 









Figure 3.3. Timescale of isolation and expansion of ECFCs from UCB and APB 
Timeline depicting the stages involved in ECFC isolation and in vitro expansion from UCB and APB. 
Mononuclear cells were first seeded on col I. coated 24 w/p’s, and non-adherent cells were re-plated 
at 24H into new wells. From 11-21 days, ECFCs appeared in culture. UCB-ECFCs appeared earlier than 
APB-ECFCs. Once confluent, ECFCs were transferred to 6w/p’s, followed by T25 flasks. ECFCs were 
frozen at ≥1x106 cells/ml. Overall more ECFCs were successfully isolated from UCB and they grew at a 
faster rate than APB-ECFC. 
 
3.3.4 IMMUNOFLUORESCENCE  
ECFC clones from healthy UCB-ECFCs, APB-ECFCs and one GD-UCB-ECFC donor were 
characterised using IF confocal imaging of antibodies against specific markers for endothelial 
cell-types. ECFCs were seeded at 2x104 cells/well on col I. coated 8-well EZ-glass slides. At 
days 2-5 ECFCs were washed for 3x 5 mins in warm dPBS to remove remnants of cell culture 
medium. Cells were fixed, permeabilised and blocked according to the protocol described in 
section 2.3.4. After 1H blocking, primary antibodies diluted to optimal working concentration 
in dPBS (see Table 3.1), were added to cells and left on a slow rocking platform overnight at 
4°C. 3x 5 mins 0.1% Tween-20 in dPBS washes at RT on a rocker removed any unbound 
primary antibody. Secondary antibodies (see Table 2.2), were added at 5µg/ml in dPBS for 45 
mins at RT on a slow rocking platform, in the dark. Cells were washed, DAPI stained and 
mounted with a glass coverslip as described in section 2.3.4. 
 
UMBILICAL CORD BLOOD ISOLATION 
11-21 days 4-10 days 2 days 
Freeze -80°C 
3-6 weeks 5-14 days 3-7days 
Freeze -80°C 
PERIPHERAL BLOOD ISOLATION 
   




Table 3.1. PRIMARY ANTIBODIES FOR IF CHARACTERISATION OF ECFCs 
 
 
3.3.5 FLOW CYTOMETRY  
Flow cytometry was performed to determine the cell surface receptors expressed by ECFCs 
isolated from either APB or UCB and from different donors. A panel of proteins was selected 
to distinguish ECFCs from mature ECs. Cells were prepared for flow as described in section 
2.3.5. Each clone was photographed before flow cytometry to compare morphology and to 
record confluence (target~80-90% confluent). 
 
Primary Antibody  Species Supplier/Code Concentration 

































































Conjugated Phallotoxin    





   




3.3.6 GROWTH CURVES 
To determine the growth rate of ECFCs, cells were grown for 21 days in EGM-2 with 10% FBS 
medium. Cells were seeded at 5x103, 1x104, 2x104 and 4x104 cells/well in col I. coated TC 
plastic 24 w/p, to determine the effects of seeding density and time on cell growth rate. For 
fixing and quantification procedure see section 2.3.6. 
3.3.7 OPTIMISING CELL-SPECIFIC MEDIUM 
To determine if ECFCs were viable in the optimised healthy and diabetic conditions of the co-
culture model, ECFCs were grown in healthy (5.5mM glucose + 20% O2), hypoxic (5.5mM 
glucose + 2% O2) and diabetic (33mM glucose + 2% O2) conditions for 4 days and their 
metabolic activity was tested. ECFCs were seeded at 2.5x104 cells/well on col I. coated TC 
plastic 24 w/p in EGM-2 with 10% FBS and left to form a monolayer for 48H. 48H after seeding 
(experimental time point 0) a resazurin assay was performed (see section 2.3.8), to 
determine metabolic activity of ECFCs at baseline. Culture medium was changed and ECFCs 
were moved to low or normal oxygen conditions and healthy or diabetic glucose levels. 
Subsequent resazurin assays were performed at 24H and 4 days of experimental conditions, 
with media changed at 48H. Data presented was normalised to healthy controls (5.5mM 
glucose and 20% O2), and data was adjusted across plates using standard curve to account 
for gain (Figure 2.2). Images of the cells were captured from experimental day 0-21, to 
monitor cell morphology and cell number. 
To determine if ECFC were viable in the optimised healthy and diabetic conditions of the co-
culture model, switching from EGM-2 with 10% FBS to MV with 5% FBS medium, ECFCs were 
grown in healthy (20% O2 and 5.5mM glucose) and diabetic (2% O2 and 33mM glucose) 
conditions and compared to ECFC metabolic activity in the same conditions, but in their 
original EGM-2 with 10% FBS growth medium. UCB-ECFCs were seeded at 2x104 cells/well on 
col I. coated TC plastic 24w/p’s, straight in to healthy or diabetic conditions with either MV 
with 5% FBS or EGM-2 with 10% FBS medium. As a control, hREC were seeded at 2x104 
cells/well on TC plastic 24w/p straight in to healthy or diabetic conditions in MV with 5% FBS 
medium. Media was changed every 48H. Resazurin assays were performed (see section 2.3.8) 
to determine ECFC and hREC metabolic activity in different media, oxygen and glucose 
conditions at 48H and 7 days after seeding. Results were adjusted for gain across plates. 
Results were reported as relative fluorescence units. Images were captured of cells in each 
condition at 48H and day 7, to assess cell morphology and cell number. 
   




3.3.8 INCORPORATION OF CELLTRACKER LABELLED ECFCs  
To enable monitoring of attachment and growth of ECFC with hREC on TC plastic and PET 
membranes, CellTracker Green (CTG) and CellTracker Red (CTR) dyes were used. hREC were 
labelled with CTR and UCB-ECFCs were labelled with CTG, according to the protocol described 
in section 2.3.10. Culture medium was MV with 10% FBS for ECFC incorporation with hREC 
experiments. ECFC and hREC were seeded 1:1 at the same time, at 1x104 or 6.67x104 
cells/well in a 24-well TC plate, or 1.5x103 or 1x104 cells/well in PET transwell inserts. 
Densities represent low or high seeding density and are scaled up from optimised transwell 
cell density to TC plastic, taking in to account surface area. Cells were imaged at 24H and 72H 
to explore incorporation and retention of ECFC in 1:1 culture with hREC.  
To test APB-ECFC incorporation into an established hREC monolayer in diabetic or healthy 
conditions, hREC were seeded first at 2x104 or 1.334x105cells/well on col I. coated TC plastic, 
and grown for 48H, in MV with 10% FBS medium. APB-ECFCs from two donors were labelled 
with CTG (CTG-ECFC) (section 2.3.10), and added to hREC at 48H. Due to slow growth of APB-
ECFC, the cell number added was as close to 2x104 as possible (17,188 ECFC/well from donor 
#1042 ad 11,975 ECFC/well from donor #332). Cells in healthy and diabetic and at lower and 
high seeding density were imaged at 24 and 48H using fluorescent Nikon E-Tie microscope. 
48H after seeding CTG-ECFC on to hREC monolayer, cells were fixed using 10% NBF and 
processed for IF imaging (see section 2.3.4), to explore expression of the GJ protein ZO-1 and 
the hypoxic response (HIF1α). 
3.3.9 VIRAL TRANSDUCTION OF GFP INTO ECFCs  
To enable long term monitoring of ECFC on PET transwell inserts and on pεK hydrogel 
microparticles, stable GFP expression was achieved by lentiviral mediated transduction of 
pGIPz. This plasmid uses CMV to drive expression of tGFP, puromycin and a validated non-
silencing shRNA sequence from the same promoter. Lentiviral particles were generated as 
previously described262 (DNA/RNA Delivery Core, Northwestern University, Chicago, IL) using 
293T packaging cells (Gene Hunter Corporation, Nashville, TN). The vector map is shown 







   










Figure 3.4. GFP lentiviral particle composition 
Vector map. hCMV (human cytomegalovirus)=promoter. tGFP= green fluorescent protein. IRES= 
internal ribosomal entry site; allows for two transcripts to be driven from the same promoter. Puro= 
puromycin resistance cassette. shRNA is where the non-silencing shRNA is inserted. WPRE=woodchuck 
hepatitis virus posttranscriptional regulatory element: increases expression of genes. 3’ SIN LTR and 
5’LTR are long tandem repeats used for integration into the viral genome. Psi= is a lentiviral protein. 
RRE= rev response elements, a binding site for retrovirus specific enzymes.  Amp, pUC and SV40 are 
for growing in bacteria. Virus was added to confluent ECFCs in 6w/p and incorporated into cells over 
a 48H period. 
 
To generate stable clones, ECFCs were seeded at 100-200,000/well in a 6 w/p and grown for 
24-48H, until 80-90% confluent. The flow diagram (Figure 3.5) outlines the procedure of viral 
transduction. In brief, virus was added at 20µl/well into fresh EGM-2 with 10% FBS media 
containing 6ug/ml of sterile filtered polybrene (Sigma, TR-1003-G) at a total volume of 500µl 
media/well. After 24H, media volume was replenished to total volume of 1.5ml/well. 48H 
after adding virus, cells were imaged using Nikon E-Tie fluoresecent microscope to determine 
percentage of green cells in ECFC cultures. Once cells were confluent, to remove any non-
transduced ECFCs, cells were treated with sterile filtered puromycin (Gibco, A1113803) at 
2ug/ml in fresh growth media. Virally-transduced cells had puromycin resistance, therefore 
only transduced ECFCs survived after puromycin treatment.  
Transduced ECFCs were monitored for 7 days (or until confluent), with fresh puromycin 
added at 2ug/ml in EGM-2 with 10% FBS media every 48H. From days 4-7 post-puromycin 
treatment, wells became confluent with ECFCs virally transduced with GFP (GFP-ECFC) 
(excitation 488 nm, emission510 nm). Confluent cells were sub-cultured (as described in 
section 2.3.3) and each well from a  6 w/p was transferred to a T25 flask, in EGM-2 with 10% 
FBS containing 2ug/ml puromycin, to prevent expansion of any remaining non-transduced 
ECFCs. Once GFP-ECFC were 90% confluent in T25 flasks, cells were used in experiments or 
sub-cultured in T75 flasks for further expansion. 
pGIPz 
   




3.3.10 INTEGRATION OF GFP-ECFCs INTO HEALTHY hREC MONOLAYERS 
To determine if GFP-ECFCs integrated in the same way as CTG-ECFCs, integration 
experiments similar to section 3.3.8 were performed. 2x104 or 6.67x104 GFP-ECFCs/well were 
seeded at the same time, 1:1, with hREC on col I. coated TC plastic 24 w/p’s in MV with 10% 
FBS medium. 1.5x103 or 1x104 GFP-ECFCs/insert were seeded at the same time, 1:1 with hREC 
on to the apical surface of PET transwell inserts. Cells were imaged at 24H and day 7 to 
determine the presence of GFP-positive cells. 
To assess the ability of GFP-ECFCs to incorporate into an already established hREC monolayer, 
hREC were seeded first at low (2x104/well) or high density (1.334x105 cells/well) on col I. 
coated TC plastic 24 w/p’s, or low (3x103) or high density (2x104 cells/well) on transwell 
inserts and grown for 48H.  At 48H, 2x104/well GFP-ECFCs were added to hREC in TC plastic 
or transwell inserts, and fresh MV with 10% FBS medium was added. Cells were imaged at 
24H and day 7. On day 7, cultures were fixed using 10% NBF and processed for confocal IF 
imaging (see section 2.3.4), to explore expression of pro-angiogenic protein Ang-2, and 



















   




























Figure 3.5. Steps to virally transduce GFP expression in ECFCs  
Flow diagram of lentiviral mediated transduction of pGIPz, to enable stable GFP expression in UCB- 
ECFC. Polybrene enabled virus to enter ECFCs during vrial transduction. Successful transduction 
resulted in GFP expression and antibiotic resistance. Puromycin treatment killed non-transduced 
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3.3.11 ASSESSING INCORPORATION OF GFP-ECFCs INTO MONO AND CO-CULTURES 
IN DIABETIC CONDITIONS 
GFP-ECFCs from healthy and GD-UCB were added to mono- and co-cultures grown under 
healthy and diabetic conditions, to test their ability to incorporate into the hREC layer. Co-
cultures of hREC and hRP seeded at 1:1 ratio on transwell inserts, were grown for 72H, then 
moved to either healthy or diabetic conditions for a further 7 days (see Figure 2.6). On 
experimental day 7 of co-culture, 2x104 GFP-ECFCs from either healthy or GD-UCB were 
added to the hREC layer (apical side of insert) in 200µl MV with 5% FBS medium with either 
5.5mM or 33mM glucose. Co-cultures were placed back into healthy or diabetic conditions 
for 24H. 24H after seeding UCB-GFP-ECFCs, inserts were imaged using Nikon E-Tie live cell 
fluorescence microscope to assess GFP-positive cell incorporation. Cells were then fixed 
using 10 % NBF and processed for confocal IF imaging (see section 2.3.4). In both mono- and 
co-cultures, GFP-positive cells were assessed for expression of junctional proteins (VE-Cad 
and ZO-1), and hREC and ECFC morphology and cell number were analysed. For co-cultures, 
Z-stack images were produced to confirm the presence of hRP on the underside of the PET 
membrane, using the Volume Viewer plug-in 2.01.1, on ImageJ software. 
3.3.12 MICROSCOPY 
The Zeiss Axiovert25 with TopupView 86 software was sued to capture phase contrast images 
of the ECFCs during isolation and expansion of the cells. The Nikon Eclipse TS100 fluorescence 












   





3.4.1 APB AND UCB-ECFCs WERE SUCCESSFULLY ISOLATED AND EXPANDED IN 
VITRO 
ECFCs were isolated the protocol described by Medina et al.153. UCB-ECFCs were present in 
culture from 11-21 days, recognisable by their cobblestone morphology (Figure 3.6A). APB-
ECFCs were also successfully expanded in culture, but took longer to become established (3-
6 weeks), although ultimately presenting the same cobblestone morphology as those 
isolated from UCB (Figure 3.6B). Once 24 w/p’s were confluent, when cultured with medium 
supplemented with 20% FBS, both APB and UCB-ECFCs were transferred first to 6 w/p’s, 
followed by T25 flasks for continued expansion in medium containing 10% FBS. APB-ECFCs 
were successfully expanded from 5 out of 10 (50%) donors. UCB-ECFCs were successfully 
















Figure 3.6. Timescale of UCB and APB-ECFC in vitro expansion from the mononuclear 
cell fraction 
Isolation of ECFCs using col I. coated TC plastic and EGM-2 with 20% FBS medium, for EC-specific 
attachment and expansion. (A) Expansion of ECFCs from umbilical cord blood, where ECFC grew out 
as colonies and filled the well from D14-21. (B) Expansion of ECFCs from adult peripheral blood, where 
ECFC grew out as colonies and filled the well from D21-35. Images were captured using the Zeiss 
Axiovert 25 microscope, x10 magnification. Scale bars= 200µm.  
UCB-ECFC ISOLATION 
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3.4.2 ECFCs EXPRESSED EC-SPECIFIC MARKERS CONFIRMING THEIR ENDOTHELIAL 
LINEAGE 
IF imaging of ECFCs isolated from APB, healthy UCB and cord blood from mothers with 
gestational diabetes (GD-ECFCs), showed some variation in expression of a panel of 
endothelial-specific antibodies, although overall cell morphology remained uniformly 
cobblestoned. APB-ECFCs showed positive expression for CD31, VE-Cadherin and vWF and 
did not express CD90 or αSMA (Figure 3.7A). Healthy UCB-ECFCs expressed ZO-1 and vWF 
(Figure 3.7B) and were negative for CD90 and αSMA (Figure 3.7C). CD31 and VE-Cad were 
present, but not at their expected location at the lateral border of the cytoplasm (Figure 3.7B 
and C). GD-ECFC had positive expression of ZO-1 (Figure 3.8A), vWF (C) and CD31 (E), and 
50% of cells positively expressed Ang-2 (H). As with the ECFCs sourced from healthy umbilical 
cords, VE-Cad was present, but not specifically at the cell-cell borders where it would be 
involved in cell-cell adhesion. VEGFR-2 was expressed across the membrane of APB and UCB-
ECFCs (Figure 3.7A, B and C), and expressed less in the GD-ECFCs (Figure 3.8). CD90 and αSMA 
were not present on GD-ECFCs. Phalloidin staining shows the cytoskeletal arrangement of F-
actin, and there is one very large cell (white arrow, Figure 3.8), with different F-actin 
arrangements to the other cells, which may be a contaminating mononuclear cell-type which 
adhered during the ECFC selective isolation method (Figure 3.8F). Results for CD34 












   


























Figure 3.7. APB and UCB-ECFC express markers confirming their EC-lineage 
IF antibody analysis of APB-ECFCs fixed at day 5 (A) and UCB- ECFCs fixed at 48H (B and C), where all 
expressed vWF. APB-ECFC expressed CD31 and VE-cad. All ECFCs were CD90 and αSMA negative. 
Images were captured using the Zeiss M800 confocal microscope, x40 oil magnification. Scale bars= 
50µm. 
















   







































































































































































































































































































































































































































































































































































   




3.4.3 UCB AND APB-ECFCs WERE POSITIVE FOR EC-SPECIFIC CELL SURFACE 
MARKERS AND NEGATIVE FOR HAEMATOPOIETIC LINEAGE MARKERS 
8 healthy UCB clones from 7 donors, 2 GD-UCB clones from 1 donors, 3 healthy APB clones 
from 3 donors were analysed for expression of cell surface markers (Figure 3.9). Cells were 
used at early passage (3-5) and similar confluence wherever possible (Figure 3.9A). There was 
variation in CD34 expression analysed using flow cytometry, ranging from 0.1-63.1% 
positivity. The majority of clones had low CD34 expression but APB clones P#322 and P#942B 
had much higher CD34 expression than APB clone P#1042 and all of the UCB clones, at 63.1% 
and 24% respectively (Figure 3.9B). Putative ECFCs from all donors showed CD31 expression 
89.5-100%, CD105 expression 98.5-100% and CD146 expression 98.5-100%. Putative ECFC 
from all donors were negative for CD45 0-3%, negative for CD14 0-0.1% and negative for 
CD90 0-3.6% expression. Collectively, these cells were positive for endothelial markers, 
negative for fibroblast marker (CD90) and negative for haematopoietic/immune cell markers 



















   




























Figure 3.9. Flow cytometry analysis confirmed APB and UCB-ECFCs were of EC-lineage 
and not haematopoietic or fibroblastic cells 
(A) Phase contrast images were captured before flow cytometry analysis of ECFCs, with the aim of 
analysis at similar confluence and passage number. (B) Flow cytometry analysis of cell surface markers 
used to determine EC/progenitor-lineage (CD34, CD31, CD105, and CD146), haematopoietic lineage 
(CD14, CD45) or a common fibroblast marker (CD90). UCB-ECFCs= green, GD-UCB-ECFCs= magenta 
and APB-ECFCs= black. Phase contrast images were captured using the Nikon DIAPHOT or Zeiss 
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3.4.4 ECFCs DISPLAYED SIMILAR GROWTH PATTERNS TO MATURE hREC 
ALTHOUGH OVERALL CELL NUMBERS WERE HIGHER BY DAY 21 
UCB-ECFCs seeded at 5x103-4x104 cells/well on 24 w/p’s showed an increase in cell number 
up to 7 days (Figure 3.10). This increase was at a similar rate for all seeding densities except 
4x104 cells/well, which plateaued earlier. From day 7 to 21 there was a decline in ECFC 
number, at the same rate for all seeding densities. By day 21 ECFCs seeded at 4x104 cells/well 
had the lowest remaining cells at 10210 ±1844.3cells/cm2, which was significantly lower than 
those seeded at 5x103 cells/well (p=0.0047) and those seeded at 1x104 cells/well (p=0.0043). 
ECFCs seeded at 1x104 cells/well had the highest number of cells remaining at 16118 ±2388.9 
cells/cm2. Overall, there was a reduction in ECFC number after 7 days for all seeding densities, 
and the cell loss is greatest at the highest seeding density. However ECFCs were used in 
subsequent experiments with the co-culture for a maximum of 7 days, where the growth 










Figure 3.10. Growth curves of ECFCs at different seeding densities 
UCB-ECFCs, P5, were seeded at 5x103, 1x104, 2x104 and 4x104cells/well on col I. coated 24 w/p’s in 
healthy conditions (20% O2 and 5.5mM glucose), with EGM-2 containing 10% FBS medium, to 
determine the effect of seeding density and time on cell growth rate. At time points day 1, 3, 5, 7, 14 
and 21 cells were washed, fixed in 10% NBF, permeabilised using 0.5% Triton-X and DAPI stained, in 
preparation for cell counting using the Nikon E-Tie fluorescence microscope, x10 objective. ImageJ 
software was used to write a micro to perform automated cell counting. n=4 or 5 and lines represent 
average for each seeding density. One-way ANOVA with Tukey’s correction was used to perform 
statistical analysis. n=5. **p<0.01  comparing 4x104 cells/well vs. 5x103 cells/well and 1x104 cells/well. 
** 
   




3.4.5 UCB-ECFCs SURVIVED LOW OXYGEN HIGH GLUCOSE IN VITRO CULTURE 
CONDTIONS 
There was no significant difference in the metabolic activity of UCB-ECFCs grown in 2% 
oxygen and physiological glucose (5.5mM) or UCB-ECFCs grown in 2% oxygen and high 
glucose (33mM) when compared to healthy controls (20% oxygen and 5.5mM glucose) for 4 
days (Figure 3.11A). Micrographs of ECFCs gown on col I. coated glass slides show cells 
retained their cobblestone morphology for up to 21 days, forming a confluent layer, in both 
healthy and diabetic conditions (Figure 3.11B). These data support the hypothesis of UCB-













Figure 3.11. UCB-ECFCs withstood diabetic in vitro culture conditions 
UCB-ECFCS, P6, were seeded at 2.5x103 cells/well in col I. coated TC plastic 24w/p’s and left to form a 
monolayer for 48H. At experimental time point 0 (48H after seeding), ECFC metabolic activity was 
assessed using resazurin sodium salt colorimetric assay, then cells were transferred into 20% or 2% 
oxygen and 5.5mM or 33mM glucose. Results were adjusted for gain across plates. Results were 
normalised to Normoxia + NG control (A). There were no statistical differences in ECFC metabolic 
activity in the different conditions. n= 6 or 8, assayed in duplicate. Phase images were captured of the 
ECFCs grown in healthy and diabetic conditions over 21 days, using the Nikon DIAPHOT microscope, 
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3.4.6 ECFC METABOLIC ACTIVITY WAS NOT ALTERED DUE TO THE SWITCH TO 
OPTIMISED CO-CULTURE MEDIUM 
ECFC metabolic activity was within normal range when grown in healthy or diabetic 
conditions, in EGM-2 with 10% FBS medium or MV with 5% FBS medium for 7 days. From day 
2-7, metabolic activity remained within healthy range for both hREC and ECFCs when 
switched from healthy conditions to diabetic conditions and also when ECFCs were changed 
from their preferred growth medium (EGM-2 with 10% FBS) to the optimised co-culture 
medium (MV 5% with FBS) (Figure 3.12). Micrographs of hREC and ECFCs at days 2 and 7 
showed cells have expanded in number in all conditions and the reduction in serum from 
10% to 5% did not appear to prevent ECFC viability and expansion, confirming the MV with 

















   























Figure 3.12. ECFC metabolic activity was not affected when cells were cultured in 
optimised co-culture medium 
(A) UCB-ECFCs, P6 were seeded at 2x104 cells/well in col I. coated TC plastic 24 w/p’s, straight in to 
healthy or diabetic conditions, in either MV with 5% FBS or EGM-2 with 10% FBS media. hREC, P8 were 
seeded at 2x104 cells/well on TC plastic 24 w/p’s, straight in to healthy or diabetic conditions in MV 
with 5% FBS medium. At day 2 and day 7 cells were tested for metabolic activity using resazurin sodium 
salt colorimetric assay. Results were adjusted for gain across plates. n=6, assayed in duplicate. (B) 
Phase contrast images were captured of the cells at days 2 and 7 using the Nikon DIAPHOT microscope, 
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3.4.7 ECFCS RETAINED THEIR ENDOTHELIAL PHENOTYPE AFTER 21 DAYS IN 
HEALTHY OR DIABETIC CONDITIONS 
ECFCs from healthy UCB were successfully grown on col I. coated 8-well EZ glass slides for up 
to 21 days in both healthy and diabetic conditions (Figure 3.13). At day 21 junctional proteins 
VE-Cad and CD31 were expressed on the lateral borders of ECFCs grown in both healthy and 
diabetic conditions, with no noticeable differences. ECFC in both healthy and diabetic 
conditions expressed vWF, confirming their endothelial phenotype. CD34, VEGFR-2 and SOD-
1 did differ in expression between ECFCs in healthy or diabetic conditions for 21 days. CD34 
was expressed at the lateral border of the cell cytoplasm in ECFCs grown in diabetic 
conditions, but was expressed in the perinuclear area of ECFCs grown in healthy conditions 
for 21 days. VEGFR-2 expression was minimal in ECFCs in diabetic conditions, but was 
expressed across the cytoplasm of ECFCs grown in healthy conditions. SOD-1 appeared 
upregulated in the cytoplasm of ECFCs grown in healthy conditions compared to those grown 
in diabetic conditions. Comparing cell number, size and the shape of ECFCs grown in healthy 
or diabetic conditions, there was no major differences. IgG isotype, no primary and no 
secondary controls showed background/non-specific staining, used to validate the 
antibodies used for IF characterising of ECFC. 
3.4.8 HEALTHY UCB-ECFCs ADHERED AND GREW SUCCESSFULLY WITH MATURE 
hREC 
hREC and ECFCs both integrate on to TC plastic and PET transwell inserts when seeded at a 
1:1 ratio at the same time, in healthy conditions (Figure 3.14). ECFCs tagged with CTG (CTG-
ECFC) and hREC tagged with CTR (CTR-hREC) (Figure 3.14A) both integrated at 1:1 seeding 
density of 2x104 cells/well and 6.67x104 cells/well on TC plastic. Both cell-types with 
CellTracker were visualised for up to 72H after seeding. However, some cells took up both 
dyes, making it difficult to determine between hREC and ECFCs (white circles Figure 3.14B). 
CTG-ECFCs and CTR-hREC both also integrated successfully on to the transwell inserts (Figure 
3.14C), at both low and high seeding density and could be monitored for up to 72H after 
seeding. Beyond 72H, the CellTracker faded and therefore cannot be used for long term 




   























Figure 3.13. ECFCs maintained their phenotype for 21 days in healthy or diabetic 
conditions 
UCB-ECFCs, P5 were seeded at 2x104 cells/well on col I. coated glass 8-well EZ glass slides. Cells were 
grown in either healthy (20% O2 and 5.5mM glucose) or diabetic conditions (2% O2 and 33mM glucose) 
for 21 days, in EGM-2 with 10% FBS, changed every 24-48H. On day 21, cells were fixed and processed 
for IF antibody labelling. No primary, no secondary and IgG isotype controls were included to exclude 
non-specific staining. Images were captured using the Zeiss M800 confocal microscope, x40 oil 
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Figure 3.14. UCB-ECFCs adhered and grew when seeded 1:1 with hREC 
hREC, P8 tagged with CTR were added at same time as CTG-tagged UCB-ECFCs, P6 at a 1:1ratio in 24 
w/p’s or transwell inserts. (A) hREC and ECFCs used for the experiment. (B) 1:1 seeding at low 
(1x104/cell-type) or high (6.67x104/cell-type) density, on TC plastic. (C) 1:1 seeding at low (1.5x103/cell-
type) or high (1x104/cell-type) density, on 24 w/p PET transwell inserts. Magnified boxes (white dotted 
lines) highlight cells (white circles) which have taken up both CTR and CTG. Phase images were 
captured using the Nikon DIAPHOT microscope and IF images were captured using the Nikon E-Ti live 
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3.4.9 APB-ECFCs INTEGRATED INTO AN ESTABLISHED hREC MONOLAYER 
APB-ECFCs integrated into an already established hREC monolayer on TC plastic, in both 
healthy and diabetic conditions. Two different APB donor ECFC clones were analysed 
concurrently, tagged with CTG, and ECFCs from both donors integrated  into a low and high 
seeding density hREC monolayer and successfully integrated in both healthy and diabetic 
conditions (Figure 3.15 A and B). CTG-ECFCs were still present at 48H. Beyond 72H, green 












Figure 3.15. APB-ECFCs integrated into an established hREC monolayer 
hREC, P8 were seeded at 2x104 (left panel) or 1.334x105 cells/well (right panel) on a 24 w/p’s, directly 
in to healthy (H) or diabetic (D) conditions. At 48H, CTG-APB-ECFCs #1042 P6 were seeded at 17,188 
cells/well (A) and CTG-APB-ECFCs #322 P5 were seeded at 11,875 cells/well (B). Images were captured 
at 24H and 48H after seeding the CGT-APB-ECFCs, using the Nikon E-Ti live cell microscope, x10 
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3.4.10 SOME APB-ECFCs TRANSITIONED INTO SENESCENT OR DEDIFFERENTIATED 
CELLS WHEN INTEGRATED INTO A hREC MONOLAYER 
The incorporated ECFC were fixed and stained to determine if ECFCs physically incorporated 
into a hREC monolayer or remained on top. CTG-APB-ECFCs #1042 and the surrounding hREC 
were positive for ZO-1 staining, in both healthy and diabetic conditions, and ZO-1 was still 
present, even with some gaps between neighbouring cells in the healthy conditions (Figure 
3.16A). Cell-cell contact and monolayer integrity appeared tighter at high hREC seeding 
density in diabetic conditions. CTG-APB-ECFCs #322 and the surrounding hREC expressed ZO-
1 in both healthy and diabetic conditions, but similar to the #1042 APB-ECFCs, ZO-1 positivity, 
cell-cell contacts and monolayer integrity looked more cell-cell border/GJ-specific in the 
diabetic conditions compared to healthy conditions (Figure 3.16B). Some of the CTG-APB-
ECFC #1042 appeared to be undergoing cell senescence (red circle, Figure 3.16A), APB-ECFCs 
#322 tagged with CTG had a different morphology to UCB-ECFCs, due to their larger size and 
finger-like projections (white circles, Figure 3.16B). There was also contamination of 
multinucleated, very large cells in the 1:1 hREC-APB-ECFC #322 healthy cultures (red arrow 
heads, Figure 3.16A), suggesting APB-ECFCs #322 have de-differentiated, or are 
contaminated with immune cells as remnants from the isolation process. HIF1-α remains 
unchanged in all conditions.  
3.4.11 HEALTHY AND GD-UCB-ECFCS WERE SUCCESSFULLY TRANSDUCED TO 
EXPRESS GFP USING LENTIVIRUS  
UCB-ECFCs were successfully transduced with GFP using GIPz-lentivirus, to remove the time 
limiting factor of using CellTracker dye. UCB-ECFCs from multiple donors were grown on 6 
w/p’s in healthy conditions and by day 9-12 (donor variability) after initial seeding, UCB-
ECFCs were successfully transduced with GFP (Figure 3.17). GFP transduction via lentivirus 
was successful in all healthy and GD UCB-ECFCs, although the rate of transduction was 
variable, with the example of clone #18-241 showing better transduction rate than clone #17-
321. However, with continued puromycin treatment over time, the result was close to ≥95% 
GFP expression as non-transduced cells were killed and transduced cells grew into the new 
spaces. If no virus was added, cells were killed when puromycin was added (right panel). 
Lentivirus transduction of GFP was not possible for APB-ECFCs, which failed to expand after 
puromycin treatment, on multiple attempts (data not show).  
 
 
   























Figure 3.16. APB-ECFCs integrated with hREC but some APB-ECFCs transitioned in 
vitro 
hREC, P8 were seeded at 2x104 or 1.334x105 cells/well on 24 w/p’s, directly in to healthy or diabetic 
conditions. At 48H, CTG-APB- ECFCs #1042, P6 were seeded at 1.7188x104 cells/well (A) and CTG-APB- 
ECFCs #322, P5 were seeded at 1.1875x104 cells/well (B). Red circles highlights senescent cells, white 
circles highlight de-differentiated ECFCs and arrowheads highlight large multinuclear cell 
contamination. Cells were fixed 48H after adding APB-ECFCs. Images were captured using the Nikon 
E-Ti microscope, x20 objective. Scale bars= 100µm. 
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Figure 3.17. UCB-ECFCs were transduced to express GFP using lentivirus  
UCB-ECFCs #17-321 and #18-241, both P5, were seeded at 1.5x105 cells/well in 6 w/p’s for 48H. 20µl 
of virus was added to each well, with 500µl EGM-2with 10% FBS and 6ug/ml of sterile filtered 
polybrene. Puromycin was added 48H after virus (day 4). All non-transduced cells were killed by 
puromycin treatment (right panel). From ~day 7 GFP expressing UCB-ECFCs expanded in the wells. 
GFP-UCB-ECFCs could be expanded for multiple passages. The Nikon DIPHOT microscope was used to 
capture phase images at x10 magnification and the Nikon E-Ti microscope was used for fluorescence 





at day 4 





























Virus added  
at 48H 
   




3.4.12 GFP-UCB-ECFCs SUCCESSFULLY INTEGRATED WITH MATURE hREC 
Transducing healthy UCB-ECFC with GFP did not appear to affect their ability to adhere and 
integrate with hREC when seeded at the same time, at a ratio of 1:1, on TC plastic or PET 
transwell inserts. GFP-UCB-ECFCs, (shown in green) incorporated at high and low seeding 
density on both TC plastic and PET transwell membranes, and remained for up to 7 days in 









Figure 3.18. GFP-UCB-ECFCs integrated with hREC when seeded at 1:1 ratio on TC 
plastic or PET membranes 
hREC, P7 and GFP-UCB-ECFC, P8 were seeded at same time at a 1:1 ratio, at low (1x104/cell-type) or 
high (6.67x104/cell-type) density, on TC plastic 24 w/p’s. (A). Or, 1:1 seeding at low (1.5x103/cell-type) 
or high (1x104/cell-type) density, on 24 w/p PET transwell inserts (B). Images were captured using the 
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3.4.13 GFP-UCB-ECFCs SUCCESSFULLY INTEGRATED INTO AN ESTABLISHED hREC 
MONOLAYER 
To mimic the scenario of in vivo migration of ECFCs to sites of vascular injury, hREC were 
allowed to form a monolayer for 48H, with 2x104 GFP-UCB-ECFCs added afterwards. GFP-
UCB-ECFCs incorporated in to both low and high hREC seeding density cultures, on both TC 









Figure 3.19. GFP-UCB-ECFCs integrated into both high and low density hREC 
hREC, P8 were seeded at 2x104 or 1.334x105 cells/well on 24 w/p’s (A), and 3x103 or 2x104 cells/well 
on PET transwell inserts (B). 48H later, 2x104 GFP-UCB-ECFCs, P8 were added to each well/insert. 
Images were captured at 24H and 7 days after seeding GFP-UCB-ECFCs, using the Nikon E-Ti Live cell 
microscope, x10 magnification. Scale bars= 200µm. 
 
 
3.4.14 GFP-UCB-ECFCs FORMED GJS AND ADHERENS JUNCTIONS WITH 
NEIGBOURING hREC 
7 days after seeding 2x104 GFP-UCB-ECFCs on to the hREC monolayers on PET transwell 
inserts in healthy conditions, both ECFCs and mature hREC expressed ZO-1 and VE-Cad, at 
both high and low hREC seeding density (Figure 3.20). These data confirm that the GFP-UCB-
ECFCs physically incorporated into the mature hREC monolayer. VEGFR-2 expression 
appeared upregulated in hREC seeded at lower density. Ang-2 expression was upregulated 
at high hREC seeding density. The cells expressing Ang-2 were GFP-negative, suggesting they 
are hREC, although one GFP-positive ECFC is expressing both Ang-2 and CD34 at high levels.  
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Figure 3.20. GFP-UCB-ECFCs formed GJs and adherens junctions with neighbouring 
hREC 
hREC were seeded at 3x103 or 2x104 cells/well on PET transwell inserts. 48H later, 2x104 GFP-UCB-
ECFCs, P8 were added to each well/insert. All cells were grown in healthy conditions (20% O2 and 
5.5mM glucose). Cells were fixed at 7 days after seeding GFP-UCB-ECFCs. Cells were processed for IF 
imaging to assess integration of ECFCs into a mature hREC layer. Antibodies against ZO-1 and VE-Cad 
were used to assess the formation of GJs and adherens junctions and VEGFR-2 and Ang-2 were used 
to assess the angiogenic response of the two cell-types. Images were captured using the Zeiss M800 
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3.4.15 HEALTHY GFP-UCB-ECFCs INCORPORATED INTO THE hREC LAYER OF 
HEALTHY AND DIABETIC CO-CULTURE MODELS 
Healthy GFP-UCB-ECFCs incorporated into a monolayer of hREC grown on PET transwell 
inserts and a layer of hREC grown with hRP in co-culture, on the underside of the PET 
membrane (see Figure 2.4), which were subjected to healthy conditions for 7 days. 24H after 
UCB-ECFCs were added to the hREC layer in mono- or co-cultures in healthy conditions, VE-
Cad was present on the cell membranes of GFP-UCB-ECFCs and mature hREC (Figure 3.21). 
ZO-1was present on mature hREC membranes, but not on GFP-UCB-ECFC membranes. Z-
stack projections confirmed the presence of hRP on the underside of the PET membrane in 
















Figure 3.21. GFP-UCB-ECFCs formed VE-Cad adherens junctions with hREC when 
added to the healthy co-culture model at day 7 
hREC P8 and hRP P8 were seeded at 2x104 cells/insert on either side of the PET membrane, or hREC 
were seeded alone, and grown for 3 days to enable hREC to form a monolayer. Cells were then 
cultured in healthy conditions for 7 days. Healthy GFP-UCB-ECFCs, P6 were seeded at 2x104 cells/insert 
on the apical hREC monolayer, on day 7. 24H later, cells were fixed and processed for IF analysis of ZO-
1 and VE-Cad expression to analyse ECFC integration. Images were captured using the Zeiss M800 
confocal microscope, x40 oil magnification, and z-stacking to images cells on both sides of the PET 

















   




Healthy GFP-UCB-ECFCs incorporated into the same conditions described above, but the 
mono- and co-cultures had been subjected to diabetic conditions for 7 days. 24H after UCB-
ECFCs were added to the hREC layer in mono or co-culture in diabetic conditions, both ZO-1 
and VE-Cad were present on the cell membranes of GFP-UCB-ECFCs and mature hREC (Figure 
3.22). The staining specificity of ZO-1 at the cell-cell junction, confirms GJ formation, with 
tighter contact with cell neighbours compared to the healthy co-culture hREC and ECFCs 














Figure 3.22. GFP-UCB-ECFCs formed ZO-1 GJs and VE-Cad adherens junctions with 
hREC when added to the diabetic co-culture model at day 7 
hREC P8 and hRP P8 were seeded at 2x104 cells/insert on either side of the PET membrane, or hREC 
were seeded alone, and grown for 3 days in healthy conditions to enable hREC to form a monolayer. 
Cells were then cultured in diabetic conditions for 7 days. Healthy GFP-UCB-ECFCs, P6 were seeded at 
2x104 cells/insert on the apical hREC monolayer, on day 7. 24H later, cells were fixed and processed 
for IF analysis of ZO-1 and VE-Cad expression to analyse ECFC integration. Images were captured using 
the Zeiss M800 confocal microscope, x40 oil magnification, and z-stacking to images cells on both sides 
of the PET membrane. White scale bars= 50µm, black Scale bars= 200µm. 
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3.4.16 GD-GFP-UCB-ECFCs INCORPORATED INTO THE hREC LAYER OF HEALTHY 
AND DIABETIC MONO-AND CO-CULTURE MODELS 
GD-GFP-UCB-ECFCs were lentivirally transduced with GFP the same way as healthy UCB-
ECFCs were. GD-GFP-UCB-ECFCs incorporated into established hREC layers grown in both 
healthy and diabetic conditions for 7 days, and grown either as mono-culture or co-culture 
with hRP, all on PET transwell inserts. Green GD-UCB-ECFCs were present at 24H and 5 days 















Figure 3.23. GD-GFP-UCB-ECFCs integrated into mono- and co-cultures models in both 
healthy and diabetic conditions 
hREC P8 and hRP P8 were seeded at 2x104 cells/insert on either side of the PET membrane, or hREC 
were seeded alone, and grown for 3 days in healthy conditions to enable hREC to form a monolayer. 
Cells were then cultured in either healthy or diabetic conditions for 7 days. At day 7 of healthy or 
diabetic conditions, 2x104 cells/well GD-GFP-UCB-ECFCs, P5 were added to the hREC layer of each 
insert. Images were captured at 24H and day 5 after ECFCs were added. Images were captured using 
the Nikon Eclipse TS100, the Nikon DIAPHOT and the Nikon E-Ti live cell microscopes, all at x10 
magnification. Scale bars=200µm. 
 
24H after adding GD-GFP-UCB-ECFCs to mono-cultured hREC subjected to 7 days of healthy 
or diabetic conditions, both mature hREC and GD-GFP-UCB-ECFCs showed positive staining 
for ZO-1, specifically at the cell-cell borders, confirming GJ formation (Figure 3.24). 24H after 
































   




adding GD-GFP-UCB-ECFCs to a diabetic co-culture model, subjected to 7 days of diabetic 
conditions, both mature hREC and ECFC expressed ZO-1, specifically at the cell-cell borders, 
confirming GJ formation. The Z-stack projection confirmed the presence of hRP on the 





















Figure 3.24. GD-GFP-UCB-ECFCs formed ZO-1 GJs and VE-Cad adherens junctions 
with hREC when added to healthy and diabetic hREC and the diabetic co-culture model 
at day 7 
hREC P8 and hRP P8 were seeded at 2x104 cells/insert on either side of the PET membrane, or hREC 
were seeded alone, and grown for 3 days in healthy conditions to enable hREC to form a monolayer. 
Cells were then cultured in either healthy or diabetic conditions for 7 days. GD-GFP-UCB-ECFCs, P9 
were seeded at 2x104 cells/insert on the apical hREC monolayer, on day 7. 24H later, cells were fixed 
and processed for IF analysis of ZO-1 and VE-Cad expression to analyse ECFC integration. Images were 
captured using the Zeiss M800 confocal microscope, x40 oil magnification, and z-stacking to images 
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3.5 DISCUSSION  
3.5.1 OVERVIEW 
The aim of this chapter was to determine if ECFCs isolated from umbilical cord (UCB) or adult 
peripheral blood (APB) were capable of re-populating a mature retinal microvascular EC layer 
subjected to diabetic conditions in vitro, and therefore a potential candidate for allogeneic 
or autologous cell therapy to repair the damaged retinal microvasculature in early-stage DR. 
In healthy adults, ECFCs repair damage to the vasculature during normal tissue homeostasis, 
however wound healing and vascular maintenance is impaired in people with T2DM, leading 
to gradual decline in microvascular function. Ultimately this can lead to DR and sight loss, 
neuropathy, chronic wounds and limb amputation. It is not yet fully understood if ECFCs 
decline in number due to constant renewal of the EC damaged by hyperglycaemia, or due to 
a dysfunction in either migration or integration at sites of damage. This question has been 
studied by hundreds of researchers in the past 20 years, since the discovery of ECFCs. In order 
to test ECFC capability of repopulating the damaged retinal microvasculature, this study used 
the optimised co-culture model from Chapter 2 for in vitro testing of survival and integration 
of GFP-labelled ECFCs (GFP-ECFCs) into established hREC layers in healthy or diabetic co-
culture conditions. 
UCB-ECFCs and APB-ECFCs could be expanded in vitro for multiple passages, although APB-
ECFCs took longer to initiate at P0, were slower to grow and began to transition in vitro when 
tested for their incorporation capability with hREC. UCB-ECFCs grew at a fast rate, retained 
their phenotype throughout passaging and successfully incorporated in to hREC monolayers. 
GFP-UCB-ECFCs could withstand diabetic insult and incorporated into the optimised co-
culture model in both healthy and diabetic conditions, suggesting UCB-ECFCs may be a 
suitable allogeneic cell population to aid in retinal microvascular repair in people with T2DM 
and early-stage DR. 
3.5.2 ECFCs WERE SUCCESSFULLY ISOLATED AND EXPANDED IN VITRO FROM 
HUMAN UCB AND APB 
Historically, correct nomenclature and identification of true ECFCs from a heterogeneous EPC 
population has been highly debated, but according to a recent review summarising two major 
EPC populations: MACs and ECFCs, the present study defines ECFCs according to the 
definition agreed by Medina et al.155. To date, the minimal requirement to distinguish true 
ECFCs from MACs in vitro assesses: cell proliferative capacity, morphology, expression of 
specific cell-surface antigens and IF antibody labelling of endothelial-specific antigens. In the 
   




present study, analysis of putative ECFCs from each donor was carried out before using the 
cells in experiments. ECFCs were isolated from the mononuclear layer of blood, seeded on 
col I. coated plates (rather than fibronectin), in EGM-2 with 20% FBS, and clones appeared in 
culture from day 14-40 (Figure 3.6), similar to reports from the literature153,173,263. Colonies 
appeared earlier in the cells isolated from UCB compared to APB. UCB-ECFCs and APB-UCBs 
were positive for CD31, CD105 and CD146 expression, and negative for CD45, CD14 and CD90 
expression (Figure 3.9B) and had general cobblestone morphology (Figure 3.9A). CD34 
expression was generally low 0.1-15.6%, although clones from two adult peripheral blood 
donors expressed much higher CD34; 24% and 63.1%. This variation in CD34 expression by 
ECFCs has been reported in the literature, where CD34+ ECFCs had higher proliferative 
potential264. A generally held opinion is that CD34 expression reduces over time during 
culture of ECFCs155, therefore CD34 alone no longer confirms ECFCs in vitro. Importantly, in 
the present study, ECFCs were negative for CD45 (common leukocyte antigen), CD90 
(mesenchymal stem-cell marker) and CD14 (haematopoietic-specific), clearly indicating the 
isolated cells were not from a haematopoietic lineage149. 
Some endothelial-specific markers are not expressed on the cell surface so cannot be 
assessed using flow cytometry, therefore, to confirm the cells isolated were true ECFCs, IF 
antibody labelling and confocal microscopy was performed on early passage cells from 
multiple donors. All UCB and APB donors were healthy, except for one GD-UCB donor. 
Healthy UCB-ECFCs and APB-ECFCs had positive expression for CD31 and vWF, confirming 
their endothelial-specificity (Figure 3.7, Figure 3.8). As with mature ECs, ECFCs make 
connections with neighbouring cells, therefore, VE-Cad should be present40. VE-Cad was 
present on APB-ECFCs (Figure 3.7A), although there was variability in VE-Cad expression on 
UCB-ECFCs, most likely due to time of fixation, considering the UCB-ECFC were fixed at 48H 
(Figure 3.7 B and C) and APB-ECFC were fixed later, at Day 5. ECFCs isolated from the one GD-
UCB donor expressed vWF, CD31 and ZO-1, confirming endothelial-lineage, and similar to the 
healthy UCB donors, VE-Cad was not expressed at the cell borders, even though these cells 
had been fixed at day 5 (Figure 3.8). All UCB- and APB-ECFCs were negative for CD90 and 
αSMA, evidence they had not transitioned to a fibroblastic phenotype in vitro.  
VEGFR-2 (KDR) was one of the earlier cell surface receptors reported as highly expressed by 
EPCs138,143,156. IF data from the present study suggests VEGFR-2 was dispersed across the cell 
membrane of UCB- and APB-ECFCs (Figure 3.7A, B and C), although lower expression levels 
were observed in GD-UCB- ECFCs (Figure 3.8). VEGFR-2 expression in healthy and diabetic 
   




retinae was analysed using immunohistochemistry, and was moderate/intense in intra- and 
pre-retinal vessels in retinae with pre-retinal neovascularisation, compared to healthy 
controls265. Successful laser therapy diminished this VEGFR-2 overexpression in intra-retinal 
vessels, highlighting the dynamic expression of VEGFR-2 throughout disease progression and 
treatment, which may explain why VEGFR-2 expression was variable between healthy UCB- 
and GD-UCB-ECFCs.  
A characteristic of ECFCs is their high proliferation rate in vitro147, and the UCB-ECFCs isolated 
in the current study, seeded at four increasing densities, shared this highly proliferative 
characteristic, demonstrated by the steep increase in cell number over 7 days at all seeding 
densities, all peaking at a similar number of ~50,000 cells/well by day 7 (Figure 3.10). 
Comparable to the growth behaviour exhibited by the mature hREC (Figure 2.13), ECFC 
numbers decline from day 7-21, although numbers remaining at day 21 were over 10 times 
higher than the average number of hREC remaining (1,203 hREC vs. 13,357 UCB-ECFC). This 
decline in ECFC number after day 7 may in part be due to contact inhibition caused by 
overcrowding in the well, which is a limiting factor for expanding cell numbers in vitro. 
Overall, the UCB-ECFCs isolated for this study displayed a rapid growth stage (0-7 days) 
followed by a gradual decline phase (7-14 days) and a final plateau stage (14-21 days) in vitro. 
A general observation with the UCB-ECFCs, was retention of morphology throughout 
continuous growth (Figure 3.6, Figure 3.9, Figure 3.11B, Figure 3.12B, Figure 3.13), and 
expression of endothelial-specific antigens throughout passaging, as others have found141,144. 
ECFCs were successfully isolated from fewer APB donors (5/10) compared to UCB donors 
(16/17), and the number of wells producing ECFC colonies from each donor was much higher 
from the UCB, which also grew at a faster rate than the APB-ECFCs. This outcome has been 
reported by other groups, where the number of endothelial colonies/ml of blood was 15-fold 
higher in UCB compared to APB141. Taken together with the comprehensive cell phenotyping 
data from IF and flow analysis using a comprehensive and up-to-date panel of widely used 
ECFC markers, the ECFC growth potential data further validate that ECFCs were successfully 
isolated and expanded from UCB and APB. 
Throughout ECFC passaging and from numerous donors, there was evidence of minor 
contamination with multinuclear (Figure 3.16) or very large cells (Figure 3.8F). This is a 
common issue when isolating blood from a mononuclear layer where multiple cell-types are 
present. Selective culture techniques such as; col I. coating plates, endothelial specific 
medium (EGM-2) and selective trypsinisation improves EC expansion173, but some non-ECs 
   




can persist. The enlarged cells with peripheral expression of phalloidin (Figure 3.8F) could 
represent senescent cells, although this would need to be further investigated. Overall, the 
level of contaminating cells was very low, so should have had minimal effect on results.  
ECFCs have been successfully transfected with GFP by several groups8,264,266, and for the 
present study stable GFP expression was achieved by lentiviral mediated transduction of 
pGIPz into healthy and GD-UCB-ECFC, for the purposes of long term fluorescence monitoring 
in vitro (Figure 3.17). With continuous puromycin treatment during expansion, UCB-ECFC 
cultures became ~80% GFP expressing. These GFP-UCB-ECFC were expanded and passaged 
further in vitro, over at least 3 passages and used in experiments, where due to their GFP 
expression they could be easily distinguished from hREC when grown in co-culture.  
3.5.3 EXPANDED ALLOGENEIC UCB-ECFCs OFFER A POTENTIAL CELLULAR 
THERAPY FOR REPAIRING DAMAGED VESSELS IN EARLY STAGE DR  
In order to be considered as a cellular therapy option, ECFCs need to show the capacity to 
incorporate into damaged EC layers in challenging environments, such as the high glucose, 
low oxygen environment of the retinal tissue during DR. It has been reported that ECFCs show 
a robust response to oxidative stress, and may in fact expand more successfully in vitro in 
low (5%) oxygen conditions267,268, suggesting they may be a good candidate for repairing the 
damaged vasculature in the diabetic retina. Therefore, UCB-ECFCs in the present study were 
tested for their ability to withstand the in vitro diabetic insults optimised for the co-culture 
model (see section 2.3.7) (2% O2 and 33mM glucose). UCB-ECFCs successfully grew on col I. 
coated glass slides in both healthy and diabetic conditions for 21 days (Figure 3.11B, Figure 
3.13), retaining high cell number, confluent cobble-stone monolayer morphology and 
metabolic activity within a healthy range (assessed up to day 4) (Figure 3.11A), displaying no 
noticeable differences between healthy and diabetic conditions.  
To further explore any changes in antigen expression caused by the in vitro diabetic 
conditions, UCB-ECFCs were stained with endothelial-specific, junction-specific and oxidative 
stress-associated antibodies after 21 days of culture (Figure 3.13). Overall, UCB-ECFCs 
retained their EC-specific cobblestoned morphology and expressed EC-specific markers (vWF 
and CD31) in both healthy and diabetic conditions, with no noticeable difference. As with 
mature endothelium, ECFCs expressed VE-Cad at cell junctions in both healthy and diabetic 
conditions, suggesting they formed a functional monolayer with the ability to control 
permeability40. There was a reduction in VEGFR-2 expression in the diabetic compared to 
healthy conditions by day 21 (Figure 3.13). Fadini et al. defined EPCs as CD34/CD133/VEGFR-
   




2 positive, and found a reduction in EPC number in patients with T2DM by 40%, and for 
patients with the added burden of peripheral vascular disease, EPC number were reduced 
47% compared to healthy controls156. In a more recent review, Fadini et al. summarised 10 
clinical studies that report reduced VEGFR-2+ EPC/ECFCs from patients with some form of 
cardiovascular risk factor151. These data suggest either overall ECFC number, or ECFCs 
expression of VEGFR-2 is reduced in diabetic and cardiovascular disease. The ECFC used in 
the present study were isolated from healthy donors, then subsequently subjected to a 
diabetic environment in vitro, and the IF data corroborates with the literature in that VEGFR-
2 is reduced in diabetic conditions compared to healthy (Figure 3.13). This adds to the 
compiled evidence that these in vitro diabetic optimised conditions were sufficient to induce 
a switch to diabetic phenotype in ECFCs as well as hREC. 
CD34 has long been associated with haematopoietic stem/progenitor cells but is now more 
widely accepted as a common marker for diverse progenitors, including vascular endothelial 
progenitors such as ECFCs269. Its function is not fully understood although it had been 
suggested that CD34 expression is associated with migration and adhesion, and is often 
found at the luminal membranes when analysed in capillary tissue, where more ECs of the 
small vessels were CD34 positive compared to ECs from large vessels270. In the present study, 
CD34 expression in early passage ECFCs, fixed at 2-5 days, was variable, with different 
expression patterns observed between the two different monoclonal antibodies used (Figure 
3.7, Figure 3.8). This brought in to question the validity of the CD34 antibodies, which can be 
a common pitfall for researchers investigating CD34, due to the sensitivity of some CD34 
antibodies to cleavage by neuraminidase and glycoprotease271. However, the rabbit 
monoclonal antibody (EP373Y- Synthetic peptide within Human CD34 a.a. 350 to the C-
terminus) used in this study has been validated by Abcam and published in over 160 papers. 
Interestingly, passage 5 UCB-ECFCs grown on col I. coated glass expressed CD34 in the 
perinuclear area in healthy conditions, compared to specifically at the cell borders in diabetic 
conditions, by day 21 (Figure 3.13). In a recent study, CD34 expression in ECFCs was found to 
be an interchangeable phenotype in vitro, whilst VE-Cad, CD31 and VEGFR-2 remained 
unchanged. CD34-negative cells could re-acquire CD34 antigens, with no influence from cell 
culture medium except for presence of TNFα, and no influence from whether FBS was 
present or not272. Tasev et al. also report that high seeding density resulted in increased CD34 
expression in ECFCs and postulate CD34 may be upregulated with increased neighbouring 
cell-cell contact, although they suggest this actually leads to reduced endothelial barrier 
function, due to the role of CD34 in destabilizing cell-cell contact in order to form a vessel 
   




lumen. Taking this into consideration, in the present study where ECFCs were cultured for 21 
days in diabetic conditions, distinct CD34 expression at the lateral borders of 100% of cells in 
field of view (Figure 3.13) may represent a weakened EC barrier, possibly mimicking a PDR 
stage where ECFCs receive signals to proliferate, due to a combination of oxidative stress and 
angiogenic signalling. The perinuclear expression of CD34 in healthy conditions may be due 
to blocked trafficking of the phosphoglycoprotein, which would normally be expressed as 
transmembrane.  
ECFCs express higher ambient SOD-2 than mature ECs267, similar to the results in the present 
study, when comparing UCB-ECFCs with retina-specific hRECs (Figure 2.10, Figure 2.16, Figure 
2.17, Figure 3.13), where ECFC SOD-2 expression was higher than hREC SOD-2 expression in 
both healthy and diabetic conditions. In an in vitro study using bovine aortic ECs, 
hyperglycaemia increased ROS inside the cells and treatment with SOD-2 haemagglutinating 
virus of Japan (HVJ)-liposomes significantly reduced activation of mitochondrial pathways 
associated with hyperglycaemia-induced pathogenesis273. Therefore, if the optimised 
diabetic conditions were causing ROS production, SOD-2 activation should be observed when 
the cells activate a protective response to this insult. High basal expression of SOD-2 may 
explain why ECFCs are more resilient to damage from oxidative stress, making them an ideal 
candidate for cell therapy to repopulate areas where oxidative stress may continue to 
contribute to tissue damage during T2DM. 
3.5.4 APB-ECFCs MAY REQUIRE FURTHER MANIPULATION IN VITRO TO BE USEFUL 
CLINICALLY 
Unfortunately, after multiple attempts, using ECFCs from different donors, it was not possible 
to transduce GFP expression in APB- ECFCs, which would initially express GFP but then fail to  
proliferative after puromycin treatment. Therefore, ABP-ECFCs could not be tested for 
incorporation into the co-culture model because it would not have been possible to 
distinguish them from the hREC without the GFP expression. APB-ECFCs have been reported 
to possess differences in 20% of a panel of genes regulating a variety of EC function: including 
permeability and vessel tone, cell activation, injury response, angiogenesis, cell survival and 
apoptosis, when compared to UCB-ECFCs274. Overall, APB-ECFCs upregulate immune and 
thrombotic response compared to UCB-ECFCs. These genotypic differences combined with 
the reduced proliferative potential of APB-ECFCs in vitro could explain why GFP-APB-ECFCs 
were unable to continue expanding for multiple population doublings after lenti-viral GFP 
transduction and puromycin treatment. 
   




A simple technique to test if APB-ECFCs were capable of integrating into a monolayer of 
mature endothelium was to label ECFCs with a fluorescent tracker (CTG) and add CTG-APB-
ECFCs 48H after hREC were seeded at high or low density on TC plastic. CTG-APB-ECFCs 
incorporated successfully in both healthy and diabetic conditions (Figure 3.15). Ideally, for 
direct comparison with CTG-UCB-ECFC incorporation experiments, 2x104 APB-ECFCs would 
have been seeded, but APB-ECFCs were much slower to expand in vitro, with some ECFCs 
expanding in size and not proliferating, which may have represented cell senescence (Figure 
3.16). Therefore, numbers as close as possible to 2x104 were seeded. APB-ECFCs that 
incorporated in to high and low density hREC in healthy and diabetic conditions were 
analysed 48H later for HIF1α (to assess response to diabetic (hypoxic) environment), and ZO-
1 expression (to assess physical incorporation and barrier formation) (Figure 3.16). HIF1α can 
mediate the cellular response to low oxygen by regulating glucose uptake and shifting to 
anaerobic respiration, activated when HIF1α translocates from the cytoplasm to the 
nucleus275. In the present study, HIF1α remained inactive (cytoplasmic) in all conditions, 
however 48H at 2% oxygen may not be sufficient time to cause this activation of major 
cellular transcriptional adaptions, in light of the low HIF1α activity reported at 3% oxygen 
compared to 1% oxygen at 8H in HEK293 cells276. Another hypothesis is; normal HIF1α 
regulation of cell proliferation and migration may have been altered due to the paradox of in 
vitro ‘standard cell culture normoxia (20% O2)’ compared to ‘physiological normoxic 
conditions (~2-8%)277. HIF1α activity is difficult to determine using IF, due to its fast 
translocation from the nucleus when re-oxygenation occurs during stages of washing and 
fixing to prepare samples for imaging. Therefore, although HIF1α expression at the protein 
levels remained cytoplasmic, exploration at the transcriptional levels may reveal otherwise. 
CTG-APB-ECFCs and hREC both expressed ZO-1, 4 days after hREC were seeded and 48H after 
APB-ECFCs were added to the monolayer, in both healthy and diabetic conditions (Figure 
3.16). ZO-1 expression at cell-cell junctions was junction-specific in diabetic conditions with 
high density hREC, where both hREC and incorporated CTG-APB-ECFC expressed ZO-1 at the 
cell-cell borders, indicating the two cell-types physically incorporated to form a monolayer 
with TJ barrier properties. These data suggest at the early stage (day 4) both hREC and APB-
ECFCs could withstand diabetic insults and in fact displayed enhanced barrier properties and 
proliferation compared to those grown in healthy conditions. A small number of CTG-APB-
ECFCs from donor #1042 appeared to become senescent in culture (Figure 3.16red circles), 
corroborating reports from the literature that adult ECFCs become senescent much earlier 
than UCB-ECFCs149. Integrated CTG-APB-ECFCs from donor #322 were larger in size and some 
   




displayed finger-like cytoplasmic projections, which may represent differentiation in vitro 
possibly to a fibroblast-like cell; considering ECFCs are human primary cells, with progenitor 
plasticity (Figure 3.16B). A small number of very large, multinuclear, CTG-positive cells were 
present amongst APB-ECFCs from donor #322, representing cells which may have 
dedifferentiated to an unknown multinuclear cell-type, only present in the healthy 
conditions, or represent a small number of contaminating cells from the selective cell culture 
procedure (Figure 3.16 arrow heads).  
Overall, this study provided evidence that APB-ECFCs from healthy donors can physically 
incorporate into hREC monolayers in both healthy and diabetic conditions. However, 
proliferative potential and growth rate of APB-ECFCs was much lower than UCB-ECFCs. 
Increase in cell size and change in morphology, particularly from donor #322, cultured in 
healthy conditions, suggests some of the APB-ECFCs transitioned in vitro. These data 
indicated donor variability relating to expansion capability of APB-ECFCs and that current cell 
culture expansion protocols, which are sufficient for UCB-ECFC expansion, may require 
modification to prevent senescence or de-differentiation of APB-ECFCs in vitro, if they are to 
be developed as an autologous cell therapy in the future. 
3.5.5 THE OPTIMISED CO-CULTURE MODEL OF THE RETINAL VASCULATURE 
PROVIDES A USEFUL TOOL TO ASSESS ECFC INTEGRATION INTO A MODEL OF 
DR 
ECFCs may fail to integrate and repair the retinal microvasculature due to either impaired 
migration, or reduced ECFC number156, both caused by chronic hypertension, dyslipidaemia 
and hyperglycaemic environment, along with persistent EC turnover as a result of long onset 
of T2DM278. In order to improve our understanding of this gradual ECFC failure, incorporation 
of ECFCs into animal models of diabetes and/or ischemia can be used to validate ECFC 
function, but with the absence of an available animal model, in vitro ECFC incorporation into 
mature EC monolayers provides proof of principle that the cell population isolated has the 
ability to physically incorporate, or ‘repair’ a simplified model of a diseased blood 
vessel153,279–281. CTG- and GFP-UCB-ECFCs successfully incorporated into high and low density 
hREC cultures when seeded at the same time, on both TC plastic and PET, and remained 
incorporated for up to 7 days (Figure 3.18). Having confirmed incorporation with hREC when 
the two cell-types were seeded at the same time, moving forward to better reflect the 
disease environment of the microvasculature during DR; where ECs become damaged and 
slough off282, hREC were seeded first at high or low density on TC plastic or PET, followed by 
   




addition of GFP-UCB-ECFCs after 48H, to analyse the ability of the ECFCs to ‘fill’ the gaps. At 
24H and day 7, GFP-UCB-ECFCs incorporated in all conditions (Figure 3.19).  
In order to confirm that the GFP-UCB-ECFCs physically incorporated with the pre-existing 
hREC (rather than settling on top), ZO-1, VE-Cad, VEGFR-2 and Ang-2 were analysed to 
explore junctional protein/barrier formation (VE-Cad and ZO-1) and angiogenic response 
(VEGFR-2 and Ang-2). In healthy conditions, GFP-UCB-ECFCs were present in all fields of view, 
proving UCB-ECFCs remained embedded within the hREC monolayer at day 7, at both low 
and high hREC seeding densities (Figure 3.19, Figure 3.20). GFP-UCB-ECFCs and GFP-negative 
hREC both expressed VE-Cad and ZO-1, confirming that the two cell-types formed functional 
cell-cell junctions with one another, mimicking how ECFCs may contribute to repair in vivo.  
Both Ang-2 and VEGFR-2 are upregulated in vivo during diabetes, linked with the proliferative 
stage of DR when new vessels are formed on the retina in response to hypoxia, induced by 
chronic ischemia, as a result of degradation of the retinal capillaries over time58,236,283. In the 
diabetic retina, VEGFR-2 and its downstream mediators are important therapeutic targets for 
anti-VEFG drugs284, to prevent uncontrolled proliferation of improperly formed, leaky blood 
vessels. In the present study, the cells expressing Ang-2 were GFP-negative, suggesting they 
were hREC rather than ECFCs, with the exception of one GFP-positive ECFC which expressed 
both Ang-2 and CD34 (Figure 3.20). This implies that hREC express Ang-2 more so than UCB-
ECFCs, and points toward the hREC ‘recruiting’ ECFCs to gaps within the EC layer via secretion 
of pro-angiogenic Ang-2, although paradoxically, VEGFR-2 is downregulated at high hREC 
seeding density. GPF-UCB-ECFCs seeded on low density hREC did not express any Ang-2, 
although VEGFR-2 expression was upregulated (Figure 3.20). It should be noted that Ang-2 is 
a secreted protein, therefore, concentrations may be high within the media even if at the 
time of fixation this may not be reflected by levels within the cell (Figure 2.32). VEGFR-2 
expression did not co-locate with GFP-UCB-ECFCs, suggesting, similar to Ang-2, it was the 
hREC expressing VEGFR-2 rather than the ECFCs. 
Testing the ability of GFP-UCB-ECFC to incorporate into the optimised co-culture model 
(Chapter 2), provided an in vitro, simplified, and high throughput option to assess ECFC 
functionality rather than using an in vivo animal model of DR. The co-culture model aims to 
better mimic the in vivo architecture of a damaged capillary compared to traditional 
monoculture experiments, and therefore, provide more relevant data on whether ECFCs are 
a suitable candidate for allogeneic cell therapy. GFP-UCB-ECFCs integrated at day 7 in both 
healthy and diabetic co-culture conditions (Figure 3.21, Figure 3.22, Figure 3.24). DAPI, VE-
   




Cad and ZO-1 labelling and z-stack confocal microscopy confirmed that GFP-UCB-ECFCs 
physically incorporated with their hREC neighbours in the presence of both hREC and hRP 
layers. ZO-1 and VE-Cad were expressed by ECs in both healthy and diabetic co-culture 
conditions, however the pattern of expression was much more junction-specific in the 
diabetic conditions, compared to a more cytoplasmic dispersed expression in the healthy co-
culture conditions. This implies the cell-cell junctions and therefore the barrier properties 
were improved in the diabetic rather than the healthy co-culture model at day 8, 24H after 
adding healthy UCB-ECFCs. 
3.5.6 ECFCs FROM GD-UCB MAY OFFER A POPULATION OF CELLS RESILIENT 
AGAINST HYPERGLYCAEMIC INSULT 
Gestational diabetes is defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy, and the prevalence may range from 1-14% of all pregnancies69. 
Due to the sudden onset and short duration of GD compared to the prolonged onset and 
progression of T2DM and DR, GD likely has different effects on progenitor cell populations. 
Also, the different nature of the diseases means results from studies investigating pre-
existing T2DM in mothers (DIP) is therefore, not directly comparable to GD. Three reviews 
focusing on the function of ECFCs in T2DM or DR, summarise multiple studies which report 
both increased and decreased ECFC number, and both increased and decreased ECFC 
functionality with risk factor or disease progression, highlighting the controversy surrounding 
the role of ECFCs in vessels repair during T2DM151,157,285. Regarding specifically GD, in a small 
study on 45 mothers with GD compared to 42 controls, ECFC numbers isolated from GD-UCB 
was significantly higher (p<0.05) than controls, which suggests altered foetal stem cell 
mobilisation in GD pregnancy286. Another group report GD-UCB-ECFCs were more 
proliferative than control UCB-ECFCs, but that GD-UCB-ECFCs had decreased tube-forming 
capacity and reached senescence earlier in vitro, however most interestingly the GD-UCB-
ECFCs were resistant to hyperglycaemia induced senescence via no change to p38MAPK71. 
Linking pre-existing T2DM to pregnancy (DIP), in a study assessing diabetic intrauterine 
environment caused by mothers’ diagnosis of Type I or T2DM pre-pregnancy, UCB-ECFCs 
displayed reduced colony formation, self-renewal capacity and tube formation in vitro72. 
These studies indicate GD and DIP have different effects on ECFC number, and that GD-UCB-
sourced ECFCs may in fact represent an enriched ECFC source, able to withstand 
hyperglycaemic insult compared to healthy UCB. 
   




In the present study, GD-UCB-ECFCs were collected from only one donor, and their ability to 
integrate with hREC was assessed using the same experiments as healthy UCB-ECFCs. GFP-
GD-UCB-ECFCs were added to monolayers of hREC, or hREC co-cultured 1:1 with pericytes 
underneath to determine: 1) if GFP-GD-UCB-ECFCs could incorporate with mature hREC just 
as healthy UCB-ECFCs did, 2) if the presence of hRP changes the incorporation behaviour and 
3) if healthy or diabetic conditions impairs GD-UCB-ECFC incorporation. When added to 
either mono- or co-cultures, GFP-GD-ECFCs successfully incorporated with hREC in all 
conditions, remaining for up to 7 days (Figure 3.23, Figure 3.24). Similar to healthy GFP-UCB-
ECFCs, GFP-GD-UCB-ECFCs expressed cell junction-specific ZO-1 with their neighbouring 
hREC (Figure 3.24). Unfortunately the healthy co-cultures were damaged during processing 
so it was not possible to analyse this. Multiple passage expansion, GFP transduction, 
phenotype retention and successful incorporation of GD-UCB-ECFCs in vitro are promising 
results, considering general agreement in the field that ECFCs become dysfunctional or 
reduced in number during diabetes. In this n=1 study, GD did not appear to have the same 
reported detrimental effects as T2DM, although ECFCs from more GD donors need to be 
tested to fully validate this result.  
3.6 LIMITATIONS & FUTURE WORK 
To improve the power of my study, more donors, and more experimental repeats are 
required, however due to time constraints and the long process of ECFC isolation from 
human blood, data reported have provided important information regarding the ability to 
expand ECFCs in vitro and test their integration into a novel in vitro model of DR. In order to 
asses barrier function, permeability assays as well as IF staining of VE-Cad and ZO-1 would 
provide quantification of functionality across different experimental conditions. As observed 
with the hREC (Chapter 2), ECFC proliferation, junctional protein expression and metabolic 
activity was resilient during in vitro diabetic conditions and this result is a recurring output 
from my data (Figure 3.11, Figure 3.13, Figure 3.22). All ECFCs were expanded in 
physiologically healthy conditions (20% O2 and 5.5mM glucose). However, in future studies 
it would be interesting to attempt to expand ECFCs in <5% O2 from the offset, following 
reports that ‘in vitro hyperoxia’ (20% O2) may in fact be detrimental and also reports that 
stem/progenitor cells grow better in low oxygen. Similarly, it would be interesting to grow a 
population of ECFCs in high glucose (33mM) from the offset, to ascertain if initial expansion 
in healthy conditions is involved in recovery or alteration of ECFCs collected from GD or T2DM 
   




patients, and if continual hyperglycaemic insult throughout in vitro expansion may provide a 
truer illustration of ECFC behaviour during diabetes. 
3.7 CONCLUSIONS 
Overall, work from this chapter covers successful isolation, stringent characterisation and 
expansion of healthy UCB-ECFCs, GD-UCB-ECFCs and APB-ECFCs in vitro, observing the 
highest proliferative potential and integration by the UCB-ECFCs. Therefore, UCB-ECFCs 
(either healthy or GD) currently show the most promise as an allogeneic cell therapy to 
repopulate depleted ECFCs in the retina in early stage or pre-diabetic patients. APB-ECFCs 
may indeed have the ability to expand and function in vitro, however genetic modification or 
manipulation of the culture environment may be necessary to prevent senescence or trans-
differentiation after passaging. UCB-ECFCs grew well in the hREC-specific growing conditions 
and were robust in withstanding diabetic insult and long term in vitro culture (21 days). ECFCs 
from both UCB and ACB consistently expressed endothelial cell-specific markers (vWF and 
CD31) and successfully incorporated into mature hREC monolayers, confirming their 
endothelial cell-type. The paradox of consistent ECFC proliferation, incorporation and 
improved cell-cell junction formation in diabetic conditions (2% O2 and 33mM glucose) may 
in fact represent an early stage compensation reaction, comparable to in vivo early stage or 
pre-diabetes. An alternative theory is that possibly after very long progressive onset of T2DM, 
ECs eventually become dysfunctional due to the hyperglycaemic environment, but rally to 
survive before finally succumbing to cell death. To confirm these theories, more in depth 








   




4 CHAPTER 4  
Assessing pεK hydrogels for in vitro expansion of ECFCs and controlled 
delivery of cells into an in vitro model of the retinal microvasculature 
4.1 OVERVIEW 
ECFCs are currently expanded in vitro on rat tail col I. coated TC plastic. To enable ECFCs to 
be used in human cell therapy in the future, xeno-free or GMP-compliant conditions must be 
met. Due to their progenitor nature and because they are primary cells, ECFCs require specific 
ECM protein coatings to adhere and expand in vitro, without differentiation or senescence. 
pεK is a naturally occurring biomaterial that is non-toxic to humans and the environment. 
Peptide hydrogels, such as those made from pεK, can provide the chemical functionality of 
the col I. which is currently used, while being non-animal derived and consistently 
reproduced. Due to free-amine groups on the surface of pεK hydrogels or microparticles, 
surfaces can be further modified according to cell-specific requirements. One example is 
covalent binding of RGD peptide, to enhance cell attachment to the pεK surface. This chapter 
focuses on using pεK hydrogels to expand ECFCs and maintain their early passage phenotype. 
pεK microparticles either unmodified or with RGD covalently bound to the surface were 
assessed as a controlled delivery tool of ECFCs to the co-culture model of DR. 
4.2 AIMS & OBJECTIVES 
To assess the capacity of pεK for ECFC attachment, viability and expansion without 
differentiation, and targeted delivery of ECFCs to an in vitro model of diabetic 
retinopathy. 
1. Determine if ECFCs can attach, expand and survive on pεK cross-linked with 
decanedioic acid gels in experimental healthy and diabetic conditions  
2. Determine if pεK microparticles can be used to delivery ECFCs to the endothelial 
layer of an in vitro co-culture model of DR 
   





4.3.1 PRODUCTION OF pεK GELS 
Hydrogels were made using poly-ε-lysine, cross-linked 60% with decanedioic (sebasic) acid. 
Compounds used to make hydrogels were as follows: poly-ε-lysine (pεK) (Bainafo- Zhengzhou 
Bainafo Bioengineering Co. Ltd. (supplied by Spheritech)), sebacic acid 98+% (A14158, Alfa 
Aesar), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide HCl (EDCI) (FD05800, Carbosynth), 
4-Methylmorpholine Reagentplus 99% (NMM) (Sigma, M56557-500ML) and N-
hydroxysuccinimide (NHS) (Sigma, 130672-100G). Gels of 1g/ml pεK and 1.33g/ml pεK were 
cast on 100mm dishes, at RT, using the compounds and amounts outlined in Table 4.1. pεK 
gel components were measured and prepared in 2 separate tubes. 
 
 Table 4.1. REAGENTS AND AMOUNTS REQUIRED TO CAST PεK GELS 
 
pεK and decanedioic acid with added NMM were fully dissolved in two separate containers 
in 1ml ddH2O each, on a rolling platform. These solutions were then mixed, and Tween 
added, to make the solution in container 1. NHS and EDC were solubilised at the very last 
moment; 1ml ddH2O was added to NHS in 7ml bijou tube, and 1.5ml dH2O was added to EDC 
in a separate bijou tube, and both vortexed for ~30 seconds until fully dissolved, then NHS 
and EDC were combined in container 2, then quickly mixed with container 1. Total volume of 
components was topped up to 5ml. Solution was inverted 10 times to ensure mixing, then 
solution was poured into 100mm dish on level surface and left with lid off at RT, for gel to set 
overnight. 
Once set, gels were washed 5x with ddH2O, to remove debris and to fully rehydrate gels. Gels 
were then UV sterilised for 5 mins at 1,500v on each side. Gels were further sterilised in 70% 
ethanol for 1H. Gels were washed 3x 5 mins in sterile PBS to remove ethanol. Gels were 
punched using 0.9m diameter tool to produce gel discs to fit into the bottom of the wells of 
 60% Cross-linked with Decanedioic acid Gels 
 5ml total volume for 1x 100mm dish 
  PεK (g) di-acid (g) NMM (ul) Tween (ul) NHS (g) EDC (g) 
Se 60% 0.1g/ml 0.49 0.174 315 50 0.165 0.826 
Se 60% 0.13g/ml 0.66 0.232 420 50 0.22 1.101 
 
tube 1- in total  
2.5ml ddH₂O 
tube 2 – in total 
2.5ml ddH₂O 
   




24 w/p (Figure 4.1). Gel discs were washed in sterile dPBS to remove any remaining debris, 
then carefully transferred to 24 w/p using sterile, blunt ended tweezers, in a class II hood. 
Sterile dPBS was added to each well with each pεK gel disc, to keep gels hydrated until ECFCs 





















Figure 4.1. Casting and punching of pεK gels into 0.9cm diameter disks  
5ml of pεK gel ingredients were poured into 100mm diameter dishes, and set as flat gels overnight.  A 
0.9cm diameter punch was used to make pεK gel disks that would fit into the bottom of the wells of a 
24 w/p. ‘GEL’ text written on paper underneath the gels made from different concentrations of pεK 




Punch 0.9cm diameter disks 
pεK 0.1g/ml pεK 0.13g/ml 
60% Cross-linked with decanedioic acid 
   




4.3.2 SEEDING ECFCs ON TO pεK GELS 
ECFCs were subcultured (as described in section 3.3.3) and prepared to seed on gel discs in 
24 w/p’s at 5x104 cells/well, in 500µl/well EGM-2 with 10% FBS, 5.5mM glucose and normal 
incubator conditions. To prevent gels floating when ECFCs in media were added, cell-media 
solution was gently added drop by drop, directly on top of the gel discs, with the aim of 
directing ECFCs to seed on the top of the gel, as opposed to the underside, or the TC plastic 
if gels floated upon agitation. Cells were left to grow in normal conditions for 48H, before 
being moved to either healthy or diabetic conditions. 
4.3.3 IMAGING CELLS ON pεK GELS 
pεK gels of 1g/ml and 1.33g/ml both had sufficient transparency for light microscopy imaging, 
enabling  monitoring of cells growing on the surface over time. For IF imaging, all solutions 
were very gently added to ECFCs on the pεK gel disks, and gel disks were handled very gently 
with rounded tweezers, to prevent ECFCs from peeling off the gel during processing. Cell 
culture medium was removed and cells on pεK gels were gently washed using warm sterile 
dPBS 3x for 5 mins. 10% NBF was added for 9 minutes, at RT, to fix ECFCs. NBF was removed 
and cells were washed 3x 5 mins in dPBS. 0.5% Triton-X in PBS was added for 4 mins at RT to 
permeabilise cells. Cells were then washed 3x 5 mins with dPBS. 5% normal goat serum (NGS) 
in dPBS was added to cells for 1H at RT to block non-specific binding sites. NGS was removed 
and primary antibodies, diluted to optimised working concentration in dPBS (Table 2.4Table 
3.1), were added to cells and left to bind overnight at 4°C in the dark. The next day, 3x 5 mins 
0.1% Tween-20 in dPBS washes at RT removed any unbound primary antibody. Secondary 
antibodies (Table 2.2), were added at 5µg/ml in dPBS for 45 mins at RT in the dark. Cells were 
washed 3x 5 mins in 0.1% Tween-20 in dPBS at RT, in the dark, to remove any unbound 
secondary antibody. 300 nM of DAPI in dPBS was added for 20 mins at RT. 2x 5 mins washes 
with 0.1% Tween-20 in dPBS, and final 10 min wash were performed to remove any unbound 
DAPI, due to strong retention of DAPI in the pεK gels. 1x 5 min dPBS wash removed any 
remnants of Tween-20. 1x 2 min ddH₂O wash removed any salt crystals from the surface of 
the cells and gels. Gel disks were then gently lifted out of 24 well plates using curved 
tweezers, and placed on to glass slides. Mounting media was dropped on top of the gel disk 
and a cover slip was placed on top, with gentle pressure. Due to the thickness of the gel disks, 
cover slips did not seal tight against glass slide, so confocal imaging was performed with 
particular care, to prevent movement which may cause cells to peel off, or gel tearing. ECFCs 
stained with IF antibodies were imaged using the Zeiss M800 confocal microscope. 
   




4.3.4 PRODUCTION OF pεK MICROPARTICLES 
PεK microparticles were manufactured and provided by Andrew Gallagher from SpheriTech. 
Briefly, 0.286g/ml pεK was cross-linked 50% with decanedioic acid, using the protocol 
described above for preparing gels, (4.3.1), and formed into microparticles via emulsification 
polymerisation. Beads were provided at 4 size ranges (Figure 4.2): 1mm-500µm (18-30-2), 
500-250µm (18-30-3), 250-150µm (18-30-4) and <150µm (18-30-5). The beads had amine 
functionality, with a loading capacity of 3mmol/g. For use unmodified, 0.04g of beads were 
weighed dry into a 7ml bijou for washes. Microparticles were left overnight in 5ml of 70% 
ethanol, on a rolling platform, to sterilise. The next morning, tubes were stood upright to 
allow microparticles to sink to the bottom, then ethanol was gently removed. 3x 10 min 
sterile dPBS washes were performed in a class II hood to remove remnants of ethanol. A final 
wash was performed in serum-free, phenol red-free EGM-2 medium, at 37°C. Microparticles 
could be left in medium for several hours if there was any delay in adding cells. Otherwise, 
beads were immediately transferred to 24-well suspension plates (Merck, M9312-100EA). 
Use of suspension plates prevented preferential attachment of ECFCs to TC treated plastic, 
rather than the surface of the microparticles. To optimise ECFC viability on pεK 
microparticles, ECFC attachment and survival was tested on both unmodified microparticles 












Figure 4.2. pεK gel microparticles of four size ranges supplied by SpheriTech 
pεK gel microparticles were formed by emulsification polymerisation and supplied in four size ranges 
Images were captured using the Nikon E-Ti microscope, x20 magnification. Scale bars= 100µm. 
1000-500µm                500-250µm                250-150µm                    <150µm 
   




4.3.5 RGD PEPTIDE BINDING TO pεK MICROPARTICLES 
Arg-Gly-Asp (RGD) peptide was synthesised by SpheriTech and provided in powder form. For 
RGD binding, microparticle sizes 500-250µm (18-20-3) and 250-150µm (18-20-4) were used. 
0.04g dry microparticles were added to a 7ml bijou. This weight was optimised for 
microparticles to fully cover the bottom of a 24 w/p, in a single layer. The calculation of how 
much RGD to add to 3x full wells of 18-20-3 microparticles and 3x wells of 18-20-4 
microparticles is found in Figure 4.3.  Before binding RGD peptide, microparticles were 
washed in bijou tubes with 10% NMM in ddH₂O 3x 10 mins, on a roller. Microparticles were 
then washed 3x10 mins in ddH₂O on a roller, with final wash having bijou tubes standing 
upright. To covalently bind RGD to ~10% of the surface of the pεK microparticles, RGD 
peptide was added to microparticles at 250µl/well volume in a 0.25M solution of NHS 
(0.0287g/ml) and EDCI (0.048g/ml) in water. Microparticles were left on a rocking platform 
at RT with RGD binding solution, for 1H. Microparticles were then washed 3x5 mins in sterile 
PBS, in a Class II hood, then left on a roller at RT in sterile PBS for an overnight wash.  
4.3.6  ADDING ECFCs TO pεK MICROPARTICLES 
Before adding ECFCs, microparticles were transferred to a 24-well suspension plate (1 bijou 
tube to 1 well) using a sterile scooper, and washed briefly in serum-free phenol red-free 
EGM-2. When adding ECFCs to microparticles, phenol red-free EGM-2 with 10% FBS medium 
was used. If phenol was present, red colour was taken up by microparticles, making light 
microscopy difficult. In a Class II hood, microparticles with or without covalently bound RGD 
peptide were scooped out of the bijou tube using a sterile scoop tool, into 24-well suspension 
plates, enough to fully cover the bottom of the well, avoiding layering of microparticles. Once 
hydrated, microparticles became aggregated to each other when trying to use various sized 
gauge needles to move the microparticles (Figure 4.4). Microparticles of the two smaller sizes 
(18-30-4 and 18-30-5) could fit though a 21G needle, but size 18-30-3 and 18-30-2 were too 
large when hydrated to fit through an 18G needle. Therefore, sterile metal scoops were used 






   
























Figure 4.3. How to calculate how much RGD to add to pεK microparticles 
This flow diagram demonstrates how the calculation steps required to achieve 10% RGD peptide 
covalent binding to amine functional groups on the surface of the pεK microparticles. Previous work 
by SpheriTech found 10% RGD surface binding improved call attachment (unpublished data), so 10% 

















18-30-3: (3.14 x 0.95² x 0.0375) x3 (for 3 wells) =318.9µl volume 
18-30-4: (3.14 x 0.95² x 0.02) x3 (for 3 wells) = 170.1µl volume 
pεK in beads = 0.286g/ml 
18-30-3:  0.286g x 0.3189ml = 0.091g pεK  
18-30-4: 0.286g x 0.1701ml = 0.049g pεK  
Capacity = 3mmol/g 
18-30-3: 1/0.091g = dilution factor of 11 ∴ 3/11 = 0.273mM for 100% RGD binding 
18-30-4: 1/0.049g = dilution factor of 20.4 ∴ 3/20.4 = 0.147mM for 100% RGD binding 
Want 10% RGD binding 
18-30-3: 0.273mM/10 = 0.027mM for 10% RGD binding 
18-30-4: 0.147mM/10 = 0.014mM for 10% RGD binding 
RGD: Mw=784g/mol  
g= moles x Mw 
18-30-3: 2.7x10
-5
 moles x 784 = 2.12x10
-2
g = 21.17mg RGD 
18-30-4: 1.47x10
-5 
moles x 784 = 1.15x10
-2
g = 11.52mg RGD 
18-30-3: 211.7µl of 0.1mg/µl stock 
18-30-4: 115.5µl of 0.1mg/µl stock 








   











Figure 4.4. Needles of various sizes were assessed for transferring microparticles 
Testing ability to transfer hydrated pεK microparticles using various gauge needles and syringe sizes. 
21G enabled some 18-30-4 beads to enter syringe. Red circles highlight where hydrated microparticles 
have aggregated at the tip of 25-19G needles and did not pass through, and the black circle highlights 
where 250-150µm microparticles passed through a 21G needle into the syringe. 
 
4.3.7 ADDITION OF ECFC LADEN pεK MICROPARTICLES TO MONO/CO-CULTURE 
MODELS 
Once GFP-ECFCs were added to microparticles and left to attach overnight in a 24 well-
suspension plate, ECFC-laden microparticles were scooped out of the 24 w/p and added 1:3 
into the apical side of the transwell membranes, with the aim of achieving roughly a single 
layer of cell-laden microparticles across the top of the hREC. When ECFCs were added, hREC 
had been grown in either healthy or diabetic conditions for 7 days, with or without hRP on 
the underside of the PET membrane, seeded at a 1:1 ratio. The apical side of the transwell 
was topped up with MV with 5% FBS medium to 200µl total volume. 24H after addition of 
ECFC-laden microparticles, microparticles were gently washed away by inverting the transwell, 
and adding dPBS drop by drop until the microparticles spilled out into a separate dish. 
Microparticles were then washed, fixed and processed for IF imaging. For analysis of transfer 
of GFP-ECFCs from microparticles onto the hREC layer, PET membranes were fixed and 
processed for IF imaging, to confirm the presence of GFP positive cells integrated into the 
hREC layer. 
4.3.8 IMAGING ECFCs ON pεK MICROPARTICLES  
To test the capability of imaging CTG-ECFCs and GFP-ECFCs on the microparticles, z-stack 
imaging was performed using the Zeiss Apotome microscope for live cell analysis. For end 
point analysis, cells on microparticles were fixed and permeabilised using 10 % NBF and 








   




to the protocol included gentle washes and removing cell supernatant very carefully to avoid 
aspirating the smaller sized microparticles. For confocal analysis of fixed ECFCs on 
microparticles, once stained, microparticles were gently aspirated with a 1000µl siliconized 
tip (DAIGGER, EF19615) with the end modified to make it wider, and slowly dropped onto a 
glass slide. PBS supernatant quickly evaporated and another volume of microparticles were 
gently dropped onto the glass slide. Once sufficient amount of cell-laden beads were on the 
glass slide, beads were covered in mounting medium and a cover slip was placed on top, with 
very gentle pressure. Cove slips did not make contact with the glass slide underneath due to 
microparticles diameter, so imaging was performed very gently, to avoid crushing of the 
microparticles between the glass. 
   





4.4.1 UCB-ECFCs MAINTAINED THEIR PHENOTYPE IN LONG TERM CULTURE ON 
pεK HYDROGELS IN HEALTHY AND DIABETIC CONDITIONS 
UCB-ECFCs seeded onto TC plastic coated with col I. or unmodified pεK gels, adhered to all 
surfaces and expanded for up to 21 days. At experimental day 0 (48H after seeding), ECFCs 
on TC plastic or pεK gels were moved to healthy or diabetic conditions. At experimental time 
point 0, the ECFCs seeded on col I. coated TC plastic formed a confluent layer, whereas very 
few ECFCs were observed on the 0.1g/ml or 0.13g/ml pεK gels (Figure 4.5, D0). At 
experimental day 7, in healthy conditions, some ECFCs had expanded in size on the col I. 
coated TC plastic (Figure 4.5, black arrow), whereas ECFCs grown at 2% oxygen on the col I. 
coated TC plastic (Figure 4.6) retained the same cobblestone morphology up to experimental 
time point 21. By day 7 in healthy (20% O2, 5.5mM glucose), hypoxic (2% O2, 5.5mM glucose) 
or diabetic (2% O2, 33mM glucose) conditions, ECFCs on the 0.1g/ml or 0.13g/ml pεK gels had 
expanded in number and formed a monolayer, comparable to ECFCs grown on col I. coated 
TC plastic at the same time point (Figure 4.5, Figure 4.6). Therefore, although initially fewer 
ECFCs appeared to adhere to the pεK gels, by day 7, ECFCs formed a confluent monolayer on 
all surfaces tested, in healthy, low oxygen and diabetic culture conditions. By day 21, ECFCs 
on pεK gels appeared to retain a more homogenous cell size and shape (cobblestone)(Figure 
4.5 D21), particularly in low oxygen (Figure 4.6 D21) compared to those grown of col I. coated 
TC plastic, which suggests pεK gels may have desirable properties to enable ECFC expansion 











   



















Figure 4.5. UCB-ECFCs adhered and expanded on col I. coated TC plastic and both pεK 
hydrogels in healthy conditions for up to 21 days 
UCB-ECFCs, P5 were grown on: TC plastic coated with collagen I (left panel), 0.1g/ml pεK gel (middle) 
or 0.133g/ml pεK gel (right) and pictures were captured at experimental days 0, 7, 14 and 21, all in 
healthy conditions (20% oxygen and 5.5mM glucose). Arrowheads indicate enlarged cells, possibly a 
mature or senescent EC phenotype. Phase contrast images were captured on The Nikon DIAPHOT 
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Figure 4.6. UCB-ECFCs adhered and expanded on col I. coated TC plastic and both pεK 
hydrogels in hypoxic and diabetic conditions for up to 21 days 
UCB-ECFCs, P5 were grown on: col I. coated TC plastic (left panel), 0.1g/ml pεK gel (middle) or 
0.133g/ml pεK gel (right) and pictures were captured at experimental days 0, 7, 14 and 21, all in 2% 
oxygen and either 5.5mM or 33mM glucose. Phase contrast images were captured on The Nikon 
DIAPHOT microscope, using x10 objective. Scale bars= 200µm. 
   




4.4.2 ECFCS GROWN ON COL I. COATED TC PLASTIC SHOWED SIGNS OF 
DIFFERENTIATION OR SENESCENCE AT DAY 14 
IF imaging was performed at day 14, on UCB-ECFCs grown on col I. coated TC plastic and 
0.1g/ml or 0.13g/ml pεK gels, to investigate differences in expression of junctional proteins, 
angiogenic response and oxidative stress response. At day 14, ECFCs grown on col I. coated 
TC plastic in healthy conditions all expressed CD31 and CD34 at cell-cell junctions suggesting 
the cells have formed a tightly packed monolayer (Figure 4.7). Ang-2 expression was confined 
to a small number of cells. Overall, across the wells, ECFCs appeared similar in size and shape 
although arrow heads indicate where two ECFCs have enlarged nuclei, suggesting the 














Figure 4.7. UCB-ECFCs adhered and expanded on col I. coated TC plastic with a small 
number of cells becoming senescent or differentiating by day 14 
UCB-ECFCs, P5 were seeded at 5x104 ECFCs/well in a 24 w/p on col I. coated TC plastic. ECFCs were 
culture in EGM with 10% FBS, in healthy conditions (20% oxygen, 5.5mM glucose) with the media 
changed every 48-72H. On day 14 cells were fixed and stained for IF analysis of proteins involved in 
junctional protein formation and angiogenic response. Black arrowheads show some enlarged ECFCs, 
which may have differentiated or become senescent on the col I. coated TC plastic. Images were 
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4.4.3 UCB-ECFCS CULTURED ON pεK GELS HYDROGELS RETAINED THEIR 
PHENOTYPE AT DAY 14 
IF imaging was performed at day 14, on UCB-ECFCs grown on 0.1g/ml and 0.133g/ml pεK gels 
(Figure 4.8, Figure 4.9) and expression of a panel of proteins was compared to ECFCs grown 
in the same conditions on col I. coated TC plastic (Figure 4.7). x10 magnification images 
provided gross morphology information on ECFCs on 0.1g/ml pεK gels. The x10 panels 
highlight some of the issues associated with the washing and handling procedure for IF 
analysis of the ECFC monolayers on pεK gels, such as; auto-fluorescence of the pεK gel (CD31 
panel and no secondary control), lifting of the ECFC layer (ZO-1 panel), the gel not flat 
mounting which creates a shadow or wrinkle (CD34 panel), cell layer tearing off (VE-Cad 
panel) or cell loss (vWF and Ang-2 panel) (Figure 4.8). Images on the right at x40 magnification 
showed that ECFCs grown on 0.1g/ml and 0.133g/ml pεK gels expressed CD31 and VE-Cad at 
cell-cell junctions, suggesting a monolayer with barrier function. ECFCs expressed vWF on 
both pεK hydrogels, confirming endothelial phenotype. ECFCs expressed SOD-2 in healthy 
conditions on 0.1g/ml and 0.133g/ml pεK gels after 14 days. ECFCs on both gels expressed 
CD34 at the lateral cell border. Surprisingly, ECFC did not express ZO-1 on either of the pεK 
gels after 14 days (data not shown). Overall, there was no difference in expression of the 
panel of proteins of interest between ECFCs grown on 0.1g/ml or 0.133g/ml pεK gels. ECFCs 












   


























Figure 4.8. UCB-ECFCs retained their phenotype when cultured on 0.1g/ml pεK 
hydrogels in healthy conditions for 14 days 
UCB-ECFCs, P5 were gently seeded at 5x104 ECFCs/well in a 24 w/p with the pεK gel disk on the bottom. 
ECFCs were culture in phenol red-free EGM-2 with 10% FBS, in healthy conditions (20% oxygen, 5.5mM 
glucose) with the media changed every 48-72H. On day 14 cells were fixed and stained for IF analysis 
of proteins involved in junctional protein formation and angiogenic response. The no secondary 
negative control highlights the issue of auto-fluorescence, particularly in the blue channel, and IgG 
Isotype controls are used to show non-specific staining. Images were captured using the Zeiss M800 
confocal microscope, x10 or x40 oil magnification. Yellow scale bars= 100µm, white scale bars= 50µm. 
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Figure 4.9. UCB-ECFCs retained their phenotype when cultured on 0.13g/ml pεK 
hydrogels in healthy conditions for 14 days 
UCB-ECFCs, P5 were gently seeded at 5x104 ECFCs/well in a 24 w/p with the pεK gel disk on the bottom. 
ECFCs were culture in phenol red-free EGM-2 with 10% FBS, in healthy conditions (20% oxygen, 5.5mM 
glucose) with the media changed every 48-72H. On day 14 cells were fixed and stained for IF analysis 
of proteins involved in junctional protein formation and angiogenic response. Images were captured 
using the Zeiss M800 confocal microscope, x10 or x40 oil magnification. Yellow scale bars= 100µm, 
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4.4.4 UCB-ECFCs NO LONGER EXPRESSED CD34 AND CD31 EXPRESSION BECAME 
HETEROGENEOUS WHEN CULTURED ON COL I. COATED TC PLASTIC FOR 21 
DAYS 
IF imaging was performed at day 21, on UCB-ECFC grown on col I. coated TC plastic and 
0.1g/ml or 0.13g/ml pεK gels, with the same proteins of interest as day 14 (Figure 4.7, Figure 
4.8, Figure 4.9). ECFCs formed a confluent monolayer when grown on col I. coated TC plastic 
in either heathy conditions, hypoxia (2% oxygen), or diabetic conditions for 21 days (Figure 
4.10).  ECFCs retained the morphology and cell number comparable to day 14 (Figure 4.7), 
showing robustness during long term culture. In healthy conditions, approximately half of 
the ECFC grown on col I. coated TC plastic did not express CD31, whereas ECFCs grown in low 
oxygen conditions all expressed CD31 at day 21. SOD-2 expression followed the same pattern 
as the 50% expression of CD31 in ECFCs grown on col I. coated TC plastic in healthy 
conditions, suggesting a heterogeneous cell population by day 21. In healthy conditions, 
ECFCs on col I. coated TC plastic did not express CD34, when compared to day 14 (Figure 4.7), 
and Ang-2 expression could only be detected on a small number of ECFCs (Figure 4.10, green 
arrow heads). Ang-2 expression was increased when ECFCs were grown in low oxygen 
conditions with both physiological and diabetic glucose levels. When comparing ECFCs grown 
in 2% oxygen in either physiological or diabetic glucose levels for 21 days on col I. coated TC 
plastic, HIF1α expression appeared different, with HIF1α having translocated to the 
perinuclear compartment in high glucose, whereas HIF1α remained dispersed across the 










   























Figure 4.10. By day 21 on col I. coated TC plastic UCB-ECFCs became a heterogeneous 
population in healthy conditions 
UCB-ECFCs, P5 were seeded at 5x104 ECFCs/well in a 24 w/p on col I. coated TC plastic. ECFCs were 
culture in EGM with 10% FBS, in healthy conditions (20% oxygen, 5.5mM glucose), low hypoxic 
conditions (2% oxygen) or diabetic conditions (2% oxygen and 33mM glucose), with the media changed 
every 48-72H. On day 21 cells were fixed and stained for IF analysis of proteins involved in junctional 
protein formation, oxidative stress angiogenic response. Green arrowheads show some Ang-2 positive 
ECFCs within the healthy conditions. Images were captured using the Nikon E-Ti fluorescence 
microscope, x20 magnification. Scale bars= 100µm. 
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4.4.5 UCB-ECFCs RETAINED A HOMOGENEOUS EC-SPECIFIC PHENOTYPE WITH TJS 
AND ADHERENS JUNCTIONS ON pεK HYDROGELS IN HEALTHY CONDITIONS 
FOR 21 DAYS 
UCB-ECFCs survived for up to 21 days when grown on 0.1g/ml or 0.13g/ml pεK gels in healthy, 
hypoxic and diabetic conditions. In all conditions, ECFCs remained on the pεK gels as 
monolayers, retaining their original cell morphology (Figure 4.11, Figure 4.12, Figure 4.13). 
ECFCs grown on 0.1g/ml or 0.13g/ml pεK gels in healthy conditions for 21 days, all expressed 
CD31, VE-Cad and ZO-1, confirming TJs, adherens junctions, EC-phenotype, and a 
homogenous cell population, which differed to the heterogeneous ECFC population when 
grown on col I. coated TC plastic for 21 days (Figure 4.11, Figure 4.12, Figure 4.13). ECFCs 
expressed ZO-1 at day 21, but not at day 14 when grown on 0.1g/ml or 0.13g/ml pεK gels in 
healthy conditions (Figure 4.8, Figure 4.9, Figure 4.11, Figure 4.12). ECFCs grown on 0.1g/ml 
or 0.13g/ml pεK gels expressed vWF, confirming EC-phenotype. All ECFCs on pεK gels 
expressed SOD-2, with no noticeable difference between those grown in healthy or 2% 
oxygen conditions for 21 days (Figure 4.11, Figure 4.12, Figure 4.13). Ang-2 expression was 

















   






















Figure 4.11. UCB-ECFCs retained their phenotype when cultured on 0.1g/ml pεK 
hydrogels in healthy conditions for 21 days 
UCB-ECFCs, P5 were gently seeded at 5x104 ECFCs/well in a 24 w/p with the pεK gel disk on the bottom. 
ECFCs were culture in phenol red-free EGM-2 with 10% FBS, in healthy conditions (20% oxygen, 5.5mM 
glucose) with the media changed every 48-72H. On day 21 cells were fixed and stained for IF analysis 
of proteins involved in junctional protein formation and angiogenic response. Images were captured 
using the Zeiss M800 confocal microscope, x10 or x40 oil magnification. Yellow scale bars= 100µm, 
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Figure 4.12. UCB-ECFCs retained their phenotype when cultured on 0.13g/ml pεK 
hydrogels in healthy conditions for 21 days 
UCB-ECFCs, P5 were gently seeded at 5x104 ECFCs/well in a 24 w/p with the pεK gel disk on the bottom. 
ECFCs were culture in phenol red-free EGM-2 with 10% FBS, in healthy conditions (20% oxygen, 5.5mM 
glucose) with the media changed every 48-72H. On day 14 cells were fixed and stained for IF analysis 
of proteins involved in junctional protein formation and angiogenic response. Images were captured 
using the Zeiss M800 confocal microscope, x10 or x40 oil magnification. Yellow scale bars= 100µm, 
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4.4.6 UCB-ECFCs RETAINED A HOMOGENEOUS EC-SPECIFIC PHENOTYPE WITH TJS 
AND ADHERENS JUNCTIONS ON pεK HYDROGELS IN LOW OXYGEN AND 
DIABETIC CONDIONS FOR 21 DAYS 
UCB-ECFCs grown on 0.1g/ml or 0.13g/ml pεK gels in 2% oxygen combined with either 5.5mM 
glucose (hypoxia) or 33mM glucose (diabetic) expressed CD31 (Figure 4.13). SOD-2 was 
expressed by all ECFCs, with no difference in expression pattern in different conditions, 
grown pεK gels for 21 days. HIF1α expression did not appear to differ in low oxygen with 
different glucose concentrations. Ang-2 expression was difficult to determine when imaging 
ECFC on pεK gels, therefore no conclusions could be drawn. Cell size and shape did not appear 
to differ across the different culture conditions, suggesting ECFCs retained their cell 
phenotype after 21 days on pεK gels. Overall ECFCs showed minimal differences when 
expanded on 0.1g/ml or 0.13g/ml pεK gels in healthy, low oxygen or diabetic conditions for 
21 days, and did not show the possible de-differentiation observed when ECFCs were 
expanded on col I. coated TC plastic in the same conditions (Figure 4.10, Figure 4.11, Figure 
4.12, Figure 4.13).  
4.4.7 UCB-ECFCs ATTACHED TO UNMODIFIED pεK MICROPARTICLES OF FOUR 
DIFFERENT SIZES RANGES 
Microparticles of 4 different sizes were made by emulsification polymerisation, 50% cross-
linked with decanedioic acid, and with 0.286g/ml pεK. UCB-ECFCs tagged with cell tracker 
green (CTG-ECFC) attached to these microparticles and were monitored for up to 72H using 
live cell IF microscopy (Figure 4.14). Without any modification, the pεK microparticles 
supported adhesion of CTG-ECFCs, although adhered cells remained rounded in shape, 
suggesting ECFC adhesion may have been weak. Beyond 72H, CTG dye began to fade and it 
was not possible to monitor ECFCs on the microparticles. The microparticles also auto-
fluoresced, combined with CTG dye increasing background noise, as seen in the 18.30.3, 48H 
image (Figure 4.14), therefore, structured illumination using an ApoTome microscope was 






   






























Figure 4.13. UCB-ECFCs retained their phenotype in low oxygen and high glucose for 
21 days when frown on pεK hydrogels 
UCB-ECFCs, P5 were seeded at 5x104 ECFCs/well in a 24 w/p with the pεK gel disk on the bottom. ECFCs 
were culture in EGM with 10% FBS, in healthy conditions (20% oxygen, 5.5mM glucose), low hypoxic 
conditions (2% oxygen) or diabetic conditions (2% oxygen and 33mM glucose), with the media changed 
every 48-72H. On day 21 cells were fixed for IF analysis of proteins involved in junctional protein 
formation, oxidative stress angiogenic response. Images were captured using the Zeiss M800 confocal 
microscope, x10 and x40 oil magnifications. Yellow scale bars= 100µm, white scale bars= 50µm. 
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Figure 4.14. UCB-ECFCs adhered to unmodified pεK microparticles of four sizes for up 
to 72H 
CTG-UCB-ECFCs, P4 were gently seeded at 5x104 ECFCs/well in a 24 w/p with unmodified pεK 
microparticles on the bottom. ECFCs were culture in phenol red-free EGM-2 with 10% FBS. Images 
were captured at 24H, 48H and 72H using the Zeiss ApoTome microscope, x10 and x20 magnifications. 




4.4.8 ECFCs SHOWED IMPROVED ATTACHMENT TO pεK MICROPARTICLES WITH 
RGD BOUND ON THE SURFACE 
CTG-ECFCs attached to microparticles with diameters in the range 500-250µm and 250-
150µm, made by emulsification polymerisation, 50% cross-linked with decanedioic acid, with 
0.286g/ml pεK, and ~10% covalently bound RGD peptide on the surface. The CTG-ECFCs could 
be monitored for up to 72H using live cell IF microscopy (Figure 4.15). When microparticles 
were covalently bound with RGD peptide on ~10% of the surface, ECFCs adhered and the cell 
cytoplasm appeared to cover a larger surface area compared to ECFCs adhered to non-
modified pεK microparticles (Figure 4.15, Figure 4.14). Using z-stack imaging, 3D images were 
constructed and CTG-ECFCs could be observed wrapping around the surface of the pεK 
microparticles of both sizes. By 72H, the CTG dye began to fade and it became difficult to 






















   

















Figure 4.15. UCB-ECFCs adhered and spread on RGD modified pεK microparticles of 
two size ranges for up to 72H 
CTG-UCB-ECFCs, P5 were gently seeded at 5x104 ECFCs/well in a 24 w/p with RGD covalently bound to 
the surface of pεK microparticles, on the bottom. ECFCs were culture in phenol red-free EGM-2 with 
10% FBS. Images were captured at 24H, 48H and 72H using the Zeiss ApoTome microscope, x20 




4.4.9 GFP-ECFCs ADHERED TO UNMODIFIED pεK MICROPARTICLES 
In order to enable longer term monitoring of ECFCs on pεK microparticles, ECFCs transduced 
with GFP, using lentivirus, were seeded onto unmodified pεK microparticles, sized 250-
150µm and <150µm. GFP-ECFCs attached to the two smaller sized beads, and at 24H after 
seeding, could be imaged using 3D z-stacks, with reduced interference from background 
caused by CTG (Figure 4.16). Viral transduction of GFP into ECFCs did not appear to have any 
effect on ECFC ability to attach and survive on the pεK microparticles. Passaging GFP-ECFCs 
did not affect GFP expression. 3D projections showed good coverage of cells all around the 
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Figure 4.16. GFP-UCB-ECFCs adhered and spread on unmodified pεK microparticles of 
two size ranges for up to 24H 
CTG-UCB-ECFCs, P6 were gently seeded at 3.5x105 ECFCs/well in a 24 w/p with unmodified pεK 
microparticles on the bottom. ECFCs were culture in phenol red-free EGM-2 with 10% FBS. Images 
were captured at 24H, using the Zeiss ApoTome microscope, x10 and x20 magnification. Yellow scale 




4.4.10 GFP-ECFCs DID NOT DETACH FROM pεK MICROPARTICLES WHEN ADDED TO 
HEALTHY OR DIABETIC MONO- OR CO-CULTURE MODELS 
UCB-GFP-ECFCs attached to unmodified 18.30.5 (<150µm) pεK microparticles were added 
into the apical surface of mono/co-culture models in either healthy or diabetic conditions 
24H or h8H, to determine if GFP-ECFCS would detach from pεK microparticles and 
incorporate into the hREC monolayer on the PET membrane. GFP-ECFCs appeared to 
attached to pεK microparticles, and did not incorporate into the hREC monolayer 
underneath ( 
Figure 4.17). During live cell imaging, no GFP-ECFCs were observed incorporated in to the 
hREC layer. After processing for IF imaging, GFP-ECFCs remained attached to pεK 
microparticles, 24-48H after adding to either mono- or co-culture models suggesting the GFP-
ECFCs preferentially remained attached to unaltered pεK microparticles, in healthy and 
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Figure 4.17. GFP-UCB-ECFCs do not detach from pεK microparticles when added to 
healthy or diabetic mono/co-cultures for 24-48H 
(A) GFP-ECFC, P6 remaining on <150µM sized microparticles 48H after being added at culture day 7 of 
a healthy co-culture model. Microparticles were scooped out of the transwell insert and imaged on a 
glass slide. Magenta= phalloidin. (B and C) GFP-ECFC, P6 remaining on <150µM sized microparticles 
24H after being added at culture day 7 of a diabetic co-culture model. Cell-laden microparticles were 
processed for IF whilst on the surface of the PET membrane. Magenta= Ang-2, Green =GFP. (D) GFP-
ECFC, P6 remaining on <150µM sized microparticles 24H after being added at culture day 7 of a 
diabetic hREC monoculture model Magenta= Cx43, yellow= VEGFR2 and green= GFP. (E) GFP-ECFC, P6 
remaining on <150µM sized microparticles 24H after being added at culture day 7 of a diabetic hREC 
monoculture model. Magenta= ZO-1, yellow= SOD-2 and green= GFP. Images were captured using the 
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4.5 DISCUSSION  
4.5.1 OVERVIEW 
The aims of this chapter were to: assess pεK hydrogels as a suitable biomaterial for expanding 
ECFCs whilst retaining early passage phenotype, and consider pεK microparticles as a tool for 
controlled delivery of ECFCs to the back of the eye. The peptide nature of pεK provides a cell 
adhesive surface which may be useful for ECFC expansion whilst maintaining a stem-like 
phenotype in order to expand numbers to levels which would be useful in the clinic (>1x107). 
ECFCs are currently expanded on rat tail collagen I coated TC plastic, which is not 
manufactured under GMP conditions. To use in vitro expanded ECFCs for a cell therapy in 
humans, xeno-free or GMP culture conditions are a requirement. Following the hypothesis 
that optimised pεK cast gels could support ECFC growth in vitro, UCB-ECFCs were seeded on 
unmodified pεK gels, 60% cross-linked with decanedioic acid. ECFCs successfully attached, 
spread and grew on pεK hydrogels, showing potential as a xeno-free replacement of rat tail 
collagen I, and a suitable non-toxic, natural polymer surface for ECFCs to expand on. 
To achieve controlled delivery of ECFCs to specific areas in the back of the eye for translation 
of cell replacement therapy to the clinic, pεK microparticles were provided from SpheriTech 
to trial this protocol. Having confirmed UCB-ECFCs were capable of incorporating into my 
novel, human, retina-specific co-culture model of the microvasculature (Chapter 3), pεK 
microparticles were assessed for cell attachment and delivery of ECFCs to the co-culture 
model, with the ultimate aim of ECFCs detaching in response to cell signalling stimulus to 
incorporate into the endothelium. To achieve this, a protocol was optimised to seed ECFCs 
onto pεK microparticles with or without peptide surface modification, then cell-laden beads 
were delivered to the healthy or diabetic co-culture model, to assess if cells could detach and 
incorporate into gaps in the hREC monolayer. 
4.5.2 CURRENT PROTOCOL FOR IN VITRO EXPANSION OF ECFCs 
Historically both human fibronectin and rat tail col I. have been used as a culture surface 
coating to isolate EPCs. However, it became clear over time that there were two distinct 
populations present in culture (CACs and ECFCs), and col I. performed better for expansion 
of the ECFC population155. Little work focused on the impact that the two different substrates 
had on the success of isolation and the expansion of ECFCs, until Colombo et al. concluded 
that ECFC isolation should take place using fibronectin, whilst col I. was best for expansion173. 
Both of these studies support rat tail col I. for expansion of ECFCs in vitro, however, steps 
   




have already been taken to produce humanised ECFC-cultures for translational purposes, 
such as replacement of FBS with human platelet lysate164. Therefore, to progress to first in 
human trials, new xeno-free, GMP compliant substrate options for optimised ECFC expansion 
needs to be investigated. pεK hydrogels provide a highly controlled peptide surface with 
amine functionality to allow cell binding, and during production, the hydrogel properties can 
be tailored to best suit any particular cell-type. 
4.5.3 pεK HYDROGELS SUPPORTED THE EXPANSION OF UBC-ECFCs  
A common goal for stem cell therapy and regenerative medicine is facilitating the 
manufacture of products, or growth of cells, suitable for delivery into humans, whilst 
reducing the amount of undesirable or non-defined components287. For the current project, 
the aim was to maintain ECFC phenotype during expansion and replacing rat tail col I. coating 
with a xeno-free, non-toxic peptide hydrogel. The advantages of using a peptide hydrogel are 
that it can provide the chemical functionality of the col I. while being non-animal derived and 
consistently reproduced. 
The peptide hydrogels were produced from poly-ε-lysine (pεK), a simple linear amino acid 
chain with around 28 residues per peptide. Once gelled this produces a surface rich in amine 
functionality. Sheets were cast in order to test their capability to support ECFC growth 
without dedifferentiation, using a xeno-free surface, to expand the number of 
undifferentiated ECFCs to levels that could be clinically useful140. pεK hydrogels were 
developed by SpheriTech using patent protected technology (EP2699620) to produce an 
antimicrobial corneal bandage lens. SpheriTech also have ongoing projects tailoring the pεK 
hydrogels for optimal expansion of various different types of cell in vitro (unpublished data). 
There is currently very little published data on the use of pεK hydrogels for cell expansion, 
however one study successfully grew HCT-E cells on pεK hydrogels cross-linked with 60% 
octanedioic acid, and these ECs expressed ZO-1, suggesting they had functional barrier 
properties288. In this study, the authors discuss the fact that pεK hydrogels can be optimised 
according to clinical need, and surface peptide modification means the pεK hydrogels can be 
tailored to become the optimal surface for attachment for multiple different types of cells, 
highlighting the huge potential of this polymer in regenerative medicine applications. In the 
present study, pεK hydrogels composed of 0.1g/ml and 0.13g/ml pεK, 60% cross-linked with 
decanedioic acid did support the expansion of UCB-ECFCs in both healthy and diabetic 
conditions for 21 days. 
   




The number of ECFCs which initially attached appeared quite low (Figure 4.5, Figure 4.6), 
however by day 7, ECFC colonies were clearly visible on the pεK hydrogels and by day 14 
ECFCs had filled the surface of the pεK hydrogels. Cells remained EC-like; small, cobble-stone, 
uniform-shaped, and maintained contacts with neighbouring cells when grown on pεK 
hydrogels, whereas a small number of ECFCs grown on col I. coated TC plastic expanded in 
size, suggesting either de-differentiation or senescence (Figure 4.5, Figure 4.7)193. The ECFCs 
grown on pεK hydrogels expressed EC-specific markers vWF, CD34, VE-Cad, CD31 and ZO-1, 
and there did not appear to be any senescent ECFCs present, assessed morphologically via 
the typical increase in size of the cell cytoplasm and nucleus.  Similar to the HCE-T reported 
by Williams et al., the ECFCs seeded on pεK hydrogels of both densities expressed junctional 
proteins ZO-1, VE-Cad and CD31 at day 21 in healthy conditions (Figure 4.11, Figure 4.12)288. 
ECFCs grown in low oxygen (2%) or double insult of low oxygen and high glucose (2% O2 and 
33mM glucose) used in the diabetic model, expressed CD31 at day 21, and cells were present 
as a monolayer (Figure 4.13). ZO-1 was not assessed in stress conditions, due to the small 
sample size. Overall pεK hydrogels appear a very promising option for expansion of ECFCs, 
and the ECFCs demonstrated robustness against prolonged hypoxia and glucose insult as well 
as in healthy conditions on the pεK hydrogels. 
4.5.4 ECFCs ATTACHED TO pεK MICROPARTICLES RANGING IN SIZE FROM 1000µm 
TO <150µm 
pεK microparticles were developed and patented by SpheriTech (EP2699619) and were 
assessed in this project as a cell delivery platform, testing if ECFCs would initially adhere then 
detach when added to a model of injured ECs. ECFCs did not attach very well to pεK 
microparticles ranging in size from 1000µm to <150µm during initial optimisation. Despite 
initial poor attachment on unmodified pεK microparticles, after seeding at much higher cell 
density (3.5x105 cell/well rather than 2x104 cells/well) ECFCs did attach to unmodified pεK 
microparticles, although they did not spread and remained rounded at all time points (Figure 
4.14). In order to improve initial attachment, RGD was covalently bound to the surface of the 
pεK. The epsilon amino group in pεK is a good nucleophile at pH >8.0 and reacts with a variety 
of reagents to form stable, covalently attached ligands on the pεK substrate surface289. The 
RGD tripeptide sequence (Arg-Gly-Asp) is associated with ECM proteins such as fibronectin, 
laminin and collagen and has been grafted to many different kinds of biomaterials including 
polymers, metals and ceramics, to modulate cell adhesion181,290. After RGD was covalently 
bound to the pεK microparticles at ~10% coverage, ECFCs attached and spread onto the pεK 
(Figure 4.15). However, for the ultimate goal of cell delivery, loose attachment may in fact be 
   




desirable, because if the ECFCs were attached too strongly to the pεK, any chemokine or 
cytokine migratory effect when added to the damaged hREC may not be sufficient to signal 
for the ECFCs to migrate off the microparticles. Therefore, unmodified pεK microparticles 
were used to deliver ECFCs to the retinal microvascular co-culture model. 
4.5.5 ECFCs DELIVERED ON pεK MICROPARTICLES DID NOT INTEGRATE INTO THE 
hREC LAYER OF THE CO-CULTURE MODEL  
ECFCs did not detach from the pεK microparticles when cell-laden pεK microparticles were 
added to either healthy or diabetic hREC monolayers, or when added to the diabetic co-
culture model. No GFP-positive ECFCs could be detected in the hREC layer of any of the 
models, and after high resolution z-stack confocal microscopy was performed, ECFCs were 
detected still adhered to the pεK microparticles ( 
Figure 4.17). Therefore, although ECFCs appeared only loosely adhered to the pεK 
microparticles, due to their rounded shape, the adhesion to the pεK microparticle surface 
was able to withstand manual transfer of beads from the well using a metal scoop.  
The optimised diabetic co-culture model conditions resulted in significant changes to the 
secretion of a number of proteins involved in angiogenesis, such as increase in secreted Ang-
2 levels and decrease in secreted TIMP-2 levels (Figure 2.32). Ang-2 is a vascular growth factor 
which is increased in inflammatory and angiogenic environments 34 and TIMP-2 is a natural 
inhibitor of MMP-2, therefore, reduced TIMP-2 leads to increased MMP-2 activity and 
increased ECM remodelling. In combination, these two growth factors represent a pro-
angiogenic environment. However, the growth factors present within the diabetic (or 
healthy) models did not cause migration of the ECFCs off the pεK microparticles in the 
present study. 
4.5.6 ALTERNATIVES TO pεK  
Hydrogels provide a biomimetic environment, with salient elements of native ECMs 
compared to protein coated TC plastic, and provide the opportunity to modify surfaces to 
best suit cell-specific needs291. There are different categories of hydrogels commonly used in 
cell culture, including naturally derived (collagen, fibrin and alginate), synthetically produced 
(polyacrylamide and polyethylene glycol) and hybrid (hyaluronic acid and polypeptide) 
hydrogels292. Each has positive and negative aspects and should be selected according to 
experimental application. Recombinant human ECM protein synthesis is an alternative xeno-
free option, and collagen represents a successful model, however optimisation is still 
necessary within the different expression systems to improve productivity and bioactivity, as 
   




well as cost and convenience293. With regards to stem cell expansion, soft polyacrylamide 
substrates have been shown to enable expansion of mouse embryonic stem cells which 
retain their pluripotency, highlighting that stiffness is involved in driving stem cell fate294. For 
clinical applications, it is important to be able to release cells from substrates in a controlled 
manner. A useful substrate for this task is thermo-responsive poly (N-isopropylacrylamide) 
(pNIPAAm), which is suitable for cell attachment and growth at 37°C, but at 20°C the 
pNIPAAm polymer chains hydrate and expand, which detaches the cells as a sheet295. For the 
present project, a hydrogel capable of expanding ECFCs and maintaining their progenitor 
phenotype in vitro was the main aim.  
4.6 LIMITATIONS & FUTURE WORK 
Modifications to the pεK microparticles to enable controlled release, such as pH-sensitive, 
temperature-sensitive or enzymatic release of ECFCs could be investigated. However, direct 
intraocular injection of ECFCs has been shown to result in successful incorporation in an OIR 
mouse model153. Using the same model, systemic injection of ECFCs through the common 
carotid artery also resulted in successful ECFC incorporation into the retinal vessels, although 
the numbers were lower than intravitreal delivery170. Therefore, ECFCs may not require a 
biomaterial for delivery purposes. An unexpected result from the co-culture model was no 
detectable secreted VEGF. Therefore addition of exogenous VEGF or any chemotactic 
molecule present in DR could be explored, to determine if ECFCs would migrate off the 
microparticles in the presence of a potent stimulator of EC migration. pεK gels could be cross-
linked with other carboxylic acids, or the percentage cross-linkage adjusted, in order to assess 
the optimal pεK hydrogel composition to expand ECFCs in the future. 
4.7 CONCLUSIONS 
In the present study, for the first time, pεK cross-linked 60% with decanedioic acid has been 
shown to enable ECFC attachment and expansion, whilst maintaining phenotype for up to 21 
days in both healthy and diabetic conditions. ECFCs also successfully adhered to pεK 
microparticles, although further modification of the surface chemistry of the pεK 
microparticles would be required to consider them for ECFC delivery to the back of the eye. 
 





5 CHAPTER 5 
5.1 DISCUSSION 
The main aim of the work undertaken in this thesis was to develop a human primary cell 
model of the diabetic retinal microvasculature which could be used to assess the ability of 
ECFCs to integrate into the EC layer of the retinal capillaries, as a cell therapy option. Isolation 
and expansion techniques of ECFCs need to be further developed to become GMP compliant 
if they are to be used as a clinical cell therapy because the current method uses rat tail 
collagen I coated surfaces to expand ECFCs from the mononuclear fraction of blood. Non-
toxic, pεK hydrogel surfaces were assessed for their capacity to expand ECFCs whilst retaining 
their endothelial progenitor properties, as a xeno-free replacement to rat tail collagen I. 
The aim of chapter 2 was development of a novel human, primary co-culture model of the 
retinal vasculature to mimic diabetic retinopathy in vitro. Multiplex data from chapter 2 
highlighted that the secretion pattern of angiogenic proteins was different when cells were 
co-cultured compared to grown individually. Human primary cells were challenging to 
expand in vitro and this may be why immortalised, non-human or large vessel cells have been 
used by others in previous studies, however, in the present study, it was possible to grow the 
two cell types in co-culture after extensive optimisation of culture conditions. Extending the 
culture period for up to 21 days was also very important because some angiogenic proteins 
were not secreted until beyond day 14, and considering the long onset of DR, some changes 
to cell behaviour may not be detected in short culture durations.  
The aim of chapter 3 was to isolate, characterise and expand ECFCs from human UCB and 
APB and test their capability to incorporate into the healthy and diabetic human primary co-
culture models of the retinal microvasculature. ECFCs were successfully isolated from APB 
and UCB, although higher numbers of ECFCs were expanded from UCB, and the ECFCs that 
did expand from APB grew slower and reached senescence earlier. GD-ECFCs showed no 
difference in expansion and integration capabilities compared to healthy UCB-ECFCs. Two 
subpopulations of EPCs can be isolated in vitro, therefore, stringent characterisation of 
putative ECFCs was carried out and data from chapter 3 confirmed that cells isolated using 
rat tail col I. coated TC surfaces and cultured in endothelial specific growth conditions for 2-
6 weeks were true ECFCs. APB and UCB-ECFCs incorporated into hREC layers in mono- and 
co-culture models, in both healthy and diabetic conditions, confirming their potential as a 
future cell therapy to repair damaged vascular endothelium.  





The aim of chapter 4 was to assess the capacity of pεK for ECFC attachment, viability and 
expansion without differentiation, and targeted delivery of ECFCs to an in vitro model of 
diabetic retinopathy. It was determined that pεK microparticles were not suitable as a 
delivery method of ECFCs, because cells remained attached to the microparticle rather than 
integrating into the hREC layer. However, long term culture of ECFCs on rat tail collagen I 
coated TC plastic surfaces lead to a heterogeneous population of cells, some of which 
expanded in size suggesting either differentiation or senescence. pεK hydrogels provided a 
xeno-free, highly reproducible, modifiable surface to expand ECFCs, and data in chapter 4 
highlights that UCB-ECFCs cultured long term on pεK hydrogels in both healthy and diabetic 
conditions retained their EC morphology, expanded well, formed a TJ barrier when in a 
monolayer and remained a homogenous population. Therefore, pεK hydrogels may provide 
a replacement for rat tail collagen I as a surface with improved properties to expand ECFCs 





















 hREC and hRP survived low oxygen (2%) and high glucose (33mM) culture conditions for 
up to 21 days 
 hREC and hRP grew on either side of a PET transwell insert seeded at 1:1 ratio to mimic 
the hRP coverage of the retinal capillary 
 Diabetic conditions induced significant changes to the secretion profile of angiogenic 
proteins from hREC and hRP compared to healthy conditions 
 hREC and hRP response to diabetic culture was different when the cells were co-cultured 
as opposed to cultured individually 
 Fewer ECFCs were isolated from APB and they grew slower and reached senescence 
earlier than UCB-ECFCs 
 Both APB, healthy and GD-UCB-ECFCs integrated into the hREC layer on PET membranes 
in healthy and diabetic conditions 
 Healthy and GD-UCB-ECFCs integrated into the hREC of the co-culture model in both 
healthy and diabetic conditions 
 UCB-ECFCs cultured for 21 days on pεK hydrogels retained their endothelial progenitor-
specific phenotype  
 UCB-ECFCs cultured for 21 days on rat tail col I. coated TC plastic began to differentiate 
or become senescent 
 Even in low oxygen (2%) and high glucose (33mM) conditions UCB-ECFCs grown on pεK 
hydrogels remained a homogenous population expressing endothelial progenitor-
specific markers 
 pεK hydrogels are a promising alternative culture surface that is xeno-free, highly 
reproducible and modifiable to enable expansion of ECFCs in vitro whilst retaining their 
progenitor phenotype 
 UCB-ECFCs adhered to unmodified pεK microparticles but did not detach when cell laden 
microparticles were delivered to the healthy or diabetic co-culture model 
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